Novel Functions of the Survival Motor Neuron Protein by Ottesen, Eric William
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2016




Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Molecular Biology Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation








Eric W Ottesen 
 
 
A dissertation submitted to the graduate faculty 
 
in partial fulfillment of the requirements for the degree of 
 
DOCTOR OF PHILOSOPHY 
 
 
Major: Molecular, Cellular, and Developmental Biology 
 
Program of Study Committee: 
Ravindra N. Singh, Major Professor 
Jeffrey K Beetham 
Jeffrey Trimarchi 
Peng Liu 













Copyright © Eric W. Ottesen, 2016. All rights reserved. 
  
 ii 




ACKNOWLEDGEMENTS	  .............................................................................................................	  	   iv	  
ABSTRACT	  ........................................................................................................................................	  	   v	  
CHAPTER	  I.	  GENERAL	  INTRODUCTION	  ............................................................................	  	   	  	  1	  	   References	  	  	  	  	  	  .............................................................................................................................	  	  	  	  	  	  13	  	   Figure	  Legends	  .........................................................................................................................	  	  	  	  	  	  	  23	  	   Figures	  	  	  	   	  ...............................................................................................................................	  	  	  	  	  	  23	  	   Tables	   	   	  ...............................................................................................................................	  	  	  	  	  	  24	  	  
CHAPTER	  II.	  SEVERE	  IMPAIRMENT	  OF	  MALE	  REPRODUCTIVE	  	  
	   ORGAN	  DEVELOPMENT	  IN	  A	  LOW	  SMN	  EXPRESSING	  MOUSE	  	  
	   MODEL	  OF	  SPINAL	  MUSCULAR	  ATROPHY	  ..............................................................	  	   	  	  26	  	   Abstract	  	   	  	  	  	  	  	  ..........................................................................................................................	  	  	  	  	  	  27	  	   Introduction	  ...............................................................................................................................	  	  	  	  	  	  	  28	  	   Results	  	  	  	   	  ...............................................................................................................................	  	  	  	  	  	  	  30	  Discussion	   	  ...............................................................................................................................	  	  	  	  	  	  	  41	  	   Materials	  and	  Methods	  .........................................................................................................	  	  	  	  	  	  	  47	  	   References	  	  	  	  ...............................................................................................................................	  	  	  	  	  	  	  58	  	   Acknowledgments,	  Funding,	  and	  Author	  Contributions	  ........................................	  	   64	  	   Figure	  Legends	  	  	  	  ......................................................................................................................	  	  	  	  	  	  	  65	  	   Figures	   	   	  ...............................................................................................................................	  	  	  	  	  	  	  71	  	  
APPENDIX	  A.	  CHAPTER	  II	  SUPPLEMENTARY	  FIGURES	  
	   AND	  TABLES	  ............................................................................................................................	  	  	  	   79	  	   Supplementary	  Figure	  Legends	  	  	  	  	  	  ...................................................................................	  	  	  	  	  	  	  79	  	   Supplementary	  Figures	  ........................................................................................................	  	  	  	  	  	  	  80	  	   Supplementary	  Tables	  	  	  ........................................................................................................	  	  	  	  	  	  83	  	  
CHAPTER	  III.	  IN VITRO SELECTION REVEALS HIGH  
 AFFINITY RNA TARGETS OF THE SURVIVAL MOTOR 
 NEURON PROTEIN ......................................................................................... 	  	  94 	   Abstract	  	   	  	  	  	  	  	  ..........................................................................................................................	  	   94	   Introduction	  ...............................................................................................................................	  	   	  	  	  95	  	   Results	  	  	  	   	  ...............................................................................................................................	  	   98	  	   Discussion	   	  ...............................................................................................................................	  	   104	  	   Materials	  and	  Methods	  .........................................................................................................	  	   108	  	   References	  	  	  	  ...............................................................................................................................	  	   116	  	   Figure	  Legends	  	  	  	  ......................................................................................................................	  	   121	  	   Figures	   	   	  ...............................................................................................................................	  	   125	  	   Tables	   	  	  	   	  ...............................................................................................................................	  	   132	  	  
 iii 
	  
APPENDIX	  B.	  CHAPTER	  III	  SUPPLEMENTARY	  FIGURES	  	  
	   AND	  TABLES	  ............................................................................................................................	  	   136	  	   Supplementary	  Figure	  Legends	  	  	  	  	  	  ...................................................................................	  	   136	  	   Supplementary	  Figures	  ........................................................................................................	  	   138	  	   Supplementary	  Tables	  	  	  ........................................................................................................	  	   140	  	  
CHAPTER	  IV.	  HIGH AFFINITY RNA TARGETS OF THE  
 SURVIVAL MOTOR NEURON PROTEIN DEFINED BY  
 UV-CROSSLINKING AND IMMUNOPRECIPITATION	  ................................	  	  	  	  142 	   Abstract	  	   	  	  	  	  	  	  ..........................................................................................................................	  	  	  	  142	   Introduction	  ...............................................................................................................................	  	  	  	  143	  	   Results	  	  	  	   	  ...............................................................................................................................	  	   145	  	   Discussion	   	  ...............................................................................................................................	  	   153	  	   Materials	  and	  Methods	  .........................................................................................................	  	   157	  	   References	  	  	  	  ...............................................................................................................................	  	   162	  	   Figure	  Legends	  	  	  	  ......................................................................................................................	  	   167	  	   Figures	   	   	  ...............................................................................................................................	  	   169	  	   Tables	   	  	  	   	  ...............................................................................................................................	  	   174	  	  
APPENDIX	  C.	  CHAPTER	  IV	  SUPPLEMENTARY	  TABLES	  ............................................	  	   176	  	   Supplementary	  Tables	  	  	  ........................................................................................................	  	   176	  	  	  





 There are many people that I would like to thank for their support and guidance 
throughout my life and graduate career. First and foremost, I would like to thank my 
advisor, Dr. Ravindra Singh, for guiding me through my graduate research and constantly 
challenging me to see beyond the day-to-day matters of research to the larger whole. I 
would like to thank all the members of the Singh lab, both past and present, who have 
contributed to the research contained in this text, both materially and intellectually. I 
would also like to thank everybody who has served on my committee, Drs. Jeffrey 
Beetham, Jeffrey Trimarchi, Peng Liu, Brian Lee, and Drena Dobbs, for their guidance 
and advice. Finally, I would like to thank my parents, Ruth and James Ottesen, for raising 
an inquisitive little daydreamer to become the inquisitive not-so-little daydreamer that I 




The Survival Motor Neuron (SMN) protein is a multi-functional protein that participates 
in a wide variety of critical pathways. Low levels of SMN cause spinal muscular atrophy 
(SMA), the most common genetic cause of infant mortality. While the role of SMN in the 
assembly of small nuclear ribonucleoproteins (snRNPs) has been well characterized, 
many of its other diverse functions have not been thoroughly explored. Here, we examine 
the critical role of SMN in the growth and development of male mammalian sex organs. 
We show that low levels of SMN in a mild mouse model of SMA cause impaired testis 
development, degenerated seminiferous tubules, reduced sperm count, and low fertility. 
Underscoring an increased requirement for SMN expression, wild type testis showed 
extremely high levels of SMN protein compared to other tissues. The testis phenotype is 
linked to increased apoptosis in seminiferous tubules and extreme perturbations in the 
testis transcriptome. We examine the RNA binding function of SMN by Systematic 
Evolution of Ligands by Exponential Enrichment (SELEX) to identify RNA sequence 
and structural motif(s) of SMN. Our results reveal a combination of sequence motifs and 
structural contexts that drive the specificity of RNA-SMN interactions. Our results of 
truncation and substitution experiments suggest a requirement for multiple contacts 
between SMN and RNA to maintain the high affinity. We demonstrate that both affinity 
and specificity of RNA-SMN interaction are influenced by salt concentrations. To 
identify in vivo RNA targets of SMN, we performed crosslinking and 
immunoprecipitation coupled with high-throughput sequencing (HITS-CLIP). HITS-
CLIP identified a variety of RNA targets of SMN with an enrichment of mRNAs 
 vi 
participating in a number of pathways, including ribosome function and actin 
cytoskeleton regulation. In order to determine whether expression levels of target RNAs 
are regulated by SMN, we performed knockdown of SMN levels followed by RNA-Seq.  
SPON2, LAMB2, and EEF1A2 in particular were all predicted by HITS-CLIP to be bound 
by SMN and were downregulated upon SMN knockdown, indicating a direct regulatory 






Spinal	  Muscular	  Atrophy	  and	  the	  SMN	  Protein	  Spinal	  Muscular	  Atrophy	  (SMA)	  is	  a	  genetic	  disease,	  primarily	  affecting	  infants	  and	  small	  children.	  It	  is	  the	  most	  common	  genetic	  cause	  of	  infant	  mortality,	  affecting	  1	  in	  10,000	  live	  births,	  with	  a	  carrier	  frequency	  of	  1	  in	  35	  (Wirth	  et	  al	  2006).	  SMA	  is	  caused	  by	  low	  levels	  of	  the	  Survival	  Motor	  Neuron	  (SMN)	  due	  to	  mutation,	  deletion,	  or	  gene	  conversion	  of	  the	  SMN1	  gene,	  resulting	  in	  progressive	  deterioration	  of	  motor	  neurons	  (Lefebvre	  et	  al	  1995).	  In	  mice,	  deletion	  of	  the	  Smn	  gene,	  which	  is	  equivalent	  to	  SMN1,	  is	  homozygous	  lethal	  (Schrank	  et	  al	  1997).	  However,	  due	  to	  a	  duplication	  of	  the	  region	  of	  chromosome	  5	  containing	  contains	  SMN1,	  humans	  have	  a	  second	  copy	  of	  the	  SMN	  gene,	  SMN2.	  SMN2	  is	  only	  a	  partially	  functional	  copy,	  due	  to	  the	  presence	  of	  a	  C-­‐T	  mutation	  in	  the	  6th	  position	  of	  exon	  7.	  Although	  the	  C-­‐T	  mutation	  is	  translationally	  silent,	  it	  alters	  the	  splicing	  pattern	  of	  SMN2	  pre-­‐mRNA,	  causing	  predominant	  skipping	  of	  SMN2	  exon	  7	  (Lorson	  et	  al	  1999).	  The	  mRNA	  isoform	  produced	  by	  skipping	  of	  exon	  7	  produces	  a	  truncated	  protein	  with	  an	  altered	  C-­‐terminus,	  SMNΔ7,	  which	  is	  highly	  unstable	  and	  deficient	  in	  several	  functions	  (Cho	  and	  Dreyfuss	  2010,	  Gupta	  et	  al	  2015).	  However,	  SMN∆7	  retains	  the	  ability	  to	  extend	  survival	  in	  a	  severe	  mouse	  model	  of	  SMA	  when	  overexpressed	  (Le	  et	  al	  2005),	  indicating	  that	  functionality	  of	  the	  protein	  is	  not	  completely	  compromised	  in	  the	  absence	  of	  exon	  7.	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Domain	  Structure	  of	  the	  SMN	  Protein	  SMN	  is	  a	  multifunctional	  protein	  and	  has	  many	  interacting	  partners	  (reviewed	  later	  in	  the	  text),	  and	  as	  such,	  has	  multiple	  functional	  domains	  (Figure	  1A-­‐1B).	  The	  region	  coded	  by	  exons	  2A	  and	  2B	  mediate	  the	  interaction	  with	  the	  SMN	  binding	  partner	  Gemin2	  (Zhang	  et	  al	  2011),	  which	  is	  crucial	  for	  a	  number	  of	  critical	  functions	  of	  SMN	  (Fischer	  et	  al	  1997,	  Liu	  et	  al	  1997,	  Sanchez	  et	  al	  2013,	  Takaku	  et	  al	  2011,	  Piazzon	  et	  al	  2013).	  In	  addition,	  an	  overlapping	  region	  is	  also	  required	  for	  the	  nucleic	  acid	  binding	  activity	  of	  the	  SMN	  protein	  (Bertrandy	  et	  al	  1999,	  Lorson	  and	  Androphy	  1998).	  Exon	  3	  codes	  for	  the	  Tudor	  domain.	  Tudor	  domains,	  mediate	  interactions	  with	  methylated	  arginine	  residues	  (Chen	  et	  al	  2011).	  Specifically,	  the	  SMN	  Tudor	  domain	  binds	  methylated	  arginine	  residues	  on	  the	  Sm	  proteins	  (Selenko	  et	  al	  2001),	  as	  well	  as	  a	  number	  of	  other	  proteins	  critical	  for	  SMN	  function	  (Hebert	  et	  al	  2001,	  Sabra	  et	  al	  2013,	  Zhao	  et	  al	  2016).	  Consistently,	  mutations	  within	  and	  antibodies	  directed	  against	  the	  SMN	  Tudor	  domain	  both	  dramatically	  impair	  snRNP	  assembly	  (Buhler	  et	  al	  1999).	  The	  domain	  coded	  for	  by	  the	  region	  spanning	  exon	  4	  through	  the	  first	  portion	  of	  exon	  6	  is	  predicted	  to	  be	  disordered,	  with	  a	  number	  of	  poly-­‐proline	  stretches.	  This	  portion	  of	  the	  SMN	  protein	  is	  predicted	  to	  interact	  with	  the	  actin	  cytoskeleton-­‐associated	  protein	  Profilin	  (Giesemann	  et	  al	  1999,	  Nolle	  et	  al	  2011).	  The	  C-­‐terminal	  region,	  in	  particular	  the	  region	  spanning	  the	  end	  of	  exon	  6	  and	  the	  beginning	  of	  exon	  7,	  contains	  the	  YG	  box,	  which	  mediates	  SMN	  protein	  oligomerization	  (Gupta	  et	  al	  2015).	  Isoforms	  of	  SMN	  with	  disrupted	  YG	  box	  structure	  also	  have	  reduced	  stability	  (Seo	  et	  al	  2016).	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   Although	  deletion	  of	  part	  or	  all	  of	  SMN1	  is	  the	  most	  common	  cause	  of	  SMA,	  a	  small	  proportion	  of	  patients	  suffer	  from	  point	  mutations	  which	  cause	  coding	  changes	  within	  the	  SMN	  protein	  (Wirth	  et	  al	  2000,	  Cusco	  et	  al	  2004,	  Sun	  et	  al	  2005,	  Zapletalova	  et	  al	  2007,	  Howell	  et	  al	  2014,	  Figure	  1C).	  These	  mutations	  are	  a	  critical	  tool	  for	  understanding	  the	  different	  domains	  of	  SMN	  because	  they	  indicate	  essential	  sequences	  that	  are	  required	  for	  either	  SMN	  function	  or	  stability.	  The	  majority	  of	  these	  point	  mutations	  localize	  to	  either	  the	  Tudor	  domain	  or	  the	  YG	  box,	  confirming	  the	  critical	  nature	  of	  these	  two	  domains	  (Figure	  1C).	  	  	  
The	  SMN	  Complex:	  A	  Multipart,	  Multifunctional	  RNP	  Assembly	  Hub	  SMN	  has	  multiple	  protein-­‐interacting	  domains,	  and,	  as	  such,	  has	  a	  number	  of	  binding	  partners	  that	  operate	  within	  numerous	  processes	  (Table	  1).	  The	  most	  well-­‐characterized	  of	  these	  by	  far	  is	  the	  SMN	  complex.	  The	  SMN	  complex,	  as	  described,	  consists	  of	  9	  different	  proteins:	  SMN,	  Gemins	  2-­‐8,	  and	  UNRIP	  (Cauchi	  2010).	  Although	  it	  is	  generally	  referred	  to	  as	  a	  single	  entity,	  in	  reality,	  the	  SMN	  complex	  consists	  of	  multiple	  sub-­‐complexes	  which	  can	  function	  independently	  (Battle	  et	  al	  2007).	  Proteins	  within	  the	  SMN	  complex	  contain	  signals	  for	  both	  nuclear	  localization	  and	  export	  (Zhang	  et	  al	  2003,	  Lorson	  et	  al	  2008).	  Consistently,	  SMN	  and	  other	  complex	  members	  are	  generally	  located	  in	  both	  the	  cytoplasm	  and	  the	  nucleus	  (Zhang	  et	  al	  2003).	  However,	  the	  cytoplasm	  is	  the	  primary	  site	  of	  snRNP	  assembly	  (Massenet	  et	  al	  2002).	  At	  its	  most	  fundamental	  core,	  the	  SMN	  functional	  unit	  consists	  of	  SMN	  and	  Gemin2	  (Zhang	  et	  al	  2011).	  Consistent	  with	  the	  concept	  of	  SMN-­‐Gemin2	  as	  a	  functional	  unit,	  it	  was	  recently	  reported	  that	  U1-­‐70K	  can	  “hijack”	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SMN-­‐Gemin2	  to	  facilitate	  U1	  snRNP	  assembly	  without	  the	  assistance	  of	  other	  Gemins	  (So	  et	  al	  2016).	  Underscoring	  its	  critical	  role,	  Gemin2	  is	  even	  more	  widely	  evolutionarily	  conserved	  than	  SMN	  itself.	  	  In	  Arabidopsis,	  for	  example,	  Gemin2	  is	  required	  for	  proper	  circadian	  rhythm	  regulation	  due	  to	  its	  effect	  on	  splicing;	  however,	  the	  protein	  that	  is	  predicted	  to	  fill	  the	  role	  of	  SMN	  is	  actually	  a	  homolog	  of	  SPF30	  rather	  than	  SMN	  (Schlaen	  et	  al	  2015).	  	  Although	  SMN	  and	  Gemin2	  are	  almost	  universally	  co-­‐regulated	  and	  found	  interacting	  with	  one	  another,	  there	  is	  slowly	  mounting	  evidence	  that	  this	  may	  not	  always	  be	  the	  case.	  For	  example,	  in	  a	  fluorescence	  microscopy-­‐based	  study	  of	  axonal	  mRNP	  transport,	  a	  portion	  of	  the	  particles	  observed	  contained	  SMN	  but	  lacked	  Gemin2,	  indicating	  a	  possible	  functional	  SMN	  unit	  that	  does	  not	  contain	  this	  critical	  interacting	  partner	  (Zhang	  et	  al	  2006).	  Supporting	  a	  lack	  of	  requirement	  for	  Gemin2	  in	  an	  axonal	  function	  for	  SMN,	  reduction	  of	  Gemin2	  had	  no	  effect	  on	  the	  outgrowth	  of	  motor	  neuron	  axons,	  unlike	  SMN	  (McWhorter	  et	  al	  2008).	  	   Gemin3	  and	  Gemin4	  form	  another	  subunit	  of	  the	  SMN	  complex	  (Battle	  et	  al	  2007).	  Gemin3,	  otherwise	  known	  as	  DDX20	  and/or	  DP103,	  is	  a	  putative	  DEAD-­‐box	  helicase	  based	  on	  sequence	  homology	  (Charroux	  et	  al	  1999,	  Campbell	  et	  al	  2000).	  The	  precise	  function	  of	  Gemin3-­‐Gemin4	  within	  the	  SMN	  complex	  is	  currently	  unknown,	  although	  they	  independently	  interact	  with	  Gemin5	  (Battle	  et	  al	  2007),	  and	  a	  requirement	  for	  ATP	  hydrolysis	  for	  snRNP	  assembly	  (Meister	  et	  al	  2001,	  Pellizzoni	  et	  al	  2002b)	  coupled	  with	  Gemin3’s	  identity	  as	  a	  putative	  helicase	  suggests	  an	  RNA	  remodeling	  function	  for	  this	  subcomplex.	  Independently	  of	  the	  SMN	  complex,	  Gemin3	  has	  also	  been	  implicated	  in	  miRNA	  biogenesis	  (Mourelatos	  et	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al	  2002).	  Gemin4	  immunoreactivity	  is	  localized	  to	  both	  gems	  and	  the	  nucleolus,	  indicating	  a	  possible	  secondary	  function	  for	  this	  protein	  in	  ribosome	  biogenesis	  (Charroux	  et	  al	  2000).	  	   Gemin5	  is	  a	  large	  (~169	  kDa)	  RNA	  binding	  protein	  (RBP)	  containing	  13	  WD	  repeat	  domains	  which	  mediate	  its	  RNA	  binding	  activity	  (Lau	  et	  al	  2009).	  Gemin5	  serves	  as	  the	  primary	  snRNA	  recruitment	  factor	  of	  the	  SMN	  complex	  (Lau	  et	  al	  2009,	  Yong	  et	  al	  2010).	  Supporting	  its	  function	  as	  a	  recruitment	  factor	  rather	  than	  as	  a	  core	  member	  of	  the	  SMN	  complex,	  the	  majority	  of	  Gemin5	  protein	  exists	  outside	  of	  the	  SMN	  complex	  (Battle	  et	  al	  2007).	  In	  order	  to	  deliver	  snRNAs	  to	  the	  SMN	  complex,	  Gemin5	  interacts	  directly	  with	  both	  Gemin2	  and	  the	  Gemin3-­‐Gemin4	  subcomplex	  (Otter	  et	  al	  2007).	  Gemin5	  also	  functions	  outside	  of	  the	  SMN	  complex	  in	  the	  regulation	  of	  translation.	  Gemin5	  is	  an	  interacting	  partner	  of	  eIF4E	  and	  is	  essential	  for	  cap-­‐independent	  translation	  of	  a	  number	  of	  viral	  mRNAs	  (Fierro-­‐Monti	  et	  al	  2006,	  Pacheco	  et	  al	  2009).	  Gemin5	  is	  also	  recruited	  to	  stress	  granules	  upon	  induction	  of	  their	  formation	  by	  arsenite	  treatment	  (Battle	  et	  al	  2007).	  	   The	  functions	  of	  Gemins6-­‐8	  and	  UNRIP	  are	  less	  well	  characterized	  than	  the	  other	  subunits	  of	  the	  SMN	  complex.	  Like	  Gemin5,	  the	  majority	  of	  these	  proteins	  are	  found	  outside	  of	  the	  SMN	  complex	  (Battle	  et	  al	  2007).	  Also	  like	  Gemin5,	  UNRIP	  has	  been	  implicated	  in	  cap-­‐independent	  translation	  (Hunt	  et	  al	  1999)	  during	  viral	  infection.	  However,	  additional	  roles	  for	  these	  proteins	  in	  the	  absence	  of	  viral	  infection	  have	  not	  been	  investigated.	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SMN	  Plays	  a	  Role	  in	  DNA	  Repair	  and	  Transcription	  In	  the	  event	  of	  DNA	  damage,	  lysine	  79	  of	  Histone	  H3	  becomes	  methylated,	  which	  in	  turn	  recruits	  SMN	  through	  its	  Tudor	  domain	  (Sabra	  et	  al	  2013).	  Further	  supporting	  a	  role	  in	  DNA	  repair,	  SMN-­‐Gemin2	  complexes	  were	  found	  to	  stimulate	  RAD51-­‐mediated	  homologous	  recombination	  and	  double-­‐stranded	  break	  repair	  (Takaku	  et	  al	  2011).	  Another	  nuclear	  target	  of	  arginine	  methylation	  is	  the	  C-­‐terminal	  domain	  of	  RNA	  polymerase	  II	  (PolII-­‐CTD)	  (Zhao	  et	  al	  2016).	  Recently	  it	  was	  found	  that	  SMN	  is	  recruited	  to	  the	  transcription	  elongation	  complex	  by	  methylation	  of	  R1810	  within	  PolII	  CTD	  and	  interacts	  with	  senataxin	  in	  order	  to	  resolve	  the	  RNA-­‐DNA	  duplex	  formed	  during	  transcription	  and	  properly	  execute	  termination	  (Zhao	  et	  al	  2016).	  Interestingly,	  this	  is	  the	  second	  case	  of	  SMN	  assisting	  in	  resolving	  nucleic	  acid	  duplexes.	  	  
SMN	  and	  Associated	  Proteins	  Form	  a	  Nuclear	  Structure	  Known	  as	  Gems	  In	  the	  nucleus,	  SMN	  is	  primarily	  located	  in	  Cajal	  bodies	  and	  in	  nuclear	  structures	  known	  as	  Gems	  (Liu	  and	  Dreyfuss,	  1996).	  It	  is	  not	  currently	  known	  exactly	  what	  the	  function(s)	  of	  these	  nuclear	  bodies	  may	  be,	  but	  a	  loss	  of	  SMN	  in	  gems	  is	  correlated	  with	  incidence	  of	  amyotrophic	  lateral	  sclerosis	  (ALS)	  (Shan	  et	  al	  2010,	  Yamazaki	  et	  al	  2012).	  The	  signature	  protein	  marking	  Cajal	  bodies	  is	  coilin,	  which	  contains	  arginines	  which	  serve	  as	  methylation	  targets,	  thereby	  recruiting	  SMN	  through	  its	  Tudor	  domain	  (Hebert	  et	  al	  2001,	  Boisvert	  et	  al	  2002).	  A	  number	  of	  other	  SMN-­‐interacting	  proteins	  also	  become	  targeted	  to	  Cajal	  bodies/gems,	  such	  as	  ZPR1,	  all	  of	  the	  Gemins,	  and	  snoRNP	  markers	  Fibrillarin	  and	  GAR1	  (Ahmad	  et	  al	  2012,	  Pellizzoni	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et	  al	  2001).	  In	  addition	  to	  Gems/Cajal	  bodies,	  SMN	  and	  associated	  proteins	  have	  been	  shown	  to	  localize	  to	  the	  nucleolus	  in	  certain	  tissues	  and	  conditions	  (Charroux	  et	  al	  2000,	  Young	  et	  al	  2001,	  Wehner	  et	  al	  2002).	  
	  
SMN	  Functions	  in	  the	  Biogenesis	  of	  the	  Signal	  Recognition	  Particle	  The	  signal	  recognition	  particle	  (SRP)	  is	  an	  RNP	  complex	  that	  interacts	  with	  elongating	  polypeptides	  with	  N-­‐terminal	  signal	  peptides	  and	  targets	  them	  for	  translocation	  into	  the	  endoplasmic	  reticulum	  (Keenan	  et	  al	  2001,	  Saraogi	  and	  Shan	  2011).	  The	  SRP	  consists	  of	  the	  7S	  RNA	  that	  has	  two	  domains,	  the	  Alu	  domain,	  and	  the	  S-­‐domain,	  which	  are	  connected	  by	  a	  long	  stem	  (Keenan	  et	  al	  2001)	  and	  several	  protein	  components,	  named	  SRP9,	  14,	  19,	  54,	  68,	  and	  72	  (Saraogi	  and	  Shan	  2011).	  The	  7S	  RNA	  was	  initially	  identified	  in	  a	  screen	  of	  potential	  in	  vitro	  interacting	  partners	  with	  purified	  SMN	  complex	  (Piazzon	  et	  al	  2012).	  It	  was	  further	  shown	  that	  Gemin5	  directly	  binds	  the	  S-­‐domain	  and	  that	  the	  SMN	  complex	  is	  required	  for	  the	  assembly	  of	  the	  SRP54	  protein	  onto	  the	  7S	  RNA	  (Piazzon	  et	  al	  2012).	  In	  addition,	  the	  level	  of	  7S	  RNA	  was	  significantly	  reduced	  in	  the	  spinal	  cord	  of	  SMA	  model	  mice,	  indicating	  a	  requirement	  for	  high	  levels	  of	  SMN	  for	  proper	  expression	  of	  functional	  SRP	  (Piazzon	  et	  al	  2012).	  	  
Neuron-­‐Specific	  Functions	  of	  the	  SMN	  Protein	  	   SMA	  is	  primarily	  a	  disease	  of	  motor	  neurons	  (Burghes	  and	  Beattie	  2009);	  therefore,	  when	  considering	  functions	  of	  the	  SMN	  protein,	  any	  processes	  that	  are	  specific	  to	  neuronal	  cells	  are	  of	  particular	  interest.	  Within	  axons	  of	  cultured	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neuronal	  cells,	  SMN	  is	  localized	  to	  actively	  transported	  granules	  (Zhang	  et	  al	  2006).	  These	  SMN-­‐positive	  granules	  colocalize	  with	  a	  number	  of	  the	  Gemin	  proteins,	  but	  not	  the	  Sm	  proteins	  or	  Fibrillarin	  (Zhang	  et	  al	  2006,	  Todd	  et	  al	  2010).	  SMN	  interacts	  with	  the	  vesicle	  coat	  protein	  COPI	  (Peter	  et	  al	  2011,	  Custer	  et	  al	  2013),	  which	  may	  be	  the	  mechanism	  by	  which	  it	  is	  targeted	  to	  axons.	  In	  elongating	  axons,	  the	  growth	  cones	  are	  the	  site	  of	  local	  translation	  (Steward	  and	  Schuman	  2003,	  Colak	  et	  al	  2013,	  Fallini	  et	  al	  2016).	  Interestingly,	  SMN	  is	  known	  to	  interact	  with	  a	  number	  of	  RNA-­‐binding	  proteins	  (RBPs)	  (covered	  later)	  and	  knockdown	  of	  SMN	  in	  primary	  motor	  neurons	  results	  in	  redistribution	  of	  poly(A)+	  mRNA	  away	  from	  the	  axons	  to	  the	  cell	  body	  (Fallini	  et	  al	  2011).	  Therefore,	  a	  new	  model	  for	  SMN	  function	  has	  emerged,	  in	  which	  SMN	  interacts	  with	  mRNPs,	  either	  through	  interactions	  with	  RBPs	  or	  a	  potential	  direct	  interaction	  with	  mRNA	  itself,	  and	  assists	  in	  targeting	  these	  complexes	  to	  axons	  for	  transport	  and	  eventually	  local	  translation.	  	  Supporting	  this	  hypothesis,	  the	  first	  mRNA	  found	  to	  colocalize	  with	  SMN	  within	  axons	  is	  β-­‐actin	  (Rossoll	  et	  al	  2003),	  whose	  local	  translation	  has	  been	  shown	  to	  be	  critical	  for	  axon	  outgrowth	  and	  steering	  (Willis	  et	  al	  2005,	  Leung	  et	  al	  2006).	  More	  recently,	  CPG15	  and	  GAP43	  mRNAs,	  both	  critical	  for	  axon	  outgrowth,	  have	  been	  identified	  as	  colocalizing	  with	  SMN	  and	  are	  dependent	  on	  SMN	  expression	  for	  transport	  (Akten	  et	  al	  2011,	  Fallini	  et	  al	  2016).	  	   In	  addition	  to	  affecting	  axon	  outgrowth	  through	  local	  mRNA	  translation,	  SMN	  can	  also	  play	  a	  more	  direct	  role	  in	  axon	  growth	  by	  affecting	  actin	  filament	  dynamics.	  SMN	  interacts	  directly	  with	  Profilin	  (Giesemann	  et	  al	  1999,	  Bowerman	  et	  al	  2007,	  Nolle	  et	  al	  2011),	  which	  plays	  a	  critical	  role	  in	  actin	  polymerization	  (Pollard	  and	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Borisy	  2003),	  Annexin	  A2,	  which	  mediates	  interactions	  between	  cell	  membranes	  and	  the	  actin	  cytoskeleton	  (Shafey	  et	  al	  2010),	  and	  myosin	  regulatory	  light	  chain	  (MRLC)	  (Shafey	  et	  al	  2010).	  Supporting	  a	  direct	  role	  for	  actin	  dynamics	  and	  axonogenesis	  in	  the	  pathogenesis	  of	  SMA,	  actin	  bundling	  protein	  Plastin	  3	  has	  been	  identified	  as	  a	  protective	  disease	  modifier	  of	  SMA	  (Oprea	  et	  al	  2008).	  	  	  
SMN	  Interacts	  with	  Numerous	  RNA	  Binding	  Proteins	  	   Of	  all	  of	  the	  SMN	  protein’s	  diverse	  interactions,	  one	  overriding	  theme,	  though	  not	  necessarily	  universal,	  is	  the	  presence	  of	  both	  nucleic	  acids	  and	  protein.	  In	  fact,	  the	  SMN	  complex	  has	  been	  referred	  to	  as	  a	  general-­‐purpose	  RNP	  assembly	  machine	  (Battle	  et	  al	  2006).	  To	  that	  end,	  it	  is	  not	  surprising	  that	  SMN	  interacts	  with	  a	  large	  number	  of	  RBPs.	  Gemin5	  and	  U1-­‐70K	  have	  already	  been	  adressed	  (Yong	  et	  al	  2010,	  So	  et	  al	  2016).	  SMN	  also	  interacts	  directly	  with	  the	  RBP	  FUS,	  which	  is	  often	  mutated	  in	  amyotrophic	  lateral	  sclerosis	  (ALS)	  (Yamazaki	  et	  al	  2012).	  In	  addition,	  expression	  of	  mutant	  forms	  of	  FUS	  or	  another	  ALS-­‐causing	  protein	  TDP-­‐43	  results	  in	  redistribution	  of	  SMN	  from	  nuclear	  gems	  into	  cytoplasmic	  granules,	  implying	  that	  ALS	  and	  SMA	  may	  share	  similar	  mechanisms	  of	  pathogenesis	  (Yamazaki	  et	  al	  2012).	  Staying	  within	  the	  realm	  of	  RBPs	  containing	  small	  RNAs,	  SMN	  interacts	  directly	  with	  both	  Fibrillarin	  and	  GAR1,	  the	  primary	  protein	  components	  of	  snoRNPs	  (Pellizzoni	  et	  al	  2001).	  The	  presence	  of	  this	  interaction,	  in	  addition	  to	  a	  proposed	  role	  for	  SMN	  in	  loading	  SRP54	  onto	  the	  7S	  RNA	  of	  the	  signal	  recognition	  particle	  (SRP)	  (Piazzon	  et	  al	  2013),	  cements	  a	  general	  role	  for	  SMN	  in	  the	  assembly	  of	  functional	  RNPs.	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   SMN	  also	  interacts	  with	  a	  number	  of	  mRNA	  binding	  proteins	  which	  are	  involved	  in	  pre-­‐mRNA	  splicing,	  as	  well	  as	  mRNA	  stability	  and/or	  transport.	  In	  terms	  of	  splicing	  factors,	  SMN	  interacts	  with	  hnRNP	  Q	  and	  KH-­‐type	  splicing	  regulatory	  protein	  (KSRP)	  (Mourelatos	  et	  al	  2001,	  Rossoll	  et	  al	  2002,	  Tadesse	  et	  al	  2008).	  Numerous	  RBPs	  have	  been	  implicated	  in	  axonal	  RNP	  transport	  along	  with	  SMN.	  These	  include	  zipcode	  binding	  protein	  (ZBP)	  (Fallini	  et	  al	  2014),	  hnRNP	  R	  (Rossoll	  et	  al	  2002,	  Glinka	  et	  al	  2010),	  and	  HuD	  (Fallini	  et	  al	  2011).	  	  
Mouse	  Models	  of	  Spinal	  Muscular	  Atrophy	  	   In	  order	  to	  study	  the	  progression	  of	  any	  disease	  or	  to	  test	  potential	  treatments,	  it	  is	  critical	  to	  have	  a	  model	  that	  recapitulates	  the	  human	  disease	  as	  closely	  as	  possible.	  However,	  despite	  its	  simple	  genetic	  origins	  as	  an	  autosomal	  recessive	  disease,	  SMA	  is	  quite	  challenging	  to	  model	  successfully.	  This	  is	  due	  to	  the	  presence	  of	  SMN2,	  which	  is	  specific	  to	  humans.	  Without	  the	  presence	  of	  SMN2	  to	  compensate,	  deletion	  of	  Smn	  in	  mice	  is	  homozygous	  lethal	  in	  early	  embryonic	  stages	  (Schrank	  et	  al	  1997).	  Therefore,	  most	  mouse	  models	  of	  SMA	  are	  generated	  by	  reducing	  the	  level	  of	  SMN	  protein	  expression	  without	  eliminating	  it	  entirely,	  either	  by	  generating	  transgenic	  lines	  containing	  human	  SMN2	  or	  by	  modulating	  the	  expression	  of	  protein	  generated	  from	  the	  mouse	  Smn	  locus,	  or	  some	  combination	  of	  the	  two.	  	   The	  first	  SMA	  mouse	  models	  were	  generated	  by	  producing	  mice	  transgenic	  for	  the	  SMN2	  locus	  and	  crossing	  them	  with	  lines	  with	  null	  mutations	  of	  the	  Smn	  gene	  (Hsieh-­‐Li	  et	  al	  2000,	  Monani	  et	  al	  2000).	  	  Depending	  on	  the	  copy	  number	  of	  the	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transgene	  in	  question,	  mice	  were	  either	  phenotypically	  normal	  (in	  high	  copy	  number	  lines)	  or	  experienced	  severe	  SMA-­‐like	  symptoms,	  including	  a	  smaller	  size,	  decreased	  motor	  ability,	  and	  a	  near	  complete	  loss	  of	  the	  righting	  reflex,	  and	  generally	  died	  within	  4-­‐6	  days	  of	  birth	  (Monani	  et	  al	  2000).	  	   Due	  to	  the	  severity	  of	  their	  symptoms,	  the	  initial	  mouse	  models	  of	  SMA	  proved	  difficult	  to	  work	  with.	  In	  order	  to	  extend	  the	  survival	  of	  SMA	  mice,	  a	  new	  model	  was	  generated	  in	  which	  mice	  carrying	  multiple	  copies	  of	  a	  cDNA	  construct	  of	  SMN	  with	  exon	  7	  deleted	  (SMNΔ7)	  were	  crossed	  with	  existing	  transgenic	  mice	  harboring	  deletion	  of	  Smn	  and	  a	  single	  copy	  of	  SMN2	  (Le	  et	  al	  2005).	  The	  resulting	  mice	  (Smn-­‐/-­‐;SMN2;SMNΔ7,	  commonly	  referred	  to	  as	  Δ7	  mice)	  had	  a	  slightly	  ameliorated	  phenotype,	  with	  a	  mean	  survival	  of	  ~10	  days	  (Le	  et	  al	  2005).	  To	  this	  date,	  the	  Δ7	  model	  remains	  the	  most	  widely	  used	  mouse	  model	  of	  SMA.	  	   A	  number	  of	  conditional	  mouse	  models	  have	  also	  been	  generated.	  These	  usually	  fall	  into	  two	  categories:	  conditional	  rescue	  and	  conditional	  knockout.	  One	  of	  the	  earliest	  studies	  used	  conditional	  rescue	  using	  transgenic	  SMN	  under	  different	  promoters	  to	  show	  that	  neuronally	  expressed	  SMN	  under	  the	  control	  of	  the	  prion	  protein	  promoter	  was	  able	  to	  rescue	  knockout	  of	  Smn,	  but	  not	  SMN	  expressed	  in	  muscles	  under	  the	  control	  of	  the	  human	  skeletal	  actin	  promoter	  (Gavrilina	  et	  al	  2008).	  Later	  models	  used	  an	  inducible	  rescue	  by	  placing	  the	  neomycin	  resistance	  cassette	  within	  the	  mouse	  Smn	  gene	  flanked	  by	  LoxP	  sites,	  with	  Cre	  recombinase	  driven	  by	  different	  promoters	  (Hammond	  et	  al	  2010).	  On	  the	  flip	  side,	  conditional	  knockouts	  have	  also	  been	  generated.	  Mice	  deficient	  in	  SMN	  expression	  in	  motor	  neurons	  alone	  (Cifuentes-­‐Diaz	  et	  al	  2002)	  or	  in	  skeletal	  muscle	  alone	  (Cifuentes-­‐
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Diaz	  et	  al	  2001)	  both	  experience	  severe	  phenotypes,	  indicating	  that	  at	  least	  some	  expression	  of	  SMN	  is	  required	  in	  both	  tissues.	  	  	   More	  recently,	  an	  alternative	  approach	  was	  taken	  to	  generate	  a	  range	  of	  mouse	  models	  with	  simplified	  genetics.	  Rather	  than	  rely	  on	  separate	  knockout	  of	  
Smn	  and	  expression	  of	  SMN	  protein	  from	  transgenic	  inserts,	  the	  Smn	  locus	  itself	  was	  modified	  to	  modulate	  SMN	  expression	  using	  4	  alternative	  constructs	  which	  could	  be	  crossed	  to	  each	  other	  to	  produce	  a	  range	  of	  phenotypes	  (Osborne	  et	  al	  2012).	  This	  approach,	  termed	  the	  allelic	  series,	  was	  the	  first	  to	  generate	  a	  truly	  intermediate	  SMA	  mouse	  in	  the	  C	  allele,	  which	  was	  generated	  by	  replacing	  the	  last	  2	  exons	  of	  Smn	  with	  those	  of	  human	  SMN2,	  followed	  by	  a	  genomic	  fragment	  containing	  the	  entire	  
SMN2	  gene	  (exons+introns)	  (Osborne	  et	  al	  2012).	  Mice	  homozygous	  for	  the	  C	  allele	  (C/C)	  have	  a	  normal	  lifespan,	  but	  suffer	  from	  peripheral	  necrosis	  of	  the	  ears	  and	  tail,	  and	  have	  reduced	  body	  weight	  (Osborne	  et	  al	  2012).	  Later	  in	  life,	  C/C	  mice	  have	  altered	  electrophysiological	  properties	  at	  the	  neuromuscular	  junction,	  but	  no	  apparent	  defects	  in	  coordination	  or	  muscular	  strength	  (Osborne	  et	  al	  2012).	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Figure	  1.	  Overview	  of	  the	  SMN	  Protein.	  (A)	  Domains	  of	  the	  SMN	  protein.	  Colored	  boxes	  represent	  different	  exons,	  with	  exon	  designation	  given	  within	  each	  box.	  Locations	  of	  individual	  domains	  are	  indicated.	  (B)	  Interaction	  sites	  of	  the	  SMN	  protein.	  Labeling	  of	  exons	  is	  the	  same	  as	  in	  (A).	  Primary	  interacting	  partner	  of	  each	  designated	  region	  is	  given.	  (C)	  Locations	  of	  known	  SMA-­‐causing	  point	  mutations.	  Labeling	  of	  exons	  is	  the	  same	  as	  in	  (A).	  Position	  of	  each	  known	  mutation	  is	  indicated,	  labels	  give	  the	  specific	  amino	  acid	  change.	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Table	  1.	  Interacting	  partners	  of	  the	  SMN	  Protein	  Protein	   Function	  of	  Interaction	   Location	   Reference	  Gemin2	   snRNP	  assembly,	  DNA	  recombination	   Nucleus,	  cell	  body,	  axon	   Fischer	  et	  al	  1997,	  Liu	  et	  al	  1997,	  Zhang	  et	  al	  2003,	  Zhang	  et	  al	  2006,	  Todd	  et	  al	  2010,	  	  Takaku	  et	  al	  2011,	  Zhang	  et	  al	  2011	  Gemin3	   snRNP	  assembly	   Nucleus,	  cell	  body,	  axon	   Charroux	  et	  al	  1999,	  Todd	  et	  al	  2010	  Gemin4	   snRNP	  assembly	   Nucleus,	  cell	  body,	  axon	   Charroux	  et	  al	  2000,	  Todd	  et	  al	  2010	  Gemin5	   snRNP	  assembly	   Nucleus,	  cell	  body,	  axon	   Gubitz	  et	  al	  2002,	  Todd	  et	  al	  2010,	  Yong	  et	  al	  2010	  Gemin6	   snRNP	  assembly	   Nucleus,	  cell	  body,	  axon	   Pellizzoni	  et	  al	  2002a,	  Pellizzoni	  et	  al	  2002b,	  Todd	  et	  al	  2010	  Gemin7	   snRNP	  assembly	   Nucleus,	  cell	  body,	  axon	   Baccon	  et	  al	  2002,	  Todd	  et	  al	  2010	  Gemin8	   snRNP	  assembly	   Nucleus,	  cell	  body,	  axon	   Carissimi	  et	  al	  2006,	  Todd	  et	  al	  2010	  Unrip	   snRNP	  assembly	   Nucleus,	  cell	  body,	  axon	   Carissimi	  et	  al	  2005,	  Todd	  et	  al	  2010	  Fibrillarin	   snoRNP	  biogenesis	   Nucleus	   Pellizzoni	  et	  al	  2001	  GAR1	   snoRNP	  biogenesis	   Nucleus	   Pellizzoni	  et	  al	  2001	  hnRNP	  Q	   pre-­‐mRNA	  splicing,	  mRNA	  transport,	  axon	  outgrowth	   Nucleus,	  axon	   Mourelatos	  et	  al	  2001,	  Rossoll	  et	  al	  2002,	  Chen	  et	  al	  2012	  hnRNP	  R	   pre-­‐mRNA	  splicing,	  mRNA	  transport,	  axon	  outgrowth	   Nucleus,	  axon	   Rossoll	  et	  al	  2002,	  Glinka	  et	  al	  2010	  huD	   pre-­‐mRNA	  splicing,	  RNA	  stability,	  mRNA	  transport,	  axon	  outgrowth	  
Nucleus,	  axon	   Fallini	  et	  al	  2011	  
IMP1	   mRNA	  transport	   Axon	   Fallini	  et	  al	  2014	  KSRP	   pre-­‐mRNA	  splicing	   Nucleus	   Tadesse	  et	  al	  2008	  MRLC	   Muscle	  function	   Muscle	  (C2C12	  cells)	   Shafey	  et	  al	  2010	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Table	  1	  Continued	  ANXA2	   Cytoskeletal	  function	   Muscle	  (C2C12	  cells),	  neurons	  (PC12	  cells)	  	  
Shafey	  etal	  2010	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Abstract	  
	  Spinal	  muscular	  atrophy	  (SMA)	  is	  caused	  by	  low	  levels	  of	  survival	  motor	  neuron	  (SMN),	  a	  multifunctional	  protein	  essential	  for	  higher	  eukaryotes.	  While	  SMN	  is	  one	  of	  the	  most	  scrutinized	  proteins	  associated	  with	  neurodegeneration,	  its	  gender-­‐specific	  role	  in	  vertebrates	  remains	  unknown.	  We	  utilized	  a	  mild	  SMA	  model	  (C/C	  model)	  to	  examine	  the	  impact	  of	  low	  SMN	  on	  growth	  and	  development	  of	  mammalian	  sex	  organs.	  We	  show	  impaired	  testis	  development,	  degenerated	  seminiferous	  tubules,	  reduced	  sperm	  count	  and	  low	  fertility	  in	  C/C	  males,	  but	  no	  overt	  sex	  organ	  phenotype	  in	  C/C	  females.	  Underscoring	  an	  increased	  requirement	  for	  SMN	  expression,	  wild	  type	  testis	  showed	  extremely	  high	  levels	  of	  SMN	  protein	  compared	  to	  other	  tissues.	  Our	  results	  revealed	  severe	  perturbations	  in	  pathways	  critical	  to	  C/C	  male	  reproductive	  organ	  development	  and	  function,	  including	  steroid	  biosynthesis,	  apoptosis,	  and	  spermatogenesis.	  Consistent	  with	  enhanced	  apoptosis	  in	  seminiferous	  tubules	  of	  C/C	  testes,	  we	  recorded	  a	  drastic	  increase	  in	  cells	  with	  DNA	  fragmentation.	  SMN	  was	  expressed	  at	  high	  levels	  in	  adult	  C/C	  testis	  due	  to	  an	  adult-­‐specific	  splicing	  switch,	  but	  could	  not	  compensate	  for	  low	  levels	  during	  early	  testicular	  development.	  Our	  findings	  uncover	  novel	  hallmarks	  of	  SMA	  disease	  progression	  and	  link	  SMN	  to	  general	  male	  infertility.	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Introduction	  Spinal	  muscular	  atrophy	  (SMA)	  is	  a	  leading	  genetic	  cause	  of	  infant	  mortality	  (Awano	  et	  al	  2014)	  and	  results	  from	  deletion	  and/or	  mutation	  of	  survival	  motor	  neuron	  1	  (SMN1),	  a	  gene	  that	  codes	  for	  SMN	  protein	  (Awano	  et	  al	  2014).	  A	  nearly	  identical	  gene,	  SMN2,	  cannot	  compensate	  for	  the	  loss	  of	  SMN1	  due	  to	  predominant	  skipping	  of	  exon	  7,	  producing	  SMNΔ7,	  a	  truncated	  protein	  that	  is	  partially	  functional	  and	  highly	  unstable	  (Cho	  and	  Dreyfuss	  2010).	  The	  severity	  of	  SMA	  correlates	  with	  the	  level	  of	  SMN,	  a	  multifunctional	  protein	  implicated	  in	  regulation	  of	  small	  nuclear	  heteronuclear	  ribonucleoprotein	  (snRNP)	  biogenesis,	  transcription,	  translation,	  stress	  granule	  formation,	  signal	  transduction	  and	  axonal	  transport	  of	  mRNA	  (references	  in	  Seo	  et	  al,	  2013).	  Motor	  neurons	  are	  particularly	  sensitive	  to	  the	  loss	  of	  SMN,	  although	  reduced	  SMN	  independently	  affects	  non-­‐neuronal	  tissues,	  including	  muscle	  (Boyer	  et	  al	  2013),	  heart	  (Heier	  et	  al	  2010),	  lungs,	  and	  intestine	  (Schreml	  et	  al	  2013).	  SMN	  is	  required	  for	  male	  germ	  cell	  maintenance	  in	  Drosophila	  (Grice	  et	  al	  2011),	  however,	  no	  parallel	  can	  be	  drawn	  with	  mammalian	  spermatogenesis,	  which	  occurs	  within	  the	  specialized	  microenvironment	  of	  seminiferous	  tubules.	  	  	   Multiple	  mouse	  models	  recapitulating	  various	  aspects	  of	  SMA	  have	  been	  generated	  (Bebee	  et	  al	  2012).	  The	  Taiwanese	  and	  Δ7	  mice,	  the	  best	  characterized	  and	  most	  widely	  utilized	  models,	  exhibit	  severe	  phenotypes,	  including	  early	  postnatal	  lethality,	  impaired	  maturation	  of	  neuromuscular	  junctions	  and	  overall	  deficient	  motor	  function	  (Awano	  et	  al	  2014,	  Bebee	  et	  al	  2012).	  However,	  due	  to	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their	  short	  lifespan,	  these	  models	  are	  not	  appropriate	  for	  examining	  the	  role	  of	  SMN	  in	  male	  reproductive	  organ	  development.	  The	  testis	  is	  unique	  in	  producing	  higher	  SMN	  levels	  due	  to	  predominant	  expression	  of	  full-­‐length	  SMN2	  transcripts	  compared	  to	  all	  other	  adult	  tissues	  and	  organs	  of	  a	  mild	  mouse	  model	  of	  SMA	  (Chen	  et	  al	  2008,	  Chen	  et	  al	  2015).	  Alternative	  splicing	  of	  several	  genes	  are	  switched	  during	  testicular	  development	  (Schmid	  et	  al	  2013).	  However,	  it	  is	  not	  known	  if	  
SMN2	  exon	  7	  undergoes	  a	  similar	  switch.	  	  	  The	  recently	  reported	  SmnC/C	  (C/C)	  model	  expresses	  a	  reduced	  amount	  of	  SMN	  (~25-­‐50%	  of	  WT)	  and	  displays	  a	  mild	  SMA-­‐like	  phenotype,	  including	  peripheral	  necrosis,	  autonomic	  nervous	  system	  dysfunction	  and	  allodynia	  (Osborne	  et	  al	  2012).	  Here	  we	  employ	  the	  C/C	  mouse	  to	  examine	  the	  role	  of	  SMN	  in	  reproductive	  organ	  development.	  We	  observed	  reduced	  testis	  size	  and	  impaired	  spermatogenesis	  in	  C/C	  mice,	  despite	  high	  SMN	  expression	  in	  testis.	  We	  show	  severe	  perturbations	  of	  the	  testicular	  transcriptome	  in	  young	  adult	  C/C	  mice,	  suggesting	  massive	  reprogramming	  of	  transcription	  and	  posttranscriptional	  regulation.	  Our	  results	  uncover	  a	  surprising	  shift	  in	  splicing	  regulation	  of	  various	  




C/C	  males	  exhibit	  small	  testes	  with	  impaired	  spermatogenesis	  and	  reduced	  
fertility	  	  To	  determine	  the	  effect	  of	  low	  SMN	  on	  reproductive	  organ	  development,	  we	  examined	  wild	  type	  (WT)	  and	  C/C	  mice	  at	  postnatal	  day	  42	  (P42).	  At	  this	  age,	  mice	  have	  completed	  the	  first	  wave	  of	  spermatogenesis.	  Notably,	  we	  observed	  substantially	  smaller	  testes	  in	  C/C	  males	  even	  after	  correcting	  for	  body	  weight	  (Figs.1a-­‐c).	  Testosterone	  is	  a	  crucial	  hormone	  regulating	  testis	  development,	  however,	  we	  observed	  no	  significant	  difference	  in	  serum	  testosterone	  between	  WT	  and	  C/C	  mice	  (Fig.	  1d).	  Histological	  analyses	  of	  C/C	  testes	  showed	  heterogeneity	  of	  seminiferous	  tubules,	  with	  evidence	  of	  degeneration,	  including	  vacuolization,	  multinucleated	  bodies	  and	  sloughed	  cells	  (Fig.	  1e,	  right	  panel).	  We	  assessed	  the	  health	  of	  seminiferous	  tubules	  using	  an	  established	  scale	  (Daigle	  et	  al	  2009).	  The	  average	  score	  for	  C/C	  testes	  indicated	  an	  overall	  reduction	  in	  post-­‐meiotic	  cells	  and	  disrupted	  spermatogenesis	  (Fig.	  1f).	  Histology	  of	  C/C	  epididymis	  showed	  a	  lack	  of	  or	  reduced	  number	  of	  spermatozoa	  in	  tubules	  of	  all	  regions	  (Fig.	  1g).	  Consistently,	  we	  observed	  a	  ~10-­‐fold	  reduction	  in	  epididymal	  sperm	  count	  in	  P60	  C/C	  males	  compared	  to	  WT	  males	  (Fig.	  1h),	  indicating	  that	  spermatogenesis	  was	  impaired,	  but	  not	  globally	  arrested.	  	   Unlike	  testes,	  C/C	  female	  reproductive	  organs	  appeared	  normal,	  although	  variable	  in	  size	  (Fig.	  2a).	  Gross	  uterus/ovaries	  mass	  was	  reduced	  for	  C/C	  females	  (Fig.	  2b),	  but	  not	  after	  correction	  by	  total	  body	  weight	  (Fig.	  2c).	  Beyond	  the	  gross	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weight	  difference,	  there	  were	  no	  overt	  histological	  changes	  in	  C/C	  uterus	  and	  ovaries	  (Fig.	  2d).	  Ovaries	  from	  females	  of	  both	  genotypes	  exhibited	  follicles	  with	  oocytes	  in	  various	  stages,	  and	  the	  corpus	  luteum	  and	  uterus	  appeared	  normal	  (Fig.	  2d).	   	  
	   In	  order	  to	  evaluate	  the	  fertility	  of	  C/C	  mice,	  we	  set	  up	  breeding	  cages	  with	  different	  combinations	  of	  WT,	  C/C,	  and	  heterozygous	  (C/+)	  mice	  (Supplementary	  Table	  1)	  and	  followed	  them	  for	  ninety	  days.	  WT	  males	  all	  sired	  multiple	  litters	  of	  pups	  (Supplementary	  Table	  1).	  In	  contrast,	  only	  two	  of	  the	  eight	  C/C	  males	  sired	  a	  litter:	  one	  male	  paired	  with	  a	  WT	  female	  and	  another	  paired	  with	  a	  C/C	  female	  (Supplementary	  Table	  1).	  Both	  sired	  only	  one	  litter	  and	  neither	  female	  appeared	  pregnant	  again	  after	  giving	  birth.	  The	  fact	  that	  two	  C/C	  males	  were	  able	  to	  sire	  at	  least	  one	  litter	  despite	  very	  low	  sperm	  count	  suggests	  no	  debilitating	  defect	  in	  sperm	  motility	  and/or	  fertilization.	  In	  contrast,	  C/C	  females	  were	  fertile;	  over	  a	  90	  day	  period,	  there	  was	  no	  significant	  difference	  in	  number	  of	  litters	  born	  (Fig.	  2e)	  or	  litter	  size	  (Fig.	  2f)	  compared	  to	  heterozygote	  females	  (Supplementary	  Table	  1).	  	  
	  
High	  levels	  of	  SMN	  are	  expressed	  in	  C/C	  testis	  	  The	  recently	  developed	  multi-­‐exon-­‐skipping	  detection	  assay	  (MESDA)	  determines	  the	  relative	  abundance	  of	  all	  SMN	  splice	  isoforms	  in	  a	  single	  reaction	  (Singh	  et	  al	  2012).	  We	  employed	  MESDA	  on	  various	  tissues	  of	  C/C	  mice.	  Consistent	  with	  previous	  reports	  (Chen	  et	  al	  2008,	  Chen	  et	  al	  2015),	  testis	  emerged	  as	  the	  only	  tissue	  to	  have	  full-­‐length	  SMN2	  transcript	  as	  the	  major	  product	  (Fig.	  3b),	  and	  the	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only	  tissue	  to	  express	  appreciable	  amounts	  of	  full-­‐length	  product	  from	  the	  hybrid	  
Smn	  gene	  (Fig.	  3c).	  Supporting	  a	  heightened	  requirement	  for	  SMN	  in	  testis,	  we	  confirmed	  that	  there	  was	  a	  very	  high	  expression	  of	  SMN	  protein	  in	  WT	  testis	  compared	  to	  all	  other	  tissues,	  including	  brain	  and	  spinal	  cord	  (Fig.	  3d).	  When	  we	  compared	  SMN	  levels	  in	  C/C	  and	  WT	  tissues,	  we	  observed	  a	  ~50%	  reduction	  in	  brain,	  liver,	  heart,	  and	  uterus/ovaries	  of	  C/C	  mice	  (Fig.	  3e-­‐h).	  However,	  there	  was	  no	  difference	  in	  SMN	  protein	  between	  WT	  and	  C/C	  testes	  (Fig.	  3h).	  Although	  consistent	  with	  the	  results	  of	  MESDA,	  the	  lack	  of	  SMN	  reduction	  in	  testis	  was	  at	  odds	  with	  the	  drastic	  phenotype	  and	  may	  indicate	  one	  or	  more	  of	  the	  following:	  (i)	  SMN	  expression	  is	  reduced	  at	  an	  earlier	  developmental	  stage	  which	  causes	  defects	  at	  later	  time	  points;	  (ii)	  the	  cell	  types	  with	  low	  SMN	  expressions	  are	  already	  lost	  by	  P42;	  (iii)	  or	  the	  testis	  phenotype	  is	  an	  indirect	  result	  of	  low	  SMN	  levels	  in	  other	  tissues,	  such	  as	  the	  nervous	  system.	  	  
C/C	  testis	  transcriptome	  is	  dramatically	  altered	  	  We	  performed	  deep	  sequencing	  of	  the	  testis	  as	  well	  as	  brain	  and	  liver	  transcriptome	  of	  WT	  and	  C/C	  mice	  (Supplementary	  Table	  2)	  to	  characterize	  molecular	  changes	  in	  these	  tissues	  (Sequence	  Read	  Archive	  accession	  number	  SRP062636).	  During	  initial	  quality	  control,	  we	  determined	  that	  one	  sample	  derived	  from	  a	  C/C	  testis	  was	  an	  outlier;	  it	  was	  removed	  from	  all	  further	  analysis.	  Using	  the	  remaining	  replicates,	  we	  identified	  3,724	  differentially	  expressed	  genes	  using	  a	  false	  discovery	  rate	  (FDR)	  cutoff	  of	  0.05,	  with	  2,186	  genes	  upregulated	  and	  1,538	  downregulated	  in	  C/C	  testes	  (Fig.	  4a).	  In	  contrast,	  very	  few	  genes	  showed	  aberrant	  expression	  in	  C/C	  brain	  and	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liver	  (Fig.	  4a)	  Summary	  statistics	  for	  the	  50	  most	  significantly	  upregulated	  and	  downregulated	  genes	  are	  given	  in	  Supplementary	  Tables	  3	  and	  4.	  	  	   Several	  Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes	  (KEGG)	  pathways	  and	  gene	  ontology	  (GO)	  terms	  were	  disproportionately	  affected	  in	  C/C	  testes.	  The	  top	  25	  enriched	  pathways	  in	  C/C	  testis	  are	  shown	  in	  Fig.	  4b,	  including	  apoptosis,	  cell	  and	  extracellular	  matrix	  interaction	  (potential	  problems	  with	  tissue	  organization	  and/or	  integrity)	  and	  cardiomyopathy	  and	  smooth	  muscle	  contraction	  (potential	  problems	  with	  blood	  flow	  and/or	  transport	  of	  spermatozoa	  to	  epididymis).	  GO	  term	  analysis	  was	  somewhat	  less	  informative	  (Supplementary	  Figs.	  S1-­‐S3),	  although	  several	  GO	  terms	  associated	  with	  spermatogenesis	  were	  enriched	  in	  the	  list	  of	  downregulated	  genes	  (Supplementary	  Fig.	  S3).	  We	  also	  examined	  expression	  of	  several	  genes	  that	  are	  previously	  identified	  to	  be	  mutated	  in	  cases	  of	  oligospermia	  (Hwang	  et	  al	  2010);	  of	  the	  fourteen	  genes,	  six	  (H19,	  Klhl10,	  Prm1,	  Shbg,	  Tssk4,	  and	  Vasa)	  showed	  significantly	  altered	  expression	  in	  C/C	  testes	  (Supplementary	  Fig.	  4).	  Aside	  from	  pathways	  and	  genes,	  we	  also	  detected	  changes	  suggesting	  altered	  enrichment	  of	  genes	  in	  specific	  groups	  of	  testicular	  cell	  types	  (Margolin	  et	  al	  2014).	  Consistent	  with	  our	  histological	  analyses,	  genes	  that	  are	  highly	  expressed	  in	  somatic	  and	  early	  spermatogenic	  cell	  types	  were	  strongly	  enriched,	  and	  genes	  expressed	  in	  late	  spermatocytes	  and	  spermatids	  were	  found	  to	  be	  downregulated	  (Fig.	  4c).	  We	  also	  examined	  the	  relative	  expression	  of	  individual	  markers	  specific	  for	  testicular	  cell	  types	  (Supplementary	  Fig.	  5).	  These	  results	  suggest	  extensive	  cell	  death	  of	  pachytene	  spermatocytes	  and/or	  arrest	  of	  zygotene	  spermatocytes	  in	  C/C	  testes.	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  We	  independently	  validated	  the	  results	  of	  RNA-­‐Seq	  by	  quantitative	  PCR	  (QPCR)	  of	  >50	  candidate	  genes	  (full	  list	  in	  Supplementary	  Table	  5).	  There	  was	  a	  strong	  correlation	  (r2=0.8376)	  between	  RNA-­‐Seq	  and	  QPCR	  results	  (Fig.	  4d).	  Five	  genes	  in	  particular	  (Lamb2,	  Ddr1,	  Apoe,	  Cpe,	  SerpinG1)	  were	  highly	  upregulated,	  ranging	  from	  ~1.5-­‐4	  fold	  above	  WT	  (Fig.	  4e).	  We	  also	  tested	  four	  genes,	  which	  were	  predicted	  by	  RNA-­‐Seq	  to	  be	  highly	  downregulated.	  Of	  these,	  Npy,	  a	  gene	  that	  codes	  for	  neuropeptide	  Y	  pro-­‐protein,	  was	  strongly	  downregulated,	  though	  Npy	  expression	  was	  highly	  variable.	  The	  other	  three	  genes	  (Tppp2,	  Ppp2r2b,	  and	  Oaz3)	  all	  trended	  downward,	  but	  the	  decrease	  was	  only	  statistically	  significant	  for	  Tppp2	  (Fig.	  4f).	  Of	  the	  five	  steroid	  biosynthesis	  genes	  (Lss,	  Msmo1,	  Dhcr7,	  Lipa,	  and	  Dhcr24)	  that	  we	  tested,	  all	  were	  significantly	  upregulated	  (Fig.	  4g).	  In	  addition,	  we	  tested	  5	  genes	  participating	  in	  spermatogenesis;	  however,	  although	  all	  trended	  downward,	  we	  observed	  a	  significant	  decrease	  only	  in	  Gapdhs	  (Fig.	  4h).	  Many	  genes	  involved	  in	  axon	  guidance	  were	  affected;	  of	  these,	  the	  five	  most	  strongly	  upregulated	  were	  
Ephb1,	  Efnb1,	  Ntn3,	  Cxcl12,	  and	  Slit3	  (Fig.	  4i).	  Ppp3r2	  was	  the	  only	  gene	  in	  this	  category	  that	  was	  significantly	  downregulated	  (Fig.	  4i).	  Several	  long	  non-­‐coding	  RNAs	  (lncRNAs)	  had	  altered	  expression	  levels	  in	  C/C	  testes.	  Of	  the	  five	  that	  were	  validated,	  Meg3,	  Neat1,	  and	  Malat1	  were	  strongly	  upregulated	  (Fig.	  4j).	  We	  examined	  the	  expression	  of	  all	  the	  Gemins,	  which	  code	  for	  proteins	  associated	  with	  SMN	  complex	  assembly	  and	  function.	  Only	  Gemin4	  was	  significantly	  downregulated	  (Fig.	  4k).	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Apoptotic	  pathways	  are	  dysregulated	  in	  C/C	  testes	  	  Our	  RNA-­‐Seq	  results	  suggested	  significant	  dysregulation	  of	  the	  apoptotic	  pathways	  in	  C/C	  testes	  (Fig.	  4b),	  with	  much	  fewer	  changes	  in	  brain	  and	  liver	  (Fig.	  5a).	  We	  confirmed	  by	  QPCR	  that	  a	  number	  of	  pro-­‐	  (Bax,	  Casp7,	  Casp8,	  Casp9,	  Capn2,	  Aifm1)	  and	  anti-­‐	  (Bcl3,	  Akt)	  apoptotic	  genes	  were	  significantly	  upregulated	  in	  C/C	  testis	  (Fig.	  5b),	  but	  not	  in	  brain	  (Fig.	  5c)	  or	  liver	  (Fig.	  5d).	  Terminal	  deoxynucleotidyl	  transferase	  dUTP	  nick	  end	  labeling	  (TUNEL)	  staining,	  which	  detects	  DNA	  fragmentation	  usually	  associated	  with	  apoptosis,	  revealed	  a	  ~3-­‐fold	  increase	  in	  the	  percentage	  of	  seminiferous	  tubules	  with	  at	  least	  one	  TUNEL-­‐positive	  cell	  (Fig.	  5e,f).	  We	  also	  observed	  a	  significant	  increase	  in	  the	  average	  number	  of	  TUNEL-­‐positive	  cells	  per	  tubule	  (Fig.	  5g).	  For	  WT	  testes,	  TUNEL-­‐positive	  cells	  were	  predominantly	  spermatocytes	  and	  the	  remaining	  were	  spermatogonia	  (Fig.	  5h).	  These	  WT	  TUNEL-­‐positive	  cells	  most	  likely	  represented	  damaged	  germ	  cells	  that	  must	  be	  eliminated	  before	  meiotic	  division	  into	  abnormal	  spermatids	  (Aitken	  et	  al	  2011).	  Most	  TUNEL-­‐positive	  cells	  in	  C/C	  testes	  were	  spermatocytes,	  similar	  to	  WT,	  but	  we	  also	  observed	  TUNEL	  staining	  of	  a	  small	  number	  of	  Sertoli	  cells	  and	  round	  spermatids	  (Fig.	  5h).	  Since	  depletion	  of	  Sertoli	  cells	  can	  have	  drastic	  consequences	  for	  germ	  cell	  health	  (Orth	  et	  al	  1988),	  increased	  apoptosis	  in	  spermatogonia	  and	  spermatocytes	  may	  be	  due	  to	  dysfunction	  of	  Sertoli	  cells,	  or	  vice	  versa.	  Immunostaining	  for	  cleaved	  caspase	  3,	  a	  marker	  for	  apoptosis,	  revealed	  positive	  spermatogonia	  (Fig.	  5i,	  panel	  I),	  spermatocytes	  (panel	  II)	  and	  multinucleated	  bodies	  (panel	  III)	  in	  C/C	  testes,	  but	  a	  lack	  of	  cleaved	  caspase	  3-­‐positive	  cells	  in	  WT	  testes	  (panel	  IV).	  This	  observation	  further	  underscores	  that	  apoptosis	  is	  dysregulated	  in	  C/C	  testes.	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SMN2	  undergoes	  splicing	  switch	  during	  testicular	  development	  	  The	  first	  wave	  of	  spermatogenesis	  in	  mice	  occurs	  from	  P10	  to	  P35.	  This	  process	  is	  characterized	  by	  synchronous	  transitions	  from	  one	  cell	  type	  to	  another	  and	  marked	  by	  predictable	  changes	  in	  the	  testis	  transcriptome	  (Bellve	  et	  al	  1977,	  Margolin	  et	  al	  2014)	  (Fig.	  6a).	  We	  employed	  MESDA	  to	  capture	  splicing	  of	  SMN2	  exons	  during	  the	  first	  wave	  of	  spermatogenesis.	  In	  particular,	  we	  compared	  the	  splicing	  pattern	  of	  
SMN2	  in	  P7	  testes,	  when	  spermatogonia	  are	  the	  predominant	  germ	  cell	  type,	  with	  testes	  undergoing	  meiosis	  (P10,	  P12	  and	  P18),	  and	  near	  the	  end	  (P30)	  and	  after	  completion	  of	  the	  first	  wave	  of	  spermatogenesis	  (P42).	  We	  observed	  a	  dramatic	  shift	  in	  SMN2	  exon	  7	  splicing	  from	  overwhelming	  skipping	  at	  P7	  to	  higher	  inclusion	  at	  P18	  and	  later	  (Fig.	  6b).	  We	  also	  observed	  increased	  skipping	  of	  exon	  5	  and	  decreased	  co-­‐skipping	  of	  exons	  3	  and	  7	  at	  later	  time	  points	  (Fig.	  6b).	  With	  regards	  to	  hybrid	  Smn	  (Fig.	  3a),	  there	  was	  an	  increase	  in	  exon	  7	  inclusion	  starting	  at	  P18	  (Fig.	  6c).	  Our	  findings	  represent	  the	  first	  report	  of	  a	  shift	  in	  SMN2	  splicing	  pattern	  during	  testis	  development.	  Increased	  SMN2	  exon	  7	  inclusion	  coincided	  with	  the	  completion	  of	  initial	  stages	  of	  meiosis	  and	  likely	  occurred	  in	  spermatocytes	  and	  spermatids.	  
SMN2	  transcripts	  of	  somatic	  testicular	  cells	  and	  spermatogonia,	  which	  are	  more	  highly	  represented	  at	  early	  time	  points	  were	  likely	  still	  dominated	  by	  exon	  7	  skipped	  forms,	  and	  therefore	  likely	  had	  a	  deficiency	  in	  SMN	  protein	  expression.	  	  	  	   Previous	  evidence	  suggested	  that	  hnRNP	  Q	  and	  Tra2β	  are	  important	  for	  
SMN2	  exon	  7	  inclusion	  in	  testes	  (Chen	  et	  al	  2008,	  Chen	  et	  al	  2015).	  Thus,	  we	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examined	  whether	  changes	  in	  expression	  of	  splicing	  factors	  known	  to	  regulate	  
SMN2	  exon	  7	  splicing	  coincided	  with	  the	  changes	  in	  SMN2	  splicing	  during	  testis	  development.	  hnRNP	  A1	  and	  Q	  protein	  levels	  were	  highest	  at	  P7	  and	  dropped	  during	  testis	  development,	  dramatically	  so	  in	  the	  case	  of	  hnRNP	  A1	  (Fig.	  6d).	  Since	  hnRNP	  Q	  was	  expressed	  at	  relatively	  low	  levels	  at	  P18	  and	  P30,	  when	  SMN2	  exon	  7	  inclusion	  increased,	  it	  likely	  did	  not	  play	  a	  role	  in	  the	  splicing	  switch.	  hnRNP	  A1,	  however,	  is	  a	  known	  negative	  regulator	  of	  SMN2	  exon	  7	  inclusion,	  so	  its	  low	  expression	  in	  later	  time	  points	  is	  consistent	  with	  the	  change	  in	  exon	  7	  splicing.	  Tra2β	  was	  expressed	  at	  the	  highest	  levels	  at	  P18	  and	  P30,	  when	  SMN2	  exon	  7	  inclusion	  is	  highest,	  followed	  by	  a	  decrease	  at	  P42	  (Fig.	  6d).	  hnRNP	  A2/B1,	  a	  negative	  regulator	  of	  SMN2	  exon	  7	  inclusion,	  had	  a	  nearly	  identical	  expression	  pattern.	  Overall,	  these	  data	  indicate	  that	  multiple	  splicing	  factors	  contribute	  to	  the	  
SMN2	  splicing	  pattern	  we	  observe	  during	  early	  stages	  of	  testicular	  development.	  	  	   In	  order	  to	  further	  verify	  that	  SMN	  levels	  are	  altered	  during	  testis	  development,	  we	  first	  established	  baseline	  expression	  during	  the	  first	  wave	  of	  spermatogenesis	  using	  primers	  targeted	  to	  mouse	  Smn	  mRNA	  in	  WT	  testes.	  Smn	  expression	  peaked	  at	  P18	  and	  P30	  and	  then	  dropped	  slightly	  at	  P42	  (Fig.	  7a).	  In	  contrast,	  full-­‐length	  SMN2	  expression	  in	  C/C	  testes	  dramatically	  increased	  at	  P18	  and	  held	  steady	  thereafter	  (Fig.	  7b).	  We	  next	  examined	  how	  SMN	  protein	  expression	  changed	  during	  testis	  development.	  In	  WT	  testes,	  SMN	  protein	  (derived	  from	  Smn)	  steadily	  increased	  and	  peaked	  at	  P30	  with	  a	  slight	  decrease	  at	  P42	  (Fig.	  7c).	  In	  C/C	  testes,	  however,	  SMN	  protein	  (derived	  from	  SMN2	  and	  hybrid	  Smn)	  was	  low	  until	  a	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marked	  increase	  at	  P18,	  peak	  expression	  at	  P30	  and	  a	  subsequent	  decrease	  at	  P42	  (Fig.	  7d).	  When	  SMN	  protein	  was	  compared	  between	  the	  genotypes,	  C/C	  SMN	  protein	  level	  was	  approximately	  half	  the	  WT	  level	  from	  P7	  to	  P12,	  but	  by	  P18	  there	  was	  no	  significant	  difference	  between	  the	  genotypes	  (Fig.	  7e,f).	  We	  also	  examined	  expression	  of	  Gemin2,	  a	  protein	  that	  interacts	  with	  SMN.	  Similar	  to	  SMN,	  Gemin2	  protein	  level	  was	  reduced	  by	  about	  half	  from	  P7	  to	  P12	  in	  C/C	  testes.	  Gemin2	  rose	  to	  near	  WT	  level	  by	  P30	  followed	  by	  a	  drop	  at	  P42	  (Fig.	  7e,g).	  This	  disparity	  in	  SMN	  and	  Gemin2	  levels	  may	  suggest	  a	  deficiency	  of	  SMN	  functions	  mediated	  by	  Gemin2.	  
	  
Dysregulation	  of	  alternative	  splicing	  in	  adult	  C/C	  testes	  To	  confirm	  that	  critical	  alternative	  splicing	  events	  are	  affected	  during	  C/C	  testes	  development,	  we	  examined	  splicing	  patterns	  of	  several	  genes	  known	  to	  undergo	  regulated	  alternative	  splicing	  during	  spermatogenesis.	  Add3	  exon	  14	  inclusion	  increases	  during	  spermatogonia	  differentiation	  (Schmid	  et	  al	  2013).	  Both	  WT	  and	  C/C	  testes	  exhibited	  a	  similar	  increase	  in	  Add3	  exon	  14	  inclusion,	  but	  at	  P42	  there	  was	  a	  decrease	  in	  exon	  14	  inclusion	  in	  C/C	  compared	  to	  WT	  (Fig.	  8a).	  Lrrc16a	  exon	  38	  splicing	  is	  somewhat	  complicated:	  pattern	  changes	  from	  predominant	  exclusion	  to	  inclusion	  during	  Sertoli	  cell	  maturation	  and	  spermatogonia	  differentiation	  while	  round	  spermatids	  exhibit	  predominant	  exclusion	  (Schmid	  et	  al	  2013).	  In	  C/C	  testes,	  exon	  38	  inclusion	  followed	  a	  pattern	  similar	  to	  WT	  at	  P7	  and	  P18,	  but	  not	  P10,	  and	  subtle	  differences	  emerged	  at	  P30	  and	  P42	  (Fig.	  8b).	  In	  Sertoli	  cells	  and	  spermatogonia,	  there	  is	  a	  mix	  of	  Picalm	  exon	  13	  inclusion	  and	  exclusion,	  while	  spermatocytes	  and	  round	  spermatids	  exhibit	  predominant	  exon	  13	  inclusion11.	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Splicing	  of	  Picalm	  was	  similar	  for	  WT	  and	  C/C	  testes	  except	  at	  P42	  where	  there	  was	  more	  exon	  13	  exclusion	  in	  C/C	  (Fig.	  8c).	  Prevalence	  of	  a	  Picalm	  exon	  13	  alternative	  3ʹ′	  splice	  site	  was	  similar	  in	  WT	  and	  C/C	  testes	  (Fig.	  8c).	  	  	  	   In	  addition,	  RNA-­‐Seq	  data	  revealed	  differential	  regulation	  of	  alternative	  splicing	  of	  several	  genes.	  We	  selected	  two	  such	  genes	  for	  validation.	  Wt1	  is	  a	  tumor	  suppressor	  gene	  and	  essential	  for	  proper	  urogenital	  development	  (Kreidberg	  et	  al	  1993).	  In	  WT	  testes,	  Wt1	  exon	  5	  is	  predominantly	  skipped	  at	  P7,	  with	  a	  gradual	  increase	  in	  inclusion	  up	  to	  P30	  (Fig.	  8d).	  C/C	  testes	  showed	  a	  similar	  pattern,	  but	  there	  was	  a	  decrease	  in	  exon	  5	  inclusion	  compared	  to	  WT	  testes	  at	  P30	  and	  P42	  (Fig.	  8d).	  Skipping	  of	  Sulf1	  exon	  21	  is	  predicted	  to	  cause	  a	  frameshift	  eliminating	  the	  stop	  codon	  and	  resulting	  in	  a	  much	  longer	  protein.	  In	  WT	  testes,	  Sulf1	  exon	  21	  shifted	  from	  complete	  inclusion	  at	  P7	  to	  roughly	  40%	  at	  P18,	  then	  subsequently	  increased	  again	  (Fig.	  8e).	  In	  C/C	  testes,	  exon	  21	  skipping	  remained	  the	  predominant	  event	  (Fig.	  8e).	  	  	  
Gene	  expression	  of	  candidate	  genes	  is	  not	  affected	  until	  after	  puberty	  Having	  observed	  the	  preponderance	  of	  splicing	  changes	  between	  P30	  and	  P42	  in	  C/C	  testes,	  we	  wanted	  to	  know	  whether	  expression	  of	  key	  genes	  followed	  a	  similar	  pattern.	  We	  tested	  mRNA	  levels	  throughout	  development	  of	  several	  genes	  that	  were	  strongly	  upregulated	  or	  downregulated	  (Fig.	  4e-­‐f)	  in	  C/C	  testes	  by	  QPCR.	  In	  WT,	  
Apoe	  was	  expressed	  highest	  at	  P18,	  followed	  by	  P30	  and	  P42,	  and	  at	  similar	  levels	  for	  all	  other	  time	  points.	  However,	  there	  was	  a	  drastic	  increase	  in	  expression	  at	  P42	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in	  C/C	  testes,	  although	  levels	  did	  not	  pass	  the	  threshold	  value	  we	  set	  for	  FDR	  (Fig.	  8f).	  Cpe	  was	  expressed	  at	  the	  highest	  level	  from	  P10	  to	  P18,	  with	  the	  lowest	  expression	  at	  P42.	  In	  C/C	  testes,	  expression	  was	  significantly	  higher	  than	  WT	  at	  P42	  (Fig.	  8g).	  In	  WT,	  Ddr1	  steadily	  decreased	  from	  P7	  onwards.	  The	  pattern	  in	  C/C	  testes	  matched	  with	  WT	  until	  a	  drastic	  increase	  at	  P42	  (Fig.	  8h).	  Lamb2	  expression	  steadily	  increased	  until	  P18	  and	  then	  fell	  again.	  In	  C/C,	  the	  pattern	  was	  the	  same	  with	  the	  exception	  that	  expression	  did	  not	  drop	  at	  P42.	  Expression	  in	  C/C	  was	  significantly	  lower	  at	  P7,	  although	  the	  absolute	  change	  in	  expression	  was	  small	  (Fig.	  8i).	  SerpinG1	  expression	  in	  WT	  increased	  slightly	  at	  P18	  and	  then	  dropped	  steadily	  until	  P42,	  whereas	  in	  C/C	  expression	  was	  highly	  increased	  at	  this	  time	  point	  (Fig.	  8j).	  	  	  
Npy	  expression	  exhibited	  quite	  large	  variation,	  both	  between	  different	  time	  points	  and	  between	  replicates.	  However,	  the	  average	  values	  at	  each	  time	  point	  were	  quite	  similar	  between	  WT	  and	  C/C	  testes,	  with	  the	  exception	  of	  P42,	  at	  which	  C/C	  exhibited	  a	  striking,	  though	  not	  statistically	  significant	  decrease,	  similar	  to	  what	  we	  observed	  before	  (Fig.	  8k).	  Tppp2,	  Oaz3,	  and	  Ppp2r2b	  exhibited	  strikingly	  similar	  expression	  patterns,	  with	  very	  low	  levels	  until	  P18,	  then	  drastically	  increased	  at	  P30	  and	  P42,	  coinciding	  with	  the	  emergence	  of	  spermatozoa.	  For	  all	  three	  genes,	  there	  were	  no	  differences	  in	  expression	  between	  WT	  and	  C/C	  testes	  until	  P42,	  when	  expression	  of	  Oaz3	  and	  Tppp2	  was	  significantly	  reduced,	  and	  expression	  of	  Ppp2r2b	  trended	  downward	  (Fig.	  8l-­‐n).	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Overall,	  none	  of	  the	  changes	  that	  we	  observed	  occurred	  until	  P42,	  after	  completion	  of	  the	  first	  wave	  of	  spermatogenesis.	  All	  the	  downregulated	  genes,	  with	  the	  exception	  of	  Npy,	  were	  only	  expressed	  at	  very	  low	  levels	  until	  P30,	  indicating	  that	  they	  are	  most	  likely	  spermatid-­‐	  or	  spermatozoa-­‐specific.	  This	  downregulation	  is	  consistent	  with	  the	  observation	  that	  C/C	  testes	  were	  generally	  lacking	  these	  cell	  types	  (Fig.	  1).	  For	  genes	  upregulated	  in	  C/C	  testes,	  expression	  in	  WT	  was	  generally	  lowest	  at	  P42,	  except	  Apoe.	  Interestingly,	  expression	  of	  Apoe	  in	  C/C	  testes	  at	  P42	  was	  higher	  than	  WT	  at	  any	  time	  point,	  indicating	  that	  there	  is	  a	  mechanism	  beyond	  developmental	  dysregulation	  causing	  increased	  expression	  of	  this	  gene.	  
	  
Discussion	  
	  In	  this	  report,	  we	  employed	  the	  C/C	  mouse	  to	  evaluate	  for	  the	  first	  time	  the	  role	  of	  SMN	  in	  mammalian	  sex	  organ	  development	  and	  fertility.	  We	  observed	  severe	  impairment	  of	  male	  reproductive	  organ	  development	  characterized	  by	  smaller	  testes,	  widespread	  degeneration	  of	  seminiferous	  tubules,	  loss	  of	  post-­‐meiotic	  cells,	  and	  a	  drastic	  reduction	  in	  male	  fertility	  in	  C/C	  mice.	  These	  surprising	  findings	  underscore	  a	  requirement	  for	  a	  relatively	  high	  level	  of	  SMN	  for	  the	  development	  and	  maintenance	  of	  male	  reproductive	  organs	  in	  mammals.	  A	  report	  published	  in	  1986	  implicated	  testis	  dysfunction	  in	  two	  mild	  SMA	  patients	  (Richert	  et	  al	  1986),	  although	  genetic	  diagnoses	  were	  not	  available	  at	  that	  time.	  A	  subsequent	  report	  briefly	  mentioned	  unexplained	  clinical	  symptoms	  due	  to	  the	  influence	  of	  male	  sex	  in	  type	  3	  SMA	  patients	  (Zerres	  and	  Rudnik-­‐Schoneborn	  2003).	  Although	  the	  authors	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did	  not	  elaborate	  on	  the	  exact	  nature	  of	  the	  symptoms,	  they	  conveyed	  the	  necessity	  for	  an	  animal	  model	  of	  mild	  SMA	  to	  examine	  male	  specific	  pathology.	  Hence,	  our	  finding	  of	  a	  unique	  testicular	  phenotype	  in	  C/C	  mice	  fills	  a	  critical	  knowledge	  gap	  with	  respect	  to	  SMN	  function.	  	  
	   The	  testis	  has	  unique	  RNA	  metabolism,	  including	  transcription,	  splicing	  and	  3ʹ′-­‐end	  processing	  (Berkovits	  et	  al	  2012,	  Schmid	  et	  al	  2013,	  Song	  et	  al	  2014)	  Given	  the	  prominent	  role	  of	  SMN	  in	  RNA	  metabolism	  and	  the	  presence	  of	  Gemin3,	  an	  SMN-­‐interacting	  protein,	  in	  germ	  cell-­‐specific	  chromatoid	  bodies	  (Meister	  and	  Fischer	  2002,	  Zhang	  et	  al	  2008,	  Ginter-­‐Matuszewska	  et	  al	  2011),	  it	  is	  not	  unexpected	  that	  SMN	  plays	  a	  critical	  role	  in	  testis	  development	  and	  spermatogenesis.	  However,	  it	  was	  somewhat	  unexpected	  that	  we	  did	  not	  observe	  drastically	  altered	  gene	  expression	  until	  an	  adult	  age,	  when	  SMN	  expression	  in	  C/C	  testes	  reached	  high	  levels	  due	  to	  high	  inclusion	  of	  SMN2	  exon	  7.	  Gemin2	  has	  a	  stabilizing	  effect	  on	  SMN	  and	  its	  interaction	  with	  SMN	  is	  critical	  for	  most	  SMN	  functions	  (Ogawa	  et	  al	  2007).	  Low	  level	  of	  Gemin2	  in	  C/C	  testes	  at	  P42	  is	  likely	  to	  impact	  all	  SMN	  functions	  dependent	  on	  SMN-­‐Gemin2	  interactions.	  A	  dramatic	  change	  in	  the	  transcriptome	  of	  C/C	  testis	  at	  P42	  underscores	  perturbations	  in	  pathways	  critical	  to	  spermatogenesis	  and	  testis	  function,	  including	  steroid	  biosynthesis,	  apoptosis,	  and	  spermatogenesis	  itself	  (Fig.	  4).	  There	  was	  an	  enrichment	  of	  markers	  of	  interstitial	  cells	  and	  somatic	  cells	  of	  the	  seminiferous	  tubules	  and	  general	  loss	  of	  expression	  of	  genes	  enriched	  in	  post-­‐meiotic	  cell	  types	  (Fig.	  4,	  Supplementary	  Fig.	  4).	  Intergenic	  lncRNAs	  and	  transposons	  expressed	  during	  meiosis	  are	  degraded	  through	  the	  Piwi-­‐interacting	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RNA	  (piRNA)	  pathway	  in	  which	  Tudor	  domain-­‐containing	  proteins	  play	  an	  essential	  role	  (Gou	  et	  al	  2014).	  SMN	  being	  a	  tudor	  domain-­‐containing	  protein	  and	  given	  the	  propensity	  of	  tudor	  domains	  to	  forge	  interactions	  among	  themselves	  (Ginter-­‐Matuszewska	  et	  al	  2011,	  Tripsianes	  et	  al	  2011),	  it	  is	  possible	  that	  SMN	  directly	  or	  indirectly	  affects	  piRNA	  pathway.	  	  It	  is	  known	  that	  lncRNAs	  are	  differentially	  regulated	  in	  testis,	  especially	  during	  spermatogenesis	  (Sun	  and	  Wu	  2015,	  Washietl	  et	  al	  2014).	  The	  most	  highly	  affected	  lncRNAs	  in	  C/C	  testes	  were	  Meg3,	  Malat1	  and	  Neat1.	  Meg3	  is	  expressed	  from	  paternally	  imprinted	  loci	  in	  mammals	  (Li	  et	  al	  2004)	  and	  is	  known	  to	  act	  as	  a	  tumor	  suppressor	  (Zhou	  et	  al	  2007).	  Malat1	  functions	  by	  affecting	  the	  phosphorylation	  of	  splicing	  factors	  (Tripathi	  et	  al	  2010),	  and	  Neat1	  serves	  as	  a	  scaffold	  for	  the	  formation	  of	  paraspeckles	  in	  which	  many	  RNA	  binding	  proteins	  are	  sequestered	  (Clemson	  et	  al	  2009).	  All	  types	  of	  non-­‐coding	  RNAs	  and	  untranslated	  regions	  impact	  the	  availability	  of	  RNA	  binding	  proteins	  and	  control	  the	  fate	  of	  mRNAs	  during	  spermatogenesis	  (Idler	  et	  al	  2012).	  Altered	  expression	  of	  lncRNAs	  reveals	  a	  novel	  function	  of	  SMN	  in	  controlling	  the	  levels	  of	  freely	  available	  RNA-­‐binding	  proteins	  in	  testes.	  	  	   Apoptosis	  plays	  an	  essential	  role	  in	  spermatogenesis	  as	  it	  eliminates	  damaged	  meiotic	  and	  post-­‐meiotic	  cells	  in	  testes	  (Aitken	  et	  al	  2011,	  Shukla	  et	  al	  2012).	  SMN	  has	  anti-­‐apoptotic	  properties	  (Kerr	  et	  al	  2000,	  Vyas	  et	  al	  2002,	  Parker	  et	  al	  2008)	  and	  interacts	  with	  Bcl-­‐2	  to	  protect	  cells	  from	  Fas-­‐mediated	  apoptosis	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(Iwahashi	  et	  al	  1997,	  Sato	  et	  al	  2000).	  Very	  low	  levels	  of	  SMN	  trigger	  DNA	  fragmentation	  in	  muscles	  and	  motor	  neurons	  of	  SMA	  patients	  (Simic	  et	  al	  2000,	  Stathas	  et	  al	  2008).	  Our	  finding	  of	  testicular	  defects	  and	  increase	  in	  TUNEL-­‐positive	  cells	  in	  C/C	  seminiferous	  tubules	  suggests	  a	  necessity	  for	  much	  higher	  levels	  of	  SMN	  to	  prevent	  the	  dysregulation	  of	  apoptotic	  pathways	  in	  this	  tissue.	  Sertoli	  cells	  regulate	  germ	  cell	  survival	  through	  the	  Fas	  system;	  Fas	  ligand	  decorating	  the	  surface	  of	  Sertoli	  cells	  interacts	  with	  Fas	  present	  on	  germ	  cells	  (Lee	  et	  al	  1997).	  Sertoli	  cells	  are	  the	  major	  cell	  type	  in	  testes	  until	  P18	  (Bellve	  et	  al	  1977),	  the	  time	  during	  which	  SMN	  is	  most	  strongly	  reduced	  in	  C/C	  testes.	  Since	  SMN	  modulates	  Fas-­‐mediated	  apoptosis,	  low	  SMN	  in	  Sertoli	  cells	  could	  disrupt	  the	  normal	  regulation	  of	  this	  process.	  Further,	  low	  SMN	  causes	  defects	  in	  snRNP	  assembly	  and	  expression	  levels	  (Zhang	  et	  al	  2008),	  resulting	  in	  accumulation	  of	  the	  aberrantly	  spliced	  mRNA	  isoforms,	  a	  condition	  to	  which	  Sertoli	  cells	  are	  particularly	  sensitive	  (Lee	  et	  al	  1997,	  Bao	  et	  al	  2015).	  SMN	  has	  also	  been	  implicated	  in	  the	  resolution	  of	  double-­‐stranded	  breaks	  requiring	  expression	  of	  functional	  H2AX	  (Takaku	  et	  al	  2011).	  Hence,	  increased	  TUNEL	  staining	  in	  C/C	  testes	  could	  be	  due	  to	  an	  increase	  in	  the	  unresolved	  double-­‐stranded	  breaks	  arising	  from	  meiotic	  recombination.	  	  Substantial	  downregulation	  of	  mRNA	  encoding	  neuropeptide	  Y	  proprotein	  suggests	  possible	  denervation	  of	  C/C	  testes	  and	  is	  likely	  a	  downstream	  effect	  of	  the	  low	  levels	  of	  SMN	  at	  the	  early	  stages	  of	  testicular	  development.	  Supporting	  this	  argument,	  SMN-­‐independent	  defects	  leading	  to	  mild	  SMA	  display	  abnormal	  male	  reproductive	  organ	  development	  and	  defective	  spermatogenesis.	  The	  most	  notable	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among	  these	  is	  the	  mutations	  in	  Vps54	  gene	  leading	  to	  a	  motor	  neuron	  disease	  similar	  to	  mild	  SMA	  and	  defects	  in	  male	  reproductive	  organ	  development	  (Schmitt-­‐John	  et	  al	  2005).	  Plastin	  3	  coded	  by	  PLS3	  is	  a	  protective	  modifier	  of	  SMA	  caused	  by	  the	  loss	  of	  SMN1	  (Oprea	  et	  al	  2008).	  Interestingly,	  the	  protective	  effect	  of	  Plastin	  3	  is	  not	  fully	  penetrant	  and	  appears	  to	  be	  specific	  to	  females.	  A	  recent	  study	  in	  rat	  testis	  implicates	  the	  role	  of	  Plastin	  3	  in	  spermatogenesis	  (Li	  et	  al	  2015).	  We	  did	  not	  observe	  aberrant	  expression	  of	  Vps54	  or	  Pls3	  genes	  in	  C/C	  testis,	  excluding	  a	  direct	  role	  of	  these	  genes	  in	  testicular	  defects	  in	  C/C	  mice.	  However,	  our	  results	  combined	  with	  the	  above	  findings	  suggest	  an	  overlapping	  pathway	  of	  neurodegeneration	  and	  male	  reproductive	  organ	  development.	  	  About	  50%	  of	  male	  infertility	  cases,	  affecting	  >5%	  of	  the	  population	  worldwide,	  are	  caused	  by	  genetic	  abnormalities	  (Comhaire	  et	  al	  1987,	  Hwang	  et	  al	  2010).	  More	  than	  20%	  of	  these	  cases	  represent	  nonobstructive	  azoospermia	  (NOA)	  in	  which	  semen	  contains	  little	  or	  no	  sperm	  (Huynh	  et	  al	  2002,	  Hwang	  et	  al	  2010).	  A	  genome-­‐wide	  association	  study	  (GWAS)	  reported	  in	  2012	  linked	  only	  6	  genes	  to	  male	  fertility	  traits	  (Kosova	  et	  al	  2012),	  none	  of	  which	  were	  linked	  to	  pre-­‐mRNA	  splicing,	  which	  is	  uniquely	  regulated	  during	  spermatogenesis.	  However,	  a	  GWAS	  conducted	  on	  Chinese	  men	  focused	  on	  serine-­‐arginine	  (SR)	  protein-­‐coding	  genes	  and	  found	  a	  strong	  correlation	  between	  NOA	  and	  mutations	  in	  SFRS9,	  encoding	  SR	  protein	  SRp30c	  (Ni	  et	  al	  2014).	  Incidentally,	  SRp30c	  regulates	  SMN	  levels	  by	  promoting	  inclusion	  of	  exon	  7	  during	  pre-­‐mRNA	  splicing	  (Young	  et	  al	  2002).	  Other	  studies	  provide	  additional	  evidence	  supporting	  the	  role	  of	  SMN	  in	  spermatogenesis.	  
 46 
For	  example,	  the	  transcription	  factor	  SP1	  is	  predicted	  to	  modulate	  SMN	  levels	  in	  both	  mouse	  and	  humans	  (Rouget	  et	  al	  2005).	  A	  critical	  role	  for	  SP1	  in	  mouse	  male	  germ	  cell	  development	  has	  been	  previously	  described	  (Thomas	  et	  al	  2007).	  Further,	  a	  recent	  study	  suggested	  that	  PRMT5,	  which	  plays	  an	  essential	  role	  in	  assembly	  of	  spliceosomal	  snRNPs	  along	  with	  SMN	  (Meister	  and	  Fischer	  2002),	  is	  required	  for	  germ	  cell	  survival	  during	  spermatogenesis	  in	  mice	  (Wang	  et	  al	  2015).	  Finally,	  upregulation	  of	  SMN	  upon	  activation	  of	  phosphatidylinositol	  3-­‐kinase	  (PI3K)/AKT	  and	  its	  positive	  impact	  on	  disease	  phenotype	  of	  severe	  SMA	  has	  been	  demonstrated	  (Branchu	  et	  al	  2013).	  Abrogation	  of	  PI3K/AKT	  pathway	  has	  been	  shown	  to	  affect	  spermatogenesis	  but	  not	  oogenesis	  (Baker	  et	  al	  2014).	  Our	  finding	  of	  a	  reproductive	  phenotype	  and	  loss	  of	  fertility	  in	  C/C	  males,	  but	  not	  females,	  are	  consistent	  with	  those	  observations.	  Incidentally,	  several	  human	  studies	  have	  revealed	  fewer	  females	  than	  males	  afflicted	  with	  the	  milder	  forms	  of	  SMA	  (Furukawa	  et	  al	  1968,	  Hausmanowa-­‐Petrusewicz	  et	  al	  1979,	  Jedrzejowska	  et	  al	  2009).	  Given	  these	  findings,	  it	  is	  rather	  expected	  that	  SMN	  plays	  	  a	  critical	  role	  in	  testis	  development	  and	  male	  germ	  cell	  survival	  in	  mammals.	  	  Humans	  are	  unique	  in	  harboring	  SMN2,	  a	  gene	  whose	  function	  is	  still	  unknown.	  Generally,	  SMN2	  is	  considered	  to	  be	  dispensable	  for	  survival,	  since	  enough	  SMN	  could	  be	  generated	  from	  SMN1.	  Our	  findings	  provide	  a	  strong	  rationale	  that	  the	  preservation	  of	  SMN2	  during	  evolutions	  of	  humans	  was	  driven	  by	  the	  heightened	  requirement	  of	  SMN	  in	  male	  reproductive	  organ	  development.	  A	  very	  specific	  splicing	  switch	  of	  SMN2	  to	  elevate	  SMN	  levels	  in	  adult	  testis	  in	  humans	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appears	  to	  be	  part	  of	  a	  fine	  regulatory	  mechanism	  that	  remains	  to	  be	  further	  understood.	  The	  presence	  of	  SMN2	  in	  SMA	  patients	  carries	  profound	  significance	  due	  to	  its	  ability	  to	  serve	  as	  a	  promising	  therapeutic	  target.	  Several	  pre-­‐clinical	  studies	  employing	  SMN2-­‐containing	  severe	  mouse	  models	  of	  SMA	  have	  shown	  extraordinary	  survival	  benefits3.	  However,	  gender-­‐specific	  efficacy	  of	  drugs	  and	  reproductive	  phenotype	  of	  severe	  SMA	  mice	  that	  survive	  much	  longer	  upon	  treatment,	  remain	  unknown.	  Lack	  of	  gender-­‐specific	  data	  in	  pre-­‐clinical	  studies	  in	  neurodegenerative	  diseases	  has	  been	  cited	  as	  one	  of	  the	  major	  sources	  of	  misinterpretations	  and	  faulty	  conclusions	  (Perrin	  2014).	  Our	  findings	  validate	  those	  concerns	  and	  provide	  a	  repertoire	  of	  histological	  and	  molecular	  markers	  that	  could	  be	  employed	  for	  the	  careful	  monitoring	  of	  male	  reproductive	  organ	  health	  as	  an	  essential	  component	  of	  drug	  development	  process	  for	  SMA.	  	  	  
Materials	  and	  Methods	  	  All	  methods	  were	  performed	  in	  accordance	  with	  the	  approved	  biosafety	  and	  radiation	  safety	  guidelines	  of	  Iowa	  State	  University	  (ISU),	  adhering	  to	  the	  federal	  and	  state	  guidelines.	  All	  animal	  experiments	  were	  carried	  our	  in	  accordance	  with	  the	  approved	  protocols	  by	  the	  Institutional	  Animal	  Care	  and	  Use	  Committee	  (IACUC)	  of	  ISU,	  adhering	  to	  the	  guidelines	  of	  American	  Veterinary	  Medical	  Association	  (AVMA),	  United	  States	  Health	  and	  Human	  Services	  (US	  HHS),	  United	  States	  Department	  of	  Agriculture	  (USDA)	  and	  State	  of	  Iowa.	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Mice	  Mice	  heterozygous	  for	  the	  C	  allele	  (Osborne	  et	  al	  2012)	  (SmnC/+)	  on	  the	  C57BL/6	  background	  were	  purchased	  from	  Jackson	  Laboratory	  (stock	  number	  008714).	  Breeding	  cages	  with	  one	  male	  and	  one	  female	  heterozygote	  were	  set	  up	  and	  maintained	  at	  ISU	  to	  generate	  the	  mice	  used	  for	  all	  experiments.	  This	  cross	  generated	  WT	  mice	  (Smn+/+)	  and	  C/C	  mice	  (SmnC/C).	  Pups	  were	  genotyped	  and	  sacrificed	  at	  the	  appropriate	  ages.	  Unless	  otherwise	  stated,	  all	  experiments	  were	  carried	  out	  at	  P42.	  
	  
Fertility	  assessment	  Monogamous	  breeding	  pairs	  were	  established	  between	  three-­‐	  to	  five-­‐month-­‐old	  mice	  and	  followed	  for	  ninety	  days.	  Once	  established,	  females	  were	  checked	  every	  twelve	  hours	  for	  a	  vaginal	  plug	  for	  the	  first	  five	  days.	  The	  number	  of	  litters	  and	  number	  of	  pups	  per	  litter	  were	  recorded.	  After	  ninety	  days	  mice	  were	  weighed,	  euthanized	  and	  tissues	  were	  collected.	  Testis	  mass	  and	  epididymal	  sperm	  count	  were	  determined	  for	  male	  mice.	  	  
Epididymal	  sperm	  counting	  P60	  WT	  and	  C/C	  mice	  were	  anesthetized	  with	  isoflurane	  and	  killed	  by	  cervical	  dislocation.	  The	  epididymides	  were	  dissected,	  minced	  with	  a	  fresh	  number	  10	  disposable	  scalpel	  and	  placed	  in	  3	  ml	  Dulbecco’s	  Modified	  Eagles’	  Medium	  supplemented	  with	  10%	  fetal	  bovine	  serum	  (Life	  Technologies)	  for	  15	  minutes	  at	  37°C.	  After	  incubation,	  the	  cell	  suspension	  was	  triturated	  15	  times.	  Dilutions	  of	  the	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sperm	  were	  prepared	  in	  water	  and	  incubated	  at	  room	  temperature	  for	  two	  minutes.	  The	  diluted	  cell	  suspension	  was	  loaded	  on	  a	  haemocytometer,	  allowed	  to	  settle,	  and	  only	  sperm	  with	  a	  head	  and	  tail	  were	  counted.	  	  
Tissue	  collection	  For	  RNA	  and	  protein	  isolation,	  P7,	  P10,	  P12,	  P18	  and	  P30	  WT	  and	  C/C	  mice	  were	  deeply	  anesthetized	  with	  isoflurane	  and	  decapitated.	  Tissues	  were	  removed	  and	  stored	  at	  -­‐80°C	  for	  future	  use.	  P42	  mice	  were	  deeply	  anesthetized	  with	  100	  mg/kg	  ketamine	  and	  10	  mg/kg	  xylazine,	  the	  carotid	  artery	  was	  pierced	  and	  blood	  collected	  and	  the	  mouse	  was	  subsequently	  transcardially	  perfused	  with	  phosphate	  buffered	  saline	  (PBS;	  137	  mM	  NaCl,	  2.7	  mM	  KCl,	  pH	  7.4).	  Unless	  otherwise	  stated,	  tissues	  were	  removed,	  flash	  frozen	  on	  dry	  ice,	  and	  stored	  at	  -­‐80°C	  for	  future	  use.	  Blood	  was	  allowed	  to	  clot	  at	  room	  temperature	  for	  15	  minutes,	  centrifuged	  at	  2,000	  x	  g	  for	  10	  minutes	  at	  4°C	  and	  the	  serum	  stored	  at	  -­‐80°C	  for	  future	  use.	  For	  histology,	  P42	  WT	  and	  C/C	  mice	  were	  weighed,	  deeply	  anesthetized	  with	  100	  mg/kg	  ketamine	  and	  10	  mg/kg	  xylazine	  and	  transcardially	  perfused	  with	  PBS	  followed	  by	  4%	  paraformaldehyde	  (pH	  7.4).	  After	  perfusion,	  the	  sex	  organs	  were	  removed,	  weighed	  with	  an	  analytical	  balance	  (Ohaus)	  and	  post-­‐fixed	  overnight	  in	  modified	  Davidson’s	  fixative	  (Electron	  Microscopy	  Diatome)	  at	  4°C.	  Organs	  were	  processed,	  embedded	  in	  paraffin,	  sectioned	  and	  stained	  with	  haemotoxylin	  and	  eosin	  (H&E).	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Histological	  analysis	  of	  tissue	  H&E	  stained	  sections	  were	  analyzed	  by	  a	  board-­‐certified	  Veterinary	  Pathologist	  to	  determine	  any	  pathological	  changes.	  Photographs	  of	  sections	  were	  taken	  with	  a	  Nikon	  microscope	  with	  SPOT	  Advanced	  software	  (Diagnostic	  Imaging,	  Inc.).	  	   We	  utilized	  a	  previously	  published	  10-­‐point	  scoring	  system	  to	  assess	  the	  progression	  of	  spermatogenesis	  within	  the	  seminiferous	  tubules	  (Daigle	  et	  al	  2009).	  Twenty	  seminiferous	  tubules	  from	  all	  areas	  of	  each	  testis	  were	  scored.	  The	  pathologist	  was	  blinded	  as	  to	  genotype	  of	  each	  sample.	  The	  scoring	  system	  is	  as	  follows:	  	   1	  -­‐	  No	  cells	  in	  tubular	  cross	  section	  	   2	  -­‐	  Sertoli	  cells	  only	  	   3	  -­‐	  Only	  spermatogonia	  present	  	   4	  -­‐	  No	  spermatozoa,	  no	  spermatids,	  but	  fewer	  than	  5	  spermatocytes	  present	  
	   5	  -­‐	  No	  spermatozoa,	  no	  spermatids,	  but	  many	  spermatocytes	  present	  
	   6	  -­‐	  No	  spermatozoa,	  but	  fewer	  than	  5-­‐10	  spermatids	  present	  	   7	  -­‐	  No	  spermatozoa,	  but	  many	  spermatids	  present	  
	   8	  -­‐	  All	  stages	  of	  spermatogenesis	  present,	  but	  fewer	  than	  5-­‐10	  spermatozoa	  	   9	  -­‐	  Many	  spermatozoa	  present,	  but	  germinal	  epithelium	  disorganized	  with	  marked	  	  sloughing	  or	  obliteration	  of	  lumen	  10	  -­‐	  Complete	  spermatogenesis	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Terminal	  deoxynucleotidyl	  transferase	  dUTP	  nick	  end	  labeling	  (TUNEL)	  
staining	  Three-­‐µm	  formalin-­‐fixed	  paraffin-­‐embedded	  testis	  cross	  sections	  from	  P42	  mice	  	  were	  subjected	  to	  TUNEL	  staining	  with	  the	  In	  situ	  Cell	  Death	  Detection	  Assay,	  Fluorescein	  (Roche)	  following	  the	  manufacturer’s	  protocol.	  For	  the	  negative	  control,	  two	  slides	  were	  incubated	  with	  only	  Labeling	  Solution	  (no	  enzyme).	  For	  the	  positive	  control,	  one	  slide	  was	  incubated	  with	  2	  U/µl	  DNase	  I,	  recombinant	  (Roche)	  for	  10	  minutes	  at	  room	  temperature	  to	  induce	  DNA	  fragmentation	  and	  then	  incubated	  as	  per	  the	  kit	  protocol.	  After	  labeling,	  sections	  were	  coverslipped	  with	  VectaShield	  Mounting	  Medium	  with	  DAPI	  (Vectastain)	  and	  imaged.	  Eight	  to	  ten	  micrographs	  from	  all	  regions	  of	  the	  testis	  were	  captured	  for	  analysis.	  TUNEL	  positive	  bodies	  were	  counted	  in	  at	  least	  50	  tubules	  from	  all	  regions	  of	  the	  testis	  for	  quantification.	  
	  
Immunohistochemistry	  Three-­‐µm	  formalin-­‐fixed	  paraffin-­‐embedded	  testis	  cross	  sections	  from	  P42	  mice	  were	  deparaffinized	  in	  xylene	  and	  rehydrated	  to	  distilled	  water.	  The	  sections	  were	  subjected	  to	  antigen	  retrieval	  for	  30	  minutes	  at	  95°C	  in	  antigen	  retrieval	  buffer	  (10	  mM	  sodium	  citrate,	  0.05%	  Tween-­‐20,	  pH	  6.0).	  The	  sections	  were	  then	  incubated	  in	  0.3%	  hydrogen	  peroxide	  (Fisher)	  for	  30	  minutes	  to	  block	  endogenous	  peroxidase	  activity.	  Immunostaining	  was	  performed	  using	  the	  VECTASTAIN	  Elite	  ABC-­‐Peroxidase	  kit	  (Vector	  Laboratories)	  following	  the	  manufacturer’s	  protocol.	  The	  primary	  antibody,	  rabbit	  anti-­‐cleaved	  caspase	  3	  (Cell	  Signaling;	  9661)	  was	  diluted	  1:100	  and	  incubated	  with	  sections	  for	  90	  minutes	  at	  room	  temperature.	  Detection	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was	  performed	  using	  the	  ImmPACT	  DAB	  substrate	  (Vector	  Laboratories).	  Slides	  were	  subsequently	  stained	  with	  modified	  Mayer’s	  hematoxylin	  (Fisher),	  dehydrated	  in	  an	  ethanol	  gradient,	  coverslipped	  with	  Permount	  (Fisher)	  and	  imaged.	  	  
Testosterone	  enzyme	  linked	  immunosorbent	  assay	  (ELISA)	  Total	  serum	  testosterone	  was	  measured	  using	  the	  Mouse/Rat	  Testosterone	  ELISA	  kit	  (CalBiotech)	  using	  the	  manufacturer’s	  instructions.	  A	  standard	  curve	  was	  constructed	  using	  GraphPad	  Prism	  v6.0	  using	  a	  sigmoidal	  4-­‐parameter	  logistics	  fit	  and	  testosterone	  concentration	  (ng/ml)	  were	  determined	  based	  on	  this	  curve.	  	  




Immunoblotting,	  silver	  staining,	  and	  densitometric	  analysis	  Protein	  lysates	  were	  diluted	  with	  2X	  Laemmli	  sample	  buffer	  (BioRad)	  with	  10%	  β-­‐mercaptoethanol	  (Sigma-­‐Aldrich).	  Samples	  were	  boiled	  for	  10	  minutes	  and	  then	  centrifuged	  at	  maximum	  speed	  for	  5	  minutes	  at	  room	  temperature.	  Different	  amounts	  of	  protein	  were	  loaded	  depending	  on	  the	  tissues:	  12.5-­‐15	  µg	  for	  testis,	  30	  
µg	  for	  uterus/ovaries	  and	  brain,	  50	  µg	  for	  liver	  and	  75	  µg	  for	  heart.	  For	  silver	  staining,	  protein	  was	  separated	  on	  10%	  SDS-­‐PAGE	  gels	  and	  then	  stained	  with	  the	  BioRad	  Silver	  Stain	  Plus	  kit	  according	  to	  the	  manufacturer’s	  protocol.	  For	  western	  blotting,	  protein	  was	  separated	  on	  10%	  SDS-­‐PAGE	  gels	  and	  then	  transferred	  to	  Immobilon	  polyvinylidene	  fluoride	  (PVDF)	  membrane	  (Millipore)	  using	  the	  Turbo	  Transfer	  system	  (BioRad).	  Membranes	  were	  briefly	  washed	  in	  1X	  Tris-­‐buffered	  saline	  with	  Tween	  20	  (TBST;	  50	  mM	  Tris,	  150	  mM	  NaCl,	  0.05%	  Tween-­‐20,	  pH	  7.4),	  and	  then	  incubated	  in	  5%	  nonfat	  milk	  prepared	  in	  TBST.	  Membranes	  were	  then	  incubated	  in	  the	  appropriate	  primary	  antibody	  diluted	  in	  5%	  milk:	  	  mouse	  anti-­‐SMN	  (BD	  Biosciences;	  610646)	  diluted	  1:2,000	  (for	  heart,	  liver,	  and	  uterus/ovaries)	  or	  1:5,000	  (for	  testes),	  mouse	  anti-­‐Gemin2	  (Clone	  2E17;	  Sigma	  G6669)	  diluted	  1:500;	  mouse	  anti-­‐hnRNPA1	  (Clone	  9H19;	  Abcam;	  ab5832)	  diluted	  1:10,000;	  mouse	  anti-­‐hnRNPA2/B1	  (Abcam;	  ab6102)	  diluted	  1:1,000;	  mouse	  anti-­‐hnRNP	  Q	  (Sigma;	  R6353)	  diluted	  1:800;	  goat	  anti-­‐Tra2β	  (Abcam;	  ab31353)	  diluted	  1:1,000;	  or	  rabbit	  anti-­‐Actin	  (Sigma;	  A2066)	  diluted	  1:2,000.	  Incubations	  were	  performed	  overnight	  at	  4°C	  with	  shaking,	  except	  anti-­‐Actin,	  which	  was	  incubated	  for	  1	  hour	  at	  room	  temperature.	  Blots	  were	  then	  washed	  three	  times	  in	  TBST	  for	  at	  least	  10	  minutes	  with	  shaking	  and	  incubated	  in	  the	  appropriate	  secondary	  antibody:	  goat	  anti-­‐mouse	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IgG,	  goat	  anti-­‐rabbit	  IgG	  or	  donkey	  anti-­‐goat	  IgG	  all	  conjugated	  to	  horseradish	  peroxidase	  (HRP)	  for	  1	  hour	  at	  room	  temperature	  or	  for	  30	  minutes	  at	  37˚C	  with	  shaking.	  Blots	  were	  then	  developed	  with	  either	  Clarity	  HRP	  substrate	  (BioRad)	  or	  West	  Femto	  substrate	  (Thermo	  Scientific	  Pierce)	  and	  visualized	  with	  the	  BioSpectrum	  AC	  Imaging	  System	  (UVP).	  For	  each	  blot,	  the	  mean	  intensity	  of	  each	  band	  was	  determined	  using	  ImageJ	  software.	  For	  each	  sample,	  the	  mean	  intensity	  of	  the	  protein	  of	  interest	  was	  divided	  by	  the	  mean	  intensity	  of	  Actin.	  For	  direct	  comparisons	  between	  WT	  and	  C/C,	  the	  WT	  average	  was	  set	  at	  1.0	  and	  all	  other	  samples	  were	  expressed	  relative	  to	  this	  value.	  For	  all	  time-­‐course	  experiments	  within	  a	  genotype,	  the	  maximum	  expression	  was	  set	  at	  1.0	  and	  all	  other	  samples	  were	  expressed	  relative	  to	  this	  value.	  	  
Deep	  sequencing	  and	  analysis	  of	  C/C	  transcriptome	  RNA	  was	  isolated	  from	  P42	  testes,	  liver,	  and	  brain	  (n=4	  WT,	  n=3	  C/C	  for	  testis,	  n=2	  males,	  2	  females	  per	  genotype	  for	  liver	  and	  brain)	  using	  Trizol	  reagent	  according	  to	  the	  manufacturer’s	  instructions.	  The	  isolated	  RNA	  was	  quantified	  using	  a	  UV	  spectrophotometer	  and	  10	  µg	  of	  total	  RNA	  was	  subjected	  to	  digestion	  with	  RQ1	  RNase-­‐free	  DNase	  (Promega).	  After	  DNase	  treatment,	  the	  RNA	  was	  repurified	  using	  phenol:chloroform	  extraction	  followed	  by	  ethanol	  precipitation.	  Quality	  and	  quantity	  of	  samples	  was	  assessed	  on	  an	  Agilent	  bioanalyzer	  using	  an	  RNA	  Nano	  chip	  (Agilent).	  300	  ng	  of	  RNA	  was	  used	  as	  input	  for	  poly(A)	  +	  RNA	  enrichment	  using	  the	  NEBNext	  poly(A)	  mRNA	  Magnetic	  Isolation	  Module	  (New	  England	  Biolabs)	  and	  RNA-­‐Seq	  libraries	  were	  generated	  using	  the	  NEBNext	  Ultra	  Directional	  RNA	  Library	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Prep	  Kit	  (New	  England	  Biolabs).	  During	  library	  preparation,	  barcode	  sequences	  were	  introduced	  for	  identifying	  sequences	  from	  each	  biological	  replicate	  and	  6-­‐7	  libraries	  were	  pooled	  and	  run	  per	  lane	  on	  an	  Illumina	  HiSeq	  2500	  using	  a	  100-­‐cycle	  single-­‐end	  program.	  	   After	  sequencing,	  contaminating	  adapter	  sequences	  and	  low-­‐quality	  ends	  were	  removed	  using	  the	  cutadapt	  program	  (Martin	  2011).	  After	  trimming,	  reads	  were	  mapped	  to	  the	  mouse	  genome	  (version	  GRm38/mm10)	  using	  Tophat	  (Trapnell	  et	  al	  2009).	  For	  transcript	  identification,	  the	  Gencode	  annotation	  was	  used	  (http://www.gencodegenes.org/).	  In	  order	  to	  identify	  differentially	  regulated	  transcripts,	  read	  counts	  were	  obtained	  for	  all	  Gencode	  annotated	  genes	  using	  HTSeq-­‐count	  (Anders	  et	  al	  2015)	  and	  altered	  expression	  levels	  were	  tested	  using	  the	  DESeq	  package	  implemented	  in	  R	  (Anders	  and	  Huber	  2010).	  GO	  term	  and	  KEGG	  pathway	  analysis	  were	  performed	  using	  the	  WebGESTALT	  web	  server	  (http://bioinfo.vanderbilt.edu/webgestalt/).	  Candidate	  alternatively	  spliced	  exons	  were	  identified	  using	  MATS	  (Shen	  et	  al	  2012).	  	  
Quantitative	  PCR	  and	  semi-­‐quantitative	  RT-­‐PCR	  RNA	  was	  isolated	  from	  testes	  using	  the	  same	  protocol	  as	  total	  RNA	  extraction	  used	  for	  deep	  sequencing,	  except	  30	  µg	  of	  RNA	  was	  used	  for	  DNase	  treatment	  and	  cleanup	  was	  performed	  on	  RNeasy	  columns	  (Qiagen).	  2.5	  µg	  of	  total	  RNA	  was	  converted	  to	  cDNA	  using	  SuperScript	  III	  reverse	  transcriptase	  (Life	  Technologies)	  using	  random	  primers	  (Promega).	  For	  quantitative	  PCR,	  1.5	  µl	  of	  a	  1:20	  dilution	  of	  cDNA	  (equivalent	  to	  cDNA	  produced	  from	  9.375	  ng	  of	  RNA)	  was	  used	  as	  template	  in	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a	  20	  µl	  reaction	  containing	  300	  nM	  forward	  and	  reverse	  primers	  and	  1X	  FastStart	  Universal	  SYBR	  Green	  Master	  containing	  ROX	  reference	  dye	  (Roche).	  QPCR	  was	  performed	  using	  a	  Stratagene	  MX3005P	  thermocycler	  (Agilent)	  and	  relative	  expression	  levels	  were	  determined	  using	  the	  ΔΔCt	  method	  using	  β-­‐Actin	  as	  a	  reference	  gene.	  For	  comparisons	  in	  adult	  tissues,	  values	  are	  expressed	  as	  relative	  to	  WT	  average.	  For	  time-­‐course	  experiments,	  values	  are	  expressed	  as	  relative	  to	  WT	  average	  at	  P7.	  MESDA	  	  was	  performed	  as	  described	  previously14.	  For	  other	  semi-­‐quantitative	  PCR	  reactions,	  0.5	  µl	  of	  cDNA	  was	  used	  per	  20	  µl	  PCR	  reaction	  using	  Taq	  polymerase	  (New	  England	  Biolabs)	  in	  the	  presence	  of	  0.8-­‐1.2	  µCi	  of	  [α-­‐32P]	  dATP.	  6	  µl	  of	  PCR	  product	  was	  separated	  on	  a	  5%	  (for	  MESDA)	  or	  8%	  (for	  other	  semi-­‐quantitative	  PCR)	  TBE	  polyacrylamide	  gel,	  dried,	  and	  exposed	  to	  a	  phosphorimager	  screen.	  Gel	  images	  were	  scanned	  using	  a	  Fujifilm	  FLA-­‐5100	  and	  densitometric	  quantification	  was	  carried	  out	  using	  Multi	  Gauge	  software	  (Fujifilm).	  For	  all	  reactions	  labeled	  with	  [α-­‐32P]	  dATP,	  values	  were	  corrected	  by	  dividing	  by	  the	  number	  of	  A/T	  base	  pairs	  in	  the	  product.	  All	  primer	  sequences	  appear	  in	  Supplementary	  Table	  6.	  	  
	  
Statistical	  analysis	  Statistical	  analysis	  was	  performed	  with	  GraphPad	  software.	  All	  data	  are	  presented	  as	  mean	  ±	  standard	  error	  of	  the	  mean	  (S.E.M.)	  unless	  otherwise	  stated.	  Data	  on	  sex	  organ	  weights,	  sperm	  count,	  fertility,	  TUNEL	  staining,	  and	  protein	  densitometry	  were	  analyzed	  with	  two-­‐tailed	  unpaired	  Student’s	  t	  test.	  QPCR	  results	  were	  analyzed	  with	  unpaired	  two-­‐tailed	  unpaired	  Student’s	  t	  test	  with	  multiple	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hypothesis	  correction	  using	  the	  Benjamimi	  and	  Hochberg	  method.	  Seminiferous	  tubule	  score	  means	  were	  analyzed	  with	  the	  Mann-­‐Whitney	  U	  test.	  For	  all	  statistical	  analyses,	  p<0.05	  was	  considered	  significant.	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Figure	  1:	  	  Male	  reproductive	  organs	  and	  functions	  are	  abnormal	  in	  P42	  C/C	  
mice.	  (a)	  Representative	  photograph	  of	  WT	  (left)	  and	  C/C	  (right)	  male	  reproductive	  organs,	  including	  testis,	  epididymis	  and	  epididymal	  fat	  pad.	  Scale	  bar	  represents	  5	  mm.	  (b)	  Gross	  testis	  mass.	  (c)	  Relative	  testis	  mass	  was	  determined	  by	  dividing	  gross	  testis	  mass	  by	  total	  body	  weight	  (n=10	  WT	  and	  6	  C/C	  mice).	  (d)	  Serum	  testosterone	  level	  determined	  by	  ELISA	  (n=5	  mice	  per	  genotype).	  (e)	  Representative	  H&E	  stained	  testis	  cross-­‐sections.	  Circled	  numbers	  represent	  score	  of	  each	  tubule	  based	  upon	  a	  10	  point	  system	  that	  assesses	  morphology13.	  Damage	  and	  degeneration,	  including	  vacuolization	  (black	  arrowheads),	  multinucleated	  bodies	  (red	  arrowheads)	  and	  sloughed	  tissue	  (blue	  arrowheads)	  are	  indicated.	  Scale	  bars	  represent	  50	  µm.	  (f)	  Average	  seminiferous	  tubule	  scores	  for	  WT	  and	  C/C	  testes.	  Each	  point	  represents	  a	  single	  mouse	  (n=10	  WT	  and	  6	  C/C	  mice).	  Pie	  charts	  below	  data	  points	  represent	  the	  distribution	  of	  all	  seminiferous	  tubule	  scores	  for	  WT	  and	  C/C	  males.	  The	  legend	  underneath	  indicates	  the	  color	  for	  each	  score.	  (g)	  Representative	  H&E	  stained	  cross	  sections	  of	  epididymal	  regions.	  The	  cartoon	  to	  the	  right	  indicates	  the	  location	  of	  each	  region.	  Scale	  bars	  represent	  50	  µm.	  (h)	  Total	  epididymal	  sperm	  count	  from	  P60	  males	  (n=8	  WT	  and	  6	  C/C	  mice).	  (Statistical	  significance:	  ***p<0.001)	  	  
Figure	  2:	  	  P42	  female	  C/C	  reproductive	  organs	  exhibit	  minimal	  abnormalities.	  (a)	  Representative	  photograph	  of	  WT	  (top)	  and	  C/C	  (bottom)	  uterus	  and	  ovaries.	  Scale	  bar	  represents	  5	  mm.	  (b)	  Gross	  uterus	  and	  ovaries	  mass.	  (c)	  Relative	  uterus	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and	  ovaries	  mass	  was	  determined	  by	  dividing	  gross	  uterus	  and	  ovaries	  mass	  by	  total	  body	  weight	  (n=10	  WT	  and	  7	  C/C	  mice).	  (d)	  Representative	  H&E	  stained	  cross-­‐sections	  of	  ovary	  and	  the	  endometrium.	  Follicle	  (F)	  and	  corpus	  luteum	  (CL)	  are	  indicated	  on	  ovary	  micrographs.	  Scale	  bars	  represent	  100	  µm.	  (e-­‐f)	  Fertility	  of	  heterozygous	  (n=11)	  and	  C/C	  (n=3)	  female	  mice.	  Females	  were	  paired	  in	  monogamous	  breeding	  cages	  with	  either	  a	  heterozygote	  or	  WT	  male.	  The	  average	  number	  of	  litters	  born	  over	  ninety	  days	  (e)	  and	  the	  average	  litter	  size	  for	  heterozygote	  or	  C/C	  mothers	  (f)	  were	  recorded.	  (Statistical	  significance	  *p<0.05)	  	  
Figure	  3:	  	  High	  levels	  of	  SMN	  are	  expressed	  in	  C/C	  testis	  (a)	  Diagram	  of	  the	  SmnC	  locus.	  Endogenous	  mouse	  Smn	  is	  interrupted	  2,195	  bp	  into	  intron	  6	  and	  replaced	  with	  the	  equivalent	  human	  SMN2	  sequence	  through	  the	  3ʹ′-­‐	  UTR,	  followed	  by	  42	  kb	  human	  SMN2	  genomic	  sequence.	  Exon	  lengths	  appear	  above	  colored	  boxes	  and	  intron	  lengths	  appear	  below	  lines.	  This	  transgene	  results	  in	  two	  genes,	  hybrid	  Smn	  and	  WT	  SMN2.	  MESDA14	  was	  used	  to	  determine	  all	  splice	  variants	  for	  SMN2	  (b)	  and	  
Smn	  hybrid	  (c)	  in	  various	  tissues.	  Band	  identities	  are	  given	  to	  the	  left	  of	  the	  lanes,	  where	  Δ	  indicates	  the	  lack	  of	  specific	  exon(s).	  Tissue	  abbreviations	  are	  indicated	  in	  panel	  (d).	  Additional	  abbreviations:	  E,	  exon;	  In,	  intron;	  UTR,	  untranslated	  region;	  FL,	  full-­‐length.	  (d)	  Western	  blots	  of	  SMN,	  Gemin2	  and	  Actin	  (top	  three	  panels)	  expression	  in	  adult	  WT	  tissue,	  and	  accompanying	  silver	  stain	  to	  confirm	  approximately	  equal	  loading.	  Samples	  were	  prepared	  by	  dissecting	  tissues	  from	  3	  WT	  males	  and	  immediately	  grinding	  them	  together	  in	  liquid	  nitrogen.	  5	  µg	  of	  protein	  was	  loaded	  for	  silver	  staining	  and	  7.5	  µg	  was	  loaded	  for	  western	  blotting.	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Tissue	  abbreviations	  appear	  to	  the	  right.	  (e-­‐h)	  Representative	  SMN	  and	  Actin	  western	  blots	  from	  male	  (M)	  and	  female	  (F)	  brain	  (e),	  heart	  (f),	  liver	  (g),	  and	  testis	  and	  uterus/ovaries	  (U/O)	  (h).	  For	  (e-­‐h),	  n=3	  or	  4	  mice	  per	  genotype.	  (Statistical	  significance:	  *p<0.05)	  	  
Figure	  4.	  RNA-­‐Seq	  reveals	  drastic	  alterations	  in	  C/C	  testis	  transcriptome.	  (a)	  MA	  plots	  for	  testis	  (top),	  brain	  (middle)	  and	  liver	  (bottom).	  The	  y-­‐axis	  depicts	  log2	  fold	  change	  (LFC)	  in	  gene	  expression	  in	  C/C	  compared	  to	  WT,	  and	  the	  x-­‐axis	  depicts	  the	  mean	  read	  count	  for	  each	  gene	  between	  all	  samples.	  Each	  dot	  represents	  one	  gene,	  with	  red	  dots	  representing	  genes	  with	  significantly	  altered	  expression	  values	  (Benjamini	  and	  Hochberg	  (B+H)	  adjusted	  p	  value	  <	  0.05).	  (b)	  KEGG	  pathways	  enriched	  for	  genes	  with	  altered	  expression	  levels	  in	  C/C	  testis.	  The	  length	  of	  each	  bar	  represents	  the	  B+H	  adjusted	  p	  value	  of	  enrichment	  for	  each	  pathway.	  The	  number	  at	  the	  top	  of	  each	  bar	  represents	  the	  number	  of	  genes	  participating	  in	  each	  pathway	  with	  significantly	  altered	  expression.	  (c)	  Percentage	  of	  genes	  upregulated	  (white	  bars)	  or	  downregulated	  (black	  bars)	  in	  C/C	  testes	  that	  are	  classified	  as	  being	  primarily	  expressed	  in	  certain	  testicular	  cell	  types.	  Abbreviations	  used:	  spermatogonia	  (SG),	  spermatocytes	  (SC).	  (d)	  LFC	  in	  C/C	  testes	  of	  several	  candidate	  genes	  as	  measured	  by	  RNA-­‐Seq	  (y	  values)	  and	  QPCR	  (x	  values).	  (e-­‐f)	  QPCR	  showing	  aberrant	  testis	  expression	  of	  genes	  that	  are	  strongly	  upregulated	  (e)	  or	  downregulated	  (f).	  (g-­‐i)	  QPCR	  for	  select	  genes	  involved	  in	  steroid	  biosynthesis	  (g),	  spermatogenesis	  (h)	  and	  axon	  guidance	  (i).	  (j)	  QPCR	  for	  expression	  of	  lncRNAs.	  (k)	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QPCR	  for	  expression	  of	  genes	  that	  encode	  members	  of	  the	  SMN	  complex.	  For	  (e-­‐k),	  n=8	  mice	  per	  genotype	  (Statistical	  significance:	  *p<0.05;	  **p<0.01;	  ***p<0.001)	  
	  
Figure	  5.	  Expression	  of	  apoptosis-­‐related	  genes	  is	  disproportionally	  affected	  
in	  C/C	  testes.	  (a)	  Heat	  map	  depicting	  the	  relative	  expression	  of	  every	  gene	  involved	  in	  apoptosis,	  as	  annotated	  by	  the	  Kyoto	  Encyclopedia	  of	  Genes	  and	  Genomes.	  Each	  colored	  bar	  indicates	  the	  LFC	  of	  expression	  in	  C/C	  compared	  to	  WT.	  The	  color	  scale	  is	  indicated	  below,	  with	  red	  colored	  bars	  indicating	  genes	  with	  lower	  expression	  in	  C/C	  and	  green	  colored	  bars	  indicating	  genes	  with	  increased	  expression	  in	  C/C.	  (b-­‐d)	  Relative	  expression	  of	  several	  candidate	  genes	  involved	  in	  apoptosis,	  as	  measured	  by	  QPCR	  in	  testes	  (b),	  brain	  (c),	  and	  liver	  (d);	  n=4	  mice	  per	  genotype.	  (e)	  Representative	  micrographs	  from	  TUNEL	  assay	  showing	  nuclei	  (DAPI,	  blue),	  TUNEL	  signal	  (green)	  and	  merged	  image.	  Individual	  seminiferous	  tubules	  are	  noted	  with	  dashed	  white	  outline.	  Scale	  bars	  represent	  50	  µm.	  (f)	  Percentage	  of	  seminiferous	  tubules	  with	  at	  least	  one	  TUNEL-­‐positive	  cell.	  (g)	  Average	  number	  of	  TUNEL	  positive	  cells	  per	  seminiferous	  tubules.	  (h)	  Percentage	  of	  TUNEL-­‐positive	  cells	  classified	  by	  cell	  type,	  including	  Sertoli	  cells,	  spermatogonia	  (SG),	  spermatocytes	  (SC)	  and	  round	  spermatids	  (RS).	  For	  (f-­‐h),	  n=4	  mice	  per	  genotype.	  (i)	  Representative	  images	  of	  cleaved	  caspse	  3	  immunostaining.	  C/C	  testes	  exhibited	  cleaved	  caspase	  3	  positive	  spermatogonia	  (panel	  I),	  spermatocytes	  (panel	  II)	  and	  multinucleated	  body	  (panel	  III)	  indicated	  by	  arrowheads.	  WT	  testes	  showed	  absence	  of	  cleaved	  caspase	  3	  (panel	  IV).	  Scale	  bars	  represent	  50	  µm.	  (Statistical	  significance:	  *p<0.05;	  **p<0.01;	  ***p<0.001)	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Figure	  6.	  SMN2	  and	  hybrid	  Smn	  mRNA	  splicing	  changes	  during	  testis	  
development.	  (a)	  Timeline	  of	  the	  ages	  and	  estimated	  WT	  cell	  type	  distribution	  of	  seminiferous	  tubules	  of	  mice	  used	  for	  this	  study.	  The	  height	  of	  each	  designated	  region	  represents	  the	  estimated	  proportion	  of	  total	  number	  of	  cells	  in	  an	  average	  seminiferous	  tubule.	  (b,c)	  MESDA	  for	  SMN2	  (b)	  and	  hybrid	  Smn	  (c);	  n=2	  mice	  per	  genotype.	  Isoform	  identities	  are	  given	  on	  the	  right	  side	  of	  each	  gel	  image	  where	  
Δ indicates	  a	  skipped	  exon.	  Each	  lane	  is	  a	  representative	  example	  taken	  from	  two	  replicates.	  Lower	  panels	  show	  results	  of	  densitometric	  quantification	  of	  the	  most	  prominent	  isoforms	  of	  each	  gene.	  (d)	  Western	  blots	  for	  Tra2β,	  hnRNP	  Q,	  hnRNP	  A1,	  hnRNP	  A2/B1,	  and	  Actin	  during	  testis	  development.	  Equal	  amounts	  of	  protein	  from	  each	  of	  3-­‐4	  C/C	  samples	  were	  pooled	  together	  and	  15	  µg	  of	  protein	  loaded	  for	  each	  time	  point.	  Densitometric	  quantifications	  are	  given	  on	  the	  right.	  Abbreviation:	  SZ,	  spermatozoa	  	  
Figure	  7.	  SMN	  mRNA	  and	  protein	  expression	  during	  testis	  development.	  (a-­‐b)	  QPCR	  measurement	  of	  relative	  quantities	  of	  Smn	  transcript	  in	  WT	  testes	  (a)	  and	  FL	  (including	  both	  exons	  5	  and	  7)	  SMN2	  transcript	  in	  C/C	  testes	  (b)	  during	  development.	  Expression	  is	  calculated	  relative	  to	  the	  average	  expression	  level	  at	  P7.	  (c-­‐d)	  Time	  course	  of	  SMN	  protein	  expression	  in	  WT	  (c)	  and	  C/C	  (d)	  mice.	  Blots	  shown	  are	  representative	  examples	  of	  each	  time	  point.	  (e)	  SMN,	  Gemin2	  and	  Actin	  expression	  in	  WT	  and	  C/C	  testes	  during	  development	  for	  each	  age.	  (f)	  Densitometric	  analysis	  for	  SMN	  western	  blots	  shown	  in	  (e).	  (g)	  Densitometric	  analysis	  for	  Gemin2	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western	  blots	  shown	  in	  (e).	  N=2-­‐4	  mice	  per	  genotype	  and	  age.	  (Statistical	  significance:	  *p<0.05;	  **p<0.01;	  ***p<0.001)	  	  
Figure	  8.	  Alternative	  splicing	  and	  gene	  expression	  in	  C/C	  testes	  during	  
spermatogenesis.	  Splicing	  patterns	  for	  Add3	  exon	  14	  (a),	  Lrrc16a	  exon	  38	  (b),	  
Picalm	  exon	  13	  (c),	  Wt1	  exon	  5	  (d)	  and	  Sulf1	  exon	  21	  (e)	  during	  testis	  development.	  The	  top	  panels	  are	  representative	  autoradiograms	  of	  semi-­‐quantitative	  PCR.	  Isoforms	  are	  labeled	  to	  the	  right	  of	  each	  gel	  image.	  The	  bottom	  panels	  portray	  autoradiogram	  quantification.	  For	  (a-­‐e),	  n=2	  mice	  per	  genotype.	  (f-­‐n)	  QPCR	  expression	  of	  candidate	  genes	  during	  testis	  development,	  including	  Apoe	  (f),	  Cpe	  (g),	  




Figure	  1.	  Male	  reproductive	  organs	  and	  functions	  are	  abnormal	  in	  P42	  C/C	  
mice.	  	   	  
 72 
	  	  
Figure	  2.	  	  P42	  female	  C/C	  reproductive	  organs	  exhibit	  minimal	  abnormalities	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Figure	  3.	  	  High	  levels	  of	  SMN	  are	  expressed	  in	  C/C	  testis	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Figure	  4.	  RNA-­‐Seq	  reveals	  drastic	  alterations	  in	  C/C	  testis	  transcriptome	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Figure	  5.	  Expression	  of	  apoptosis-­‐related	  genes	  is	  disproportionally	  affected	  
in	  C/C	  testes	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Figure	  6.	  SMN2	  and	  hybrid	  Smn	  mRNA	  splicing	  changes	  during	  testis	  
development	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Figure	  7.	  SMN	  mRNA	  and	  protein	  expression	  during	  testis	  development	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Figure	  8.	  Alternative	  splicing	  and	  gene	  expression	  in	  C/C	  testes	  during	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  Legends	  
	  
Supplementary	  Figure	  1.	  GO	  terms	  enriched	  in	  all	  significantly	  altered	  genes.	  The	  length	  of	  each	  bar	  represents	  the	  B+H	  adjusted	  p	  value	  of	  enrichment	  for	  each	  pathway.	  GO	  terms	  are	  characterized	  as	  representing	  biological	  processes	  (a),	  molecular	  functions	  (b),	  or	  cellular	  components	  (c)	  	  	  
Supplementary	  Figure	  2.	  GO	  terms	  enriched	  in	  significantly	  upregulated	  
genes.	  The	  length	  of	  each	  bar	  represents	  the	  B+H	  adjusted	  p	  value	  of	  enrichment	  for	  each	  pathway.	  GO	  terms	  are	  characterized	  as	  representing	  biological	  processes	  (a),	  molecular	  functions	  (b),	  or	  cellular	  components	  (c)	  	  	  
Supplementary	  Figure	  3.	  GO	  terms	  enriched	  in	  significantly	  downregulated	  
genes.	  The	  length	  of	  each	  bar	  represents	  the	  B+H	  adjusted	  p	  value	  of	  enrichment	  for	  each	  pathway.	  GO	  terms	  are	  characterized	  as	  representing	  biological	  processes	  (a)	  or	  cellular	  components	  (b).	  No	  GO	  terms	  corresponding	  to	  specific	  molecular	  functions	  were	  significantly	  enriched.	  	  
Supplementary	  Figure	  4.	  Expression	  of	  markers	  of	  particular	  cell	  types.	  mRNA	  expression	  level	  of	  cell-­‐type	  markers	  in	  C/C	  testes	  as	  measured	  by	  RNA-­‐Seq.	  Value	  is	  expressed	  as	  expression	  relative	  to	  WT.	  (Statistical	  significance:	  *p<0.5;	  **p<0.01;	  ***p<0.001)	  
	  
Supplementary	  Figure	  5.	  Expression	  of	  genes	  mutated	  in	  oligospermia.	  mRNA	  expression	  level	  in	  allele	  C	  testes	  of	  genes	  whose	  mutation	  causes	  oligospermia,	  as	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measured	  by	  RNA-­‐Seq.	  Value	  is	  expressed	  as	  expression	  relative	  to	  WT.	  (Statistical	  significance:	  *p<0.5;	  **p<0.01;	  ***p<0.001)	  	  
	  	  
	  
Supplementary	  Figure	  1.	  GO	  terms	  enriched	  in	  all	  significantly	  altered	  genes.	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Supplementary	  Figure	  2.	  GO	  terms	  enriched	  in	  significantly	  upregulated	  genes	  




Supplementary	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  3.	  GO	  terms	  enriched	  in	  significantly	  downregulated	  
genes	  
	  
Supplementary	  Figure	  4.	  Expression	  of	  markers	  of	  particular	  cell	  types
Supplementary	  Figure	  5	  















Total	  Pups	  Sired	  







1	   WT	   C/C	   11	  (3)	   6.4	   9.15	  
2	   WT	   C/C	   15	  (2)	   6.31	   16.5	  
3	   WT	   C/C	   13	  (2)	   5.62	   20	  
4	   C/C	   WT	   3	  (1)	   1.73	   0.165	  
5	   C/C	   WT	   0	  (0)	   1.5	   1.59	  
6	   C/C	   WT	   0	  (0)	   1.72	   0	  
7	   C/C	   WT	   0	  (0)	   1.62	   0.99	  
8	   C/C	   WT	   0	  (0)	   1.14	   1.05	  
9	   C/C	   WT	   0	  (0)	   1.43	   1.71	  
10	   C/C	   C/C	   8	  (1)	   2.25	   2.4	  
11	   C/C	   C/C	   0	  (0)	   2.02	   3.96	  *Relative	  testis	  mass	  determined	  by	  dividing	  the	  testis	  mass	  by	  total	  body	  weight.	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Supplementary	  Table	  2:	  Sequencing	  and	  mapping	  of	  WT	  and	  C/C	  
Transcriptome	  Organ	   Sex	   Mouse	  Identifier	   Genotype	   Barcode	   Millions	  of	  reads	   %	  Mapped	   %	  Multiply	  mapped	  
Testis	  
M	   817	   WT	   ACAGTG	   30.54	   89.56%	   6.34%	  M	   841	   WT	   ATCACG	   26.66	   87.67%	   6.59%	  M	   1218	   WT	   GCCAAT	   32.05	   86.60%	   6.75%	  M	   1222	   WT	   CGATGT	   23.75	   86.29%	   6.81%	  M	   818*	   C/C	   GATCAG	   20.92	   84.22%	   7.70%	  M	   839	   C/C	   ACAGTG	   23.49	   91.80%	   5.88%	  M	   1395	   C/C	   TAGCTT	   30.25	   88.66%	   5.87%	  
Liver	  
M	   841	   WT	   ATCACG	   25.29	   79.89%	   9.70%	  M	   1218	   WT	   GATCAG	   28.85	   79.86%	   12.43%	  F	   826	   WT	   CGATGT	   25.29	   80.48%	   11.40%	  F	   1241	   WT	   GGCTAC	   20.85	   81.26%	   9.98%	  M	   818	   C/C	   ACAGTG	   26.70	   79.54%	   9.88%	  M	   839	   C/C	   ATCACG	   27.08	   81.18%	   11.70%	  F	   827	   C/C	   GCCAAT	   28.78	   80.02%	   12.95%	  F	   1097	   C/C	   CGATGT	   25.27	   80.78%	   10.03%	  
Brain	  
M	   817	   WT	   ATCACG	   37.43	   86.74%	   6.65%	  M	   841	   WT	   GATCAG	   32.32	   88.05%	   6.78%	  F	   1241	   WT	   CGATGT	   31.57	   86.85%	   6.94%	  F	   1244	   WT	   TAGCTT	   36.17	   92.56%	   7.06%	  M	   1395	   C/C	   ACAGTG	   19.12	   88.65%	   6.98%	  M	   818	   C/C	   ATCACG	   31.98	   94.70%	   6.25%	  F	   827	   C/C	   GCCAAT	   27.11	   87.40%	   7.25%	  F	   833	   C/C	   CGATGT	   29.09	   95.34%	   6.48%	  *	  -­‐	  Outlier	  sample,	  which	  was	  removed	  from	  downstream	  analyses	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Supplementary	  Table	  3:	  Most	  highly	  upregulated	  genes	  identified	  by	  RNA-­‐
Seq	  Gene	  symbol	   Ensembl	  ID	   Log2	  Fold	  Change	   Standard	  error	   Adjusted	  P	  value	  Hist1h1c	   ENSMUSG00000036181	   2.03	   0.20	   8.71E-­‐21	  Lamb2	   ENSMUSG00000052911	   1.67	   0.17	   1.67E-­‐19	  Ddr1	   ENSMUSG00000003534	   1.71	   0.17	   1.67E-­‐19	  Apoe	   ENSMUSG00000002985	   1.92	   0.19	   2.26E-­‐19	  Cpe	   ENSMUSG00000037852	   1.39	   0.14	   1.42E-­‐18	  Serping1	   ENSMUSG00000023224	   1.93	   0.20	   1.42E-­‐18	  Aldh1a1	   ENSMUSG00000053279	   1.47	   0.16	   1.14E-­‐17	  Sparcl1	   ENSMUSG00000029309	   1.70	   0.18	   2.28E-­‐17	  Aebp1	   ENSMUSG00000020473	   1.82	   0.20	   8.94E-­‐16	  Timp2	   ENSMUSG00000017466	   1.12	   0.13	   8.45E-­‐15	  Wnt6	   ENSMUSG00000033227	   1.55	   0.18	   1.63E-­‐14	  Igfbp3	   ENSMUSG00000020427	   2.45	   0.29	   1.63E-­‐14	  Rcn3	   ENSMUSG00000019539	   1.97	   0.23	   2.14E-­‐14	  Lamb1	   ENSMUSG00000002900	   1.43	   0.17	   3.76E-­‐14	  C1ra	   ENSMUSG00000055172	   2.02	   0.25	   2.07E-­‐13	  Arpc1b	   ENSMUSG00000029622	   1.22	   0.15	   2.36E-­‐13	  Rgs11	   ENSMUSG00000024186	   2.16	   0.26	   2.43E-­‐13	  Clec3b	   ENSMUSG00000025784	   2.05	   0.26	   8.20E-­‐13	  Ildr2	   ENSMUSG00000040612	   2.63	   0.33	   9.31E-­‐13	  Pdgfra	   ENSMUSG00000029231	   1.55	   0.19	   1.24E-­‐12	  Prss35	   ENSMUSG00000033491	   1.96	   0.25	   1.64E-­‐12	  Kit	   ENSMUSG00000005672	   1.24	   0.16	   2.78E-­‐12	  Col6a6	   ENSMUSG00000043719	   2.38	   0.30	   3.29E-­‐12	  Lrp1	   ENSMUSG00000040249	   1.39	   0.18	   6.16E-­‐12	  Lgmn	   ENSMUSG00000021190	   1.11	   0.14	   1.00E-­‐11	  Ndrg2	   ENSMUSG00000004558	   1.42	   0.19	   1.00E-­‐11	  Dcn	   ENSMUSG00000019929	   1.87	   0.24	   1.02E-­‐11	  Tspan4	   ENSMUSG00000025511	   1.70	   0.22	   1.27E-­‐11	  Lipg	   ENSMUSG00000053846	   1.29	   0.17	   1.29E-­‐11	  Phlda3	   ENSMUSG00000041801	   2.44	   0.32	   1.34E-­‐11	  Mpeg1	   ENSMUSG00000046805	   1.53	   0.20	   1.41E-­‐11	  9030617O03Rik	   ENSMUSG00000021185	   2.73	   0.36	   1.59E-­‐11	  Sulf2	   ENSMUSG00000006800	   1.29	   0.17	   2.82E-­‐11	  Aox1	   ENSMUSG00000063558	   1.53	   0.20	   3.04E-­‐11	  Kif1c	   ENSMUSG00000020821	   1.20	   0.16	   3.26E-­‐11	  Tshz2	   ENSMUSG00000047907	   1.26	   0.17	   3.69E-­‐11	  Ctsz	   ENSMUSG00000016256	   1.77	   0.24	   4.75E-­‐11	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Supplementary	  Table	  3	  Continued	  Gene	  symbol	   Ensembl	  ID	   Log2	  Fold	  Change	   Standard	  error	   Adjusted	  P	  value	  Meg3	   ENSMUSG00000021268	   1.69	   0.23	   5.23E-­‐11	  Osr2	   ENSMUSG00000022330	   1.73	   0.23	   5.23E-­‐11	  Lamc3	   ENSMUSG00000026840	   1.34	   0.18	   5.65E-­‐11	  Myh9	   ENSMUSG00000022443	   1.18	   0.16	   6.22E-­‐11	  Vim	   ENSMUSG00000026728	   1.08	   0.15	   7.12E-­‐11	  Aplp1	   ENSMUSG00000006651	   1.39	   0.19	   9.74E-­‐11	  C1qa	   ENSMUSG00000036887	   1.89	   0.26	   9.81E-­‐11	  Timp1	   ENSMUSG00000001131	   3.08	   0.42	   1.12E-­‐10	  Aldh2	   ENSMUSG00000029455	   1.24	   0.17	   1.13E-­‐10	  Cyp27a1	   ENSMUSG00000026170	   1.56	   0.21	   1.13E-­‐10	  Akr1cl	   ENSMUSG00000025955	   1.58	   0.22	   1.15E-­‐10	  Ccdc8	   ENSMUSG00000041117	   1.45	   0.20	   1.51E-­‐10	  Cdkn1a	   ENSMUSG00000023067	   1.43	   0.20	   1.53E-­‐10	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Supplementary	  Table	  4:	  Most	  highly	  downregulated	  genes	  identified	  by	  RNA-­‐
Seq	  Gene	  symbol	   Ensembl	  ID	   Log2	  fold	  change	   Standard	  error	   Adjusted	  P	  Tmem56	   ENSMUSG00000028132	   -­‐1.06	   0.13	   1.58E-­‐12	  Tmsb15a	   ENSMUSG00000060726	   -­‐1.23	   0.17	   6.05E-­‐11	  Hypm	   ENSMUSG00000040456	   -­‐1.03	   0.14	   1.43E-­‐10	  Tppp2	   ENSMUSG00000008813	   -­‐1.02	   0.14	   3.04E-­‐10	  Oaz3	   ENSMUSG00000028141	   -­‐0.89	   0.13	   3.82E-­‐10	  Hist1h1t	   ENSMUSG00000036211	   -­‐1.55	   0.22	   6.97E-­‐10	  1700012A03Rik	   ENSMUSG00000029766	   -­‐1.00	   0.15	   2.07E-­‐09	  1700027A15Rik	   ENSMUSG00000101968	   -­‐0.95	   0.15	   2.50E-­‐08	  Ppp2r2b	   ENSMUSG00000024500	   -­‐0.92	   0.15	   3.62E-­‐08	  1700009N14Rik	   ENSMUSG00000028287	   -­‐0.83	   0.13	   3.95E-­‐08	  1700031F10Rik	   ENSMUSG00000047046	   -­‐1.31	   0.21	   7.50E-­‐08	  1700015G11Rik	   ENSMUSG00000094445	   -­‐0.81	   0.13	   8.62E-­‐08	  Spata18	   ENSMUSG00000029155	   -­‐0.84	   0.14	   1.00E-­‐07	  Lrrc8b	   ENSMUSG00000070639	   -­‐0.72	   0.12	   2.07E-­‐07	  Abcb5	   ENSMUSG00000072791	   -­‐3.26	   0.54	   2.23E-­‐07	  1700016H13Rik	   ENSMUSG00000029320	   -­‐0.75	   0.13	   4.34E-­‐07	  Yam1	   ENSMUSG00000098178	   -­‐1.04	   0.18	   5.05E-­‐07	  Hist1h2ba	   ENSMUSG00000050799	   -­‐1.06	   0.18	   5.44E-­‐07	  Clmn	   ENSMUSG00000021097	   -­‐0.74	   0.13	   8.70E-­‐07	  Gm23935	   ENSMUSG00000076258	   -­‐0.95	   0.17	   1.14E-­‐06	  Pdzd8	   ENSMUSG00000074746	   -­‐0.72	   0.13	   1.37E-­‐06	  Nsun4	   ENSMUSG00000028706	   -­‐0.79	   0.14	   1.71E-­‐06	  Tnp1	   ENSMUSG00000026182	   -­‐0.62	   0.11	   1.84E-­‐06	  H2afb1	   ENSMUSG00000062651	   -­‐0.72	   0.13	   2.16E-­‐06	  Lars2	   ENSMUSG00000035202	   -­‐0.92	   0.17	   2.52E-­‐06	  Npy	   ENSMUSG00000029819	   -­‐3.29	   0.60	   2.67E-­‐06	  1700020G17Rik	   ENSMUSG00000101801	   -­‐0.86	   0.16	   2.79E-­‐06	  Gm11780	   ENSMUSG00000085155	   -­‐0.83	   0.15	   2.98E-­‐06	  Klk1b8	   ENSMUSG00000063089	   -­‐0.87	   0.16	   3.37E-­‐06	  Prom1	   ENSMUSG00000029086	   -­‐0.68	   0.13	   3.79E-­‐06	  Prkar2a	   ENSMUSG00000032601	   -­‐0.72	   0.13	   3.79E-­‐06	  Cdrt4	   ENSMUSG00000042200	   -­‐0.73	   0.14	   4.09E-­‐06	  Gm498	   ENSMUSG00000031085	   -­‐0.77	   0.14	   4.16E-­‐06	  BB014433	   ENSMUSG00000049008	   -­‐0.71	   0.13	   4.17E-­‐06	  Rpl39l	   ENSMUSG00000039209	   -­‐0.68	   0.13	   4.24E-­‐06	  1700019O17Rik	   ENSMUSG00000036574	   -­‐0.69	   0.13	   4.35E-­‐06	  Lrrc74a	   ENSMUSG00000059114	   -­‐0.75	   0.14	   4.51E-­‐06	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Supplementary	  Table	  4	  Continued	  Gene	  symbol	   Ensembl	  ID	   Log2	  fold	  change	   Standard	  error	   Adjusted	  P	  Gm5893	   ENSMUSG00000011350	   -­‐0.66	   0.12	   5.20E-­‐06	  1700001C19Rik	   ENSMUSG00000047150	   -­‐0.71	   0.13	   5.26E-­‐06	  Dbil5	   ENSMUSG00000038057	   -­‐0.79	   0.15	   5.66E-­‐06	  St6galnac2	   ENSMUSG00000057286	   -­‐0.76	   0.14	   5.66E-­‐06	  Spem1	   ENSMUSG00000041165	   -­‐0.77	   0.14	   6.10E-­‐06	  Bpifa3	   ENSMUSG00000027482	   -­‐0.80	   0.15	   7.41E-­‐06	  Lrrc57	   ENSMUSG00000027286	   -­‐0.74	   0.14	   7.52E-­‐06	  1700080E11Rik	   ENSMUSG00000032566	   -­‐0.84	   0.16	   8.56E-­‐06	  Akap4	   ENSMUSG00000050089	   -­‐0.72	   0.14	   9.03E-­‐06	  Ubqlnl	   ENSMUSG00000051437	   -­‐0.68	   0.13	   9.06E-­‐06	  Mir6236	   ENSMUSG00000098973	   -­‐1.07	   0.21	   9.06E-­‐06	  Acsl1	   ENSMUSG00000018796	   -­‐0.71	   0.14	   9.07E-­‐06	  1700001K19Rik	   ENSMUSG00000056508	   -­‐0.74	   0.14	   9.60E-­‐06	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Supplementary	  Table	  5:	  QPCR	  validation	  of	  RNA-­‐Seq	  
	   	  
Allele	  C	  relative	  expression	  Gene	   Selected	  GO	  terms/KEGG	  pathways	   QPCR	   RNA-­‐Seq	  Unc5b	   Netrin	  receptor,	  apoptotic	  process,	  axon	  guidance	   1.327	   1.992	  Ntn3	   Receptor	  binding,	  axonogenesis	   2.292	   2.371	  Gpx4	   Response	  to	  oxidative	  stress,	  spermatogenesis	   0.824	   0.727	  Casp8	   Apoptotic	  process,	  cysteine-­‐type	  endopeptidase	  activity	   2.112	   2.277	  Bcl3	   DNA	  damage	  response,	  negative	  regulation	  of	  apoptotis	   2.721	   2.141	  Spatc1	   Gamma-­‐tubulin	  binding,	  centrosome	   0.823	   0.635	  Cdkl2	   Cyclin-­‐dependent	  protein	  serine/threonine	  kinase	  activity	   0.995	   0.697	  Hdac7	   B	  cell	  activation,	  histone	  deacetylation,	  vasculogenesis	   1.964	   1.798	  Bax	   Sertoli	  cell	  proliferation,	  apoptotic	  process	   2.171	   2.254	  Ntn1	   Axon	  guidance,	  proteinaceous	  extracellular	  matrix	   1.352	   1.529	  EphB1	   Axon	  guidance,	  angiogenesis,	  cell	  adhesion	   1.956	   1.927	  HoxD10	   Regulation	  of	  transcription,	  embryonic	  limb	  morphogenesis	   2.304	   2.813	  Mak	   Cyclin-­‐dependent	  protein	  serine/threonine	  kinase	  activity	   0.892	   0.730	  Tssk3	   Protein	  serine/threonine	  kinase	  activity,	  spermatogenesis	   0.900	   0.612	  Gapdhs	   Glycolytic	  process,	  sperm	  motility	   0.834	   0.659	  Sema7a	   Axon	  guidance,	  integrin	  binding	   1.725	   1.987	  Itgb1	   Axon	  guidance,	  cell-­‐matrix	  adhesion	   1.619	   1.778	  Npy	   GPCR	  binding,	  neuropeptide	  signaling	  pathway	   0.012	   0.103	  Lamb2	   Integrin	  binding,	  axon	  guidance,	  basement	  membrane	   2.145	   3.174	  Lss	   Cholesterol	  biosyntheic	  process	   1.628	   1.752	  Meg3	   DNA	  methylation,	  genetic	  imprinting	   3.225	   3.224	  Cxcl12	   Chemokine	  activity,	  germ	  cell	  development,	  axon	  guidance	   3.723	   2.747	  Ddr1	   Collagen	  binding,	  protein	  tyrosine	  kinase	  activity	   1.737	   3.274	  Msmo1	   Cholesterol	  biosyntheic	  process	   2.906	   2.517	  Neat1	   Protein	  binding,	  nuclear	  body	  organization	   1.977	   2.009	  Slit3	   Axon	  guidance,	  cell	  differentiation	   2.217	   1.922	  Tppp2	   Tubulin	  binding	   0.679	   0.493	  Apoe	   Cholesterol	  homeostatis,	  lipid	  homeostasis	   3.352	   3.795	  Dhcr7	   Cholesterol	  biosynthetic	  process	   1.920	   2.015	  Gm9999	   Unknown	  function	   0.855	   0.624	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  5	  Continued	  
	   	   Allele	  C	  relative	  expression	  Gene	   Selected	  GO	  terms/KEGG	  pathways	   QPCR	   RNA-­‐Seq	  Ppp3r2	   Calcium-­‐dependent	  protein	  SR	  phosphatase	  activity	   0.813	   0.752	  Oaz3	   Polyamine	  biosynthetic	  process	   0.773	   0.538	  Lipa	   Cholesterol	  biosynthetic	  process	   2.511	   2.092	  RP23-­‐402F16	   Unknown	  function	   0.931	   0.558	  Fus	   RNA	  binding	   1.356	   1.400	  Robo1	   Axon	  guidance	   1.653	   1.667	  Srgap1	   Axon	  guidance,	  Rho	  protein	  signal	  transduction	   1.425	   0.690	  Ppp2r2b	   Apoptotic	  process,	  signal	  transduction	   0.757	   0.528	  Cpe	   Peptidase	  activity,	  insulin	  processing	   2.298	   2.628	  Serping1	   Negative	  regulation	  of	  complement	  activation	   4.043	   3.798	  Dhcr24	   Cholesterol	  biosynthetic	  process	   1.740	   1.928	  Malat1	   Regulation	  of	  alternative	  mRNA	  splicing	   2.385	   1.906	  Efnb1	   Axon	  guidance,	  cell	  differentiation	   2.576	   2.889	  Srpk1	   Protein	  serine/threonine	  kinase	  activity,	  RNA	  splicing	   0.955	   0.852	  Lsm2	   RNA	  splicing	   0.874	   0.773	  Rbmxl2	   RNA	  splicing	   0.790	   0.910	  Rbmx	   RNA	  splicing,	  DNA-­‐templated	  transcription	   1.310	   1.558	  SFPQ	   RNA	  splicing,	  DNA	  repair,	  DNA-­‐templated	  transcription	   1.186	   1.068	  Gemin2	   Spliceosomal	  snRNP	  assembly	   0.903	   0.863	  Gemin3	   Helicase	  activity,	  Spliceosomal	  snRNP	  assembly	   0.996	   0.678	  Gemin4	   Spliceosomal	  snRNP	  assembly	   0.729	   0.739	  Gemin5	   snRNA	  binding,	  spliceosomal	  snRNP	  assembly	   0.929	   0.843	  Gemin6	   Spliceosomal	  snRNP	  assembly	   0.873	   0.777	  Gemin7	   Spliceosomal	  snRNP	  assembly	   1.008	   0.994	  Gemin8	   Spliceosomal	  snRNP	  assembly	   1.025	   1.037	  Ptbp1	   RNA	  splicing	   1.082	   1.124	  Ptbp2	   RNA	  splicing	   1.152	   0.845	  Hnrnpa1	   RNA	  splicing	   1.264	   1.152	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Supplementary	  Table	  6:	  Primers	  used	  for	  QPCR	  Gene	   Forward	  Primer	   Reverse	  Primer	  Gemin2	   GGAGAGTGCAGATCGAAGCA	   GCCACTTGTTGTTGTTGCCA	  Gemin3	   AGTCGGGCACTGGAAAAACT	   ACCAGGAGATCCAACAGCAA	  Gemin4	   GGAAGACCTCAACACGACGT	   GCAGGGAAGGCAGTGAGAAT	  Gemin5	   ACAGCATAACCCCTGGAAGC	   AGCCAGGACTTTGCCATCTC	  Gemin6	   GCAACTGGTAACCATGAGCG	   GGCCCATGATTCCAGTCACA	  Gemin7	   ATCCCCCAGAGTCACAGGAA	   AGGTCTGTGGCTCCAAACTG	  Gemin8	   AGAGGGAATGAAGCACGGTG	   GGTGGTTGAAGTACAGGCCA	  Ptbp1	   AGTCTGGAAACCTGGCCTTG	   GATCTTCAGGACGGTGCCAA	  Ptbp2	   GGCAACAGAGGAAGCAGCTA	   GAACTACTTGCGCACGTTGG	  Hnrnpa1	   ACGAGAGTCTGAGGAGCCAT	   TCCACTTCTTCCACAGTGGC	  Srpk1	   ACAAAGCCCAAAGGAAGCCT	   TCCCCAGCCCAATTTTCGAA	  Lsm2	   GGCAAGGATGTAGTCGTGGA	   AGGGTATTTCTCAGGGTCTGTG	  Rbmxl2	   TCTTCATCGGCGGTCTCAAC	   TTCTCGAAGGTGACGAAGGC	  Rbmx	   GTTCGTAGCAGCAGTGGACT	   TCCATCATCTCTCGGGGACA	  Sfpq	   GCCAGCAGCAAGAAAAGCAT	   TGTGCCATGCTGAGCAAAAC	  HisH1C	   GGCATCCTGGTGCAAACCAA	   CCTTTTTGGGTGTGGCAGCA	  Unc5b	   ACGGCCAACTACACCTGTGT	   ACAGAAGGCGCCTCCATTGA	  Netrin	  1	   TGTCTCAACTGCCGCCACAA	   TTGCAGGGACATTGGCCAGT	  Netrin	  3	   ATGCCGCTTCAACATGGAGC	   TGGCAGTCACAAGCTCTGCA	  Casp7	   AACCGTCCACAATGACTGCTCT	   TGTCACGCCATCTTTCCCGTAA	  Casp8	   AGCTGCGGGATCCAGACAAT	   TGCCAGCATGGTCCTCTTCT	  Casp9	   GGACCGTGACAAACTTGAGCAC	   ATCTCCATCAAAGCCGTGACCA	  Akt1	   ACACCTTTATCATCCGCTGCCT	   CTCTTCAGCCCCTGAGTTGTCA	  Apaf1	   AGAGATCCACACAGGCCATCAC	   ATCACACCGTGAACCCAACTCA	  Capn2	   TTGACGCCAATGAGGAGGACAT	   CCACTCCCATCTTCATCCAGCA	  Aifm1	   CCGTTCGGAGAGTGAGACAGAG	   TAGCACAATCCCCACCACAACT	  Bcl3	   ACAGCGGCCTCAAGAACTGT	   TGGCACTTTGGTCTGGGGAT	  Bax	   CCCACCAGCTCTGAACAGATCA	   TGTCCACGTCAGCAATCATCCT	  Fus	   AGTTGAAGGGTGAGGCAACAGT	   TTCCACCACCCCGATTGAAGTC	  HoxD10	   CGAAGTGCAGGAGAAGGAAAGC	   AGCGTTTGGTGCTTGGTGTAAG	  EphB1	   GCAGCAGGAAACGAGCTTACAG	   CGGCTTCATTGGGGTCCTCATA	  Hdac7	   CTCTTGAGCCCTTGGACACAGA	   GGGTTTGTAGCGCAACTTCAGG	  Spatc1	   ACGCCCCACCGAAAGTCTAA	   TGGCACAGGTCCTCATCCAA	  Cdkl2	   AGTCTCCCAGTCTGGCGTTG	   CGTCACCGACCAGCAGTTCT	  Mak	   CGAGGCCATCCAGCTCATGA	   CCCGGCAGGCTGATCAAGTA	  Tssk3	   CTTTGCCAAGGTGCTACCCAAG	   ATACAGGACCACACCCATGCTC	  H1fnt	   GCTAAGGACCTAGTGCGTTCCA	   GTACTGCTGCTCTTTGGCACTG	  Gpx4	   CGCTCCATGCACGAATTCTCAG	   GGCCAGGATTCGTAAACCACAC	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Supplementary	  Table	  6	  Continued	  Gene	   Forward	  Primer	   Reverse	  Primer	  Hist1h1a	   TCTACTGCCACGGAGAAACCTG	   CCACTGCGCTCTTTGGAAGAAG	  Hils1	   AAATGGTGGCTGGAGACCAAGA	   TTATGTACCCGCTTGTCAGCCA	  Dnahc8	   AGGCTGAGCTGGATAAAGTGCA	   GGTAGGAGAGAAAGCCTGTGCA	  Gapdhs	   GTGTCAGTTGTGGACCTGACCT	   GGGATTGCCGTTAAAGTCCGTG	  Efnb1	   AACGTCCAATGGGAGCTTGGAG	   TAGTCAACTGCTCGGGTGTCAC	  Sema7a	   CGGAAGCTCTATGTGACCTCCC	   GTGTGGCTCCGCTGGATTAATG	  Cxcl12	   GGTAAACCAGTCAGCCTGAGCT	   TTGTTGTTCTTCAGCCGTGCAA	  Slit3	   GTGGCGACTGACAAGGACAATG	   CCACACTGTGAAACTGGCCATC	  Itgb1	   GTGAGACATGTCAGACCTGCCT	   TCCTTGCAATGGGTCACAGGAT	  Robo1	   CTCCCCCACATAGCAACAGTGA	   GTAGGACACAGCAGCTGGAGAA	  Ppp3r2	   GCTGGTGGACAAGAGCATCTT	   AAGTCTTCTTGACCGTGTTCTACA	  Ppp3cc	   AGGAAGAACCAAGCAACTGGCT	   TGAAGTTTGGGAGCCAGTAGGG	  Srgap1	   CTGTACTTCCGAGGGCTGGAAA	   CGTCACTGTACTGGGAGAGGTG	  Npy	   CTGACCCTCGCTCTATCTCTGC	   CAGTGTCTCAGGGCTGGATCTC	  Tmsb15a	   ACCAGACTTGTCGGAAGTGGAG	   ACTCCTTCTCTTGCTCGATGGT	  Tppp2	   GGCCAAGAATGCCAGAACCATC	   TGGTGTCTGTCAACCGGTCTAC	  Oaz3	   GGATCAAGGCAACCGAGAAAGC	   TCTAACCACCTCGAAGCCCATG	  Ppp2r2b	   ACCGGAAGATCCAAGCAACAGA	   AACTTGCTGCGGAGGTAGTCAT	  Lamb2	   GGGTGAGAGACAGAAGGCAGAG	   ACCGGCAGAGTTCAGAGACTTC	  Ddr1	   GACTCCTCTGACACCTTCCCAC	   TGAGAAGCAGCAGCAGGATGAT	  Apoe	   GTCACATTGCTGACAGGATGCC	   CTTCCTGGACCTGGTCAGACAG	  Cpe	   TCTCTGTGGACGGGATAGACCA	   CAAGCTCAAAGTCCACCCCAAC	  Serping1	   CCACTTACCTGACGATGCCTCA	   TGGCAGACACCTGAAGATCTGG	  Lss	   AGGAGCACGTTTCTCGGATCAA	   AGGGCAGAAACTCAGGTCTGTG	  Msmo1	   GCTGTGCAGTCATTGAGGACAC	   GGGATGTGCGTATTCTGCTTCG	  Dhcr7	   GCCTGGACCCTCATTAACCTGT	   AAGTGGTCATGGCAGATGTCGA	  Lipa	   AATTTTGCTTCAGGCCCGCTAC	   GCGCAAAGCTCCTTCATGATGA	  Dhcr24	   GATGGACATCCTGGAGGTGGAC	   GGTCATCAAGCTCAGGCAACAC	  Meg3	   CCATCTCCACAGAAGAGCAGCT	   CCCACGCAGGATTCCAGATGAT	  Neat1	   TGTTCACCATGGCAAGCAGATG	   ACAAGCTGACTTCAACGATGGC	  Gm9999	   GGGACCCCTCTGGAAGTAAACA	   TGTGCGATTACTTTATGCGAAACCT	  RP23-­‐402F16.1	   ATGAAGACTTCTCCACCCAGCC	   CCACCCTACCTACTGTAGTACGC	  Malat1	   TTCATGGAGCTGCTCAGGACTT	   ACCTGAAGTCAAGACACCTGCA	  Smn	   AGAACAGAACACTCAGGAGAATGA	  	   CTTTCCTGGTCCTAATCCTGA	  FL	  SMN2	   TTCCTTCTGGACCACCAATAA	   TCTATGCCAGCATTTCTCCTTAATTTAAG	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IN VITRO SELECTION REVEALS HIGH AFFINITY RNA TARGETS OF THE 
SURVIVAL MOTOR NEURON PROTEIN 
 A	  manuscript	  currently	  under	  preparation 




The Survival Motor Neuron (SMN) protein is an essential protein required for survival of 
all animal cells. Low levels of SMN result in spinal muscular atrophy (SMA), a leading 
genetic disease of children and infants. Consistent with the multiple functions associated 
with SMN, several proteins interact with SMN. There is also evidence to suggest that 
SMN directly interacts with RNA. However, there is no study demonstrating the diversity 
of RNA motifs with which SMN interacts with high specificity and affinity. Here we 
employ Systematic Evolution of Ligands by Exponential Enrichment (SELEX) to 
identify RNA sequence and structural motif(s) of SMN. Our results reveal a combination 
of sequence motifs and structural contexts that drive the specificity of SMN-RNA 
interactions. Among sequence motifs that were frequently selected include but not limited 
to UGG and UGC. Mutations within these motifs caused a noticeable decrease in 
binding. All of the selected sequences had at least two terminal stem-loop (TSL) 
structures. We show that the strengthening of the stem of the 3ʹ′ TSL in one of the high-
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affinity sequences substantially improved the RNA-SMN interaction. Our results of 
truncation and substitution experiments suggest a requirement for multiple contacts 
between SMN and RNA to maintain the high affinity. We demonstrate that both affinity 
and specificity of SMN-RNA interaction are influenced by salt concentrations. Our 
findings bring a new perspective to SMN-RNA interaction and suggest a wider role of 




Spinal muscular atrophy (SMA) is a genetic disorder which leads to the progressive 
deterioration of motor neurons. It is the most prevalent genetic cause of infant mortality, 
affecting approximately 1 in 10,000 infants (Wirth et al 2006). SMA is caused by 
homozygous deletion or mutation of the Survival Motor Neuron 1 gene (SMN1) 
(Lefebvre et al 1995). Humans have a second gene, SMN2, which is only partially 
functional due to a C-to-T transition at the sixth position of exon 7. Although 
translationally silent, the C-to-T transition (C-to-U in the mRNA) interferes with efficient 
splicing of SMN2 exon 7, causing predominant skipping of this exon (Lorson et al 1999). 
The major protein produced by SMN2, SMN∆7, is extremely unstable due to the creation 
of a C-terminal degradation signal, or degron (Cho and Dreyfuss 2010).  
 The full extent of the function(s) of the SMN protein remains an active topic of 
research. The most well-studied function of SMN is the assembly of small nuclear 
ribonucleoproteins (snRNPs) (Meister et al 2001, Zhang et al 2008). The U1, U2, U4, U5, 
and U6 snRNPs form the catalytic core of the major spliceosome, which is required for 
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the removal of most eukaryotic introns (Wahl et al 2009). The snRNPs consist of a RNA 
component, known as the small nuclear RNA (snRNA) and a septameric ring of proteins 
known as the Smith (Sm) proteins (Lsm for U6), as well as proteins specific to each 
snRNA (Will and Lührman 2001, Wahl et al 2009). SMN enhances the association of 
snRNAs with the Sm ring in conjunction with a number of other proteins, which form a 
large macromolecular complex known as the SMN complex (Pellizzoni et al 2002). 
Components of the SMN complex include Gemins 2-8 and Unrip (Cauchi et al 2010). In 
the current model of snRNP assembly, Gemin5 is the sole component of the SMN 
complex that directly interacts with snRNAs (Yong et al 2010). Recently, however, it has 
been shown that U1-70K can directly recruit SMN to enhance Sm recruitment on U1 
snRNA independently of Gemin5 (So et al 2016). This is likely in order to meet an 
increased demand for U1 snRNP assembly, as U1 is more abundant than all other 
snRNPs combined (Kaida et al 2010). Currently, it is not known whether SMN in SMN 
complex directly contacts RNA in a sequence and/or structure-specific manner.  
Several implicated functions of SMN involve interaction with RNAs directly or 
indirectly. These functions include but are not limited to mRNA transport (Rossoll et al 
2003, Akten et al 2011, Fallini et al 2011, Fallini et al 2014), stress granule formation 
(Hua et al 2004, Zou et al 2011), biogenesis of the signal recognition particle (SRP) 
(Piazzon et al 2013), transcription (Strasswimmer et al 1999, Zhao et al 2016), and 
translation (Sanchez et al 2013). The SMN protein has been shown to bind RNA in vitro 
(Lorson and Androphy 1998, Bertrandy et al. 1999). This activity was localized to the N 
terminal region of the protein, specifically the region coded by exons 2A and 2B (Lorson 
and Androphy 1998). However, not much is known about SMN’s binding specificity, 
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aside from a preference for poly(G) oligonucleotides (Lorson and Androphy 1998, 
Bertrandy et al. 1999). A recent study employed RNA immunoprecipitation followed by 
microarray analysis (RIP-Chip) to capture SMN-interacting RNAs (Rage et al., 2013). 
However, sequence specificity was not investigated. 
 Systematic Evolution of Ligands by Exponential Enrichment (SELEX) is a 
powerful technique that uses iterative selection to identify high-affinity nucleic acid 
sequences (ligands) that bind a target molecule of interest including proteins, nucleic 
acids and small compounds (Tuerk and Gold 1990, Ellington and Szostak 1990, Jayasena 
2001, Stoltenburg et al 2007). SELEX has been frequently employed as a decisive tool to 
identify the sequence specificity of RNA binding proteins (RBPs) (Tacke and Manley 
1995, Dember et al 1996, Dubey et al 2005).  
Here, we use SELEX to identify the sequence specificity of RNA molecules 
(ligands) that bind to purified SMN with high affinity. We performed nine rounds of 
selection to enrich RNA pool showing about ~35 fold higher affinity for SMN than the 
initial pool used for the selection experiment. We observed that the preference of the 
selected motifs included but was not limited to UGG and UGC. Selected sequences 
folded into a variety of the predicted secondary structures. Mutations and/or deletions 
abrogating the predicted structures impacted the affinity of RNA-SMN interactions. We 
show that the RNA-SMN interaction is strongly influenced by binding conditions, 
specifically the concentration of salt in the binding reaction. Our results bring new 







Selection of high-affinity sequences by SELEX 
In order to determine whether SMN binds RNA in a sequence-specific manner, we 
performed SELEX. We began by purifying recombinant SMN from E. Coli expressing 
SMN via an IMPACT system vector (Supplementary Figure 1). The IMPACT system 
generates tag-free protein due to its self-cleaving intein tag (Chong et al 1997). The initial 
pool comprised of template oligonucleotides that contained a T7 promoter, 5ʹ′ and 3ʹ′ 
constant regions for PCR amplification, and a 25 nucleotide (nt) randomized region 
(Figure 1A). Of note, randomized regions of this length or lower have been used in a 
number of SELEX experiments (Tuerk and Gold 1990, Ghisolfi-Nieto et al 1996, 
Takagaki and Manley 1997, Dubey et al 2005, Skrisovska et al 2007). We sequenced 50 
clones from the initial pool to test for sequence bias. We did not observe any duplicate 
sequences or biased base composition in the randomized region (Table 1). We used 10 
randomly selected clones from pool 0 to establish a baseline binding affinity of SMN for 
unselected sequences by the nitrocellulose filter paper binding assay (Wong and Lohman 
1993) (Figure 2A). 
 Selection was performed using nitrocellulose filter paper to capture RNA-protein 
complexes (Figure 1B; Singh et al., 2002). The initial RNA input for selection was an 
estimated 2.4 x 1014 molecules, generated from 1.2 x 1014 molecules of DNA template, 
resulting in an estimated 2 copies of each unique molecule. In order to capture rare 
sequences with high affinity, we started with an excess of SMN protein over RNA and 
gradually increased the selection stringency over the first 4 rounds of selection by 
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reducing the amount of protein in the reaction (Table 2). After 6 rounds, we performed a 
binding assay with a limited number of sequences and discovered a mix of sequences 
with low and high affinity for SMN (Figure 2B). In order to remove the majority of low-
affinity sequences, we performed a highly stringent round of selection with more than 10-
fold less protein than RNA, followed by two more rounds with near equimolar 
concentrations (Table 1). The final pool (P9) had roughly 35-fold higher increase in 
binding than the initial pool (Table 1). 
 
Characterization of selected sequences 
We next cloned the final pool and sequenced 99 randomly selected clones (Table 3). We 
observed 10 pairs of identical sequences, suggesting that the selection was nearing 
completion. In order to reduce bias coming from identical sequences, we counted 
duplicate clones as one clone for analysis. The selected sequences tended to be G- and U-
rich with following occurrence: 11.9% A, 31.9% U, 16.5% C, and 39.8% G (Table 3). 
We examined the selected sequences for enrichment of specific trinucleotides (Table 4). 
In particular, we noticed high occurrences of UGC, UGG, GUG, and UUG. Since UGG 
was frequently represented in the initial pool as well (Table 4B), we infer that the specific 
enrichment of UGG did not occur during selection. We searched the selected sequences 
for additional enriched sequence motifs using MEME (Bailey et al 2009). We observed 
enrichment for a single motif, GUGCG (E-value=4.6x10-9). This motif frequently 
occurred at the 5ʹ′ end of the randomized region, although location varied somewhat and 
some sequences had multiple occurrences of the GUGCG motif (Table 3). We also 
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obtained high-affinity clones without GUGCG motif suggesting a pentameric motif is not 
required for the high affinity and/or specificity of RNA-SMN interaction.  
 We analyzed the binding of 78 sequences from the final pool (Table 3, 
Supplementary Figure 2). We observed a wide range of binding affinities for individual 
sequences (Supplementary Figure 2). For further analysis, we separated the sequences 
based on their binding affinity into two categories: non-binders, with <20% of the 
binding compared to pooled P9 RNA, and binders, with >20% of the binding compared 
to the pool. The base composition of the two groups of clones was similar; however, the 
SMN-binding sequences had a higher prevalence of the GUGCG motif, with a 55.6% 
(25/45) occurrence, compared to 12.1% (4/33) of the non-binders (Table 3). However, 
due to the presence of low binders with GUGCG and high binders without, we conclude 
that presence of a GUGCG motif is not the sole determinant of the strength of SMN-
RNA interaction. 
 We chose the 10 highest-affinity binders for further characterization 
(Supplementary Figure 3). Sequence-wise, they resembled the general population of 
selected clones, with high frequency of Gs and Us (Supplementary Figure 3A). We 
performed binding with these 10 clones (Supplementary Figure 3B) and selected the top 
5 for further characterization. For the 5 highest binders, we generated binding curves and 
determined the apparent dissociation constants (Kdapp) (Figure 3B-3G). For an estimate of 
nonspecific binding to RNA we used P0-44 from the initial unselected pool. The 
calculated dissociation constants ranged from 20 nM in the case of P9-74 to 46 nM for 
P9-71. (Figure 3B-3F). In contrast, for the unselected RNA, we were unable to determine 
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an exact Kdapp in this assay as binding was not saturated even at the highest concentration 
of protein tested (Figure 3G).  
We predicted the RNA secondary structures of all of the top 5 binders (Figure 
3H). In all of the Mfold (Zuker et al 2003) predicted structures, at least two terminal 
stem-loops (TSLs) were formed. The 5ʹ′ TSL generally contained the GUGCG motif, 
although its position relative to the loop was not conserved. In both TSLs, the stems and 
loops were of variable length, although in general the 5ʹ′TSL had a smaller loop, ranging 
from 4-6 bases. The 3ʹ′TSL was variable both in loop size and stem length. Of note, all of 
the TSLs comprised of bases from both the constant and selected regions (Figure 3H). 
 
Effect of RNA Sequence on Binding of SMN 
We developed a comparative binding assay based on the nitrocellulose binding assay to 
assess the relative affinity of sequences with respect to a reference RNA that is common 
in all reactions. This approach has been successfully employed for an unbiased  
determination of the relative affinities of RNAs against a given protein (Singh et al 2002, 
Singh et al 2011). We chose P9-10 as the lead candidate for the examination of RNA-
SMN interactions in further detail. We constructed P9-10E, a reference RNA, by adding 
21 bases to the 3ʹ′ end of P9-10 (Figure 4A). We used P0-44, a sequence from the initial 
pool, as a negative control. As an additional negative control, we used P9-10RV that has 
sequence reverse to that of P9-10. Both P0-44 and P9-10RV showed background level of 
binding. Within P9-10, we tested the relative contribution of G residues within the first 
(positions 16, 18, 20, 21, 22, and 26) or second (positions 30, 32, 33, 38, and 39) half of 
the selected region. Our choice of G residue was based on the prevalence of G-rich motifs 
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in the selected region.  Supporting that GUGCG motif is not critical for binding, G-to A 
substitutions within GUGCG motif or outside of this motif showed similar reductions in 
binding (Figure 4A, lanes 7-10). We next created 4 new mutants with less extensive base 
changes (Figure 4B, top panel). The first mutant, G1-3A, had a triple substitution at 
positions 16, 18, and 20 that changed the GUGCG sequence to AUACA. In addition, we 
made other G-A substitutions: G4-6A with mutations at positions 21, 22, and 26, G7-9A 
with mutations at positions 30, 32, and 33, and finally G10-11A with mutations at 
positions 38 and 39. G1-3A had the strongest effect on SMN binding, reducing the 
activity to ~30% of WT (Figure 4B, lanes 5-6), compared to ~50-65% for the other 3 
mutants (Figure 4B, lanes 7-12).  
 
Role of Flanking Sequences and Secondary Structure in SMN-RNA Interaction 
All of the structures predicted to be formed by the top binding RNAs require 
extensive base pairing between the constant and selected regions of each RNA molecule 
(Figure 3H). In order to investigate the effect of RNA structure on binding of SMN, we 
generated a set of mutants with alterations of the constant region designed to disrupt 
particular structural features of the P9-10 RNA. P9-10 forms 3 predicted stem-loops: 
stem loop 1, which is formed by 2 base pairs within the 5ʹ′ constant region, stem loop 2, 
which is formed by base pairing between the 5ʹ′ constant region and 3 bases within the 
selected region, and stem loop 3, which is formed by extensive base pairing between the 
selected region and the 3ʹ′ constant region. We designed 2 mutants within the 5ʹ′ constant 
region that disrupted stem loop 2, 2 designed to disrupt stem loop 3, and 2 that reinforce 
stem loop 3, by either adding a new base-pairing partner for the bulging base or by 
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extending the stem into the loop by 4 bases (Figure 5). Both of the mutants within the 5ʹ′ 
constant region moderately reduced binding affinity (Figure 5, lanes 5-8). Surprisingly, 
eliminating the bulging base from the 3ʹ′ stem had a strong stimulatory effect on binding 
of SMN (Figure 5, lanes 9-10). Of all the mutants, the largest reduction in activity was 
achieved by modifying the 3ʹ′-most bases, which form the base of the 3ʹ′ stem (Figure 5, 
lanes 11-12). Finally, reducing or increasing base-pairing at the distal end of the 3ʹ′ stem 
had a moderate impact on SMN binding (Figure 5, lanes 13-16). 
 
Effect of RNA Size on SMN-RNA Interaction 
We also generated a series of truncated mutants in P9-10 RNA to identify the 
minimal binding region for SMN. All 3ʹ′ truncations reduced binding to background 
levels, even Δ48-57 which retains the entire selected region (Figure 6A, lanes 5-12). This 
may be due to the loss of base pairing to the selected region. Consistent with these 
results, mutation of the 3ʹ′-most bases had a similar reduction in binding (Figure 5, lanes 
11-12). There is another noticeable drop in activity when 30 bases are deleted at the 3ʹ′ 
end, which could be due to either reduction in total size of the RNA molecule or loss of a 
secondary binding contact with SMN (Figure 6A, lanes 9-10). Yet more activity is lost 
with deletion of another 10 bases from the 3ʹ′ end (Figure 6A, lanes 11-12). This final 
deletion has lost almost all of the selected region, including the 5ʹ′ GUGCG motif (Figure 
6A, top panel). Of the 5ʹ′ deletions, removal of the first 10 bases after GGG (required for 
efficient T7 transcription) has a moderate effect on SMN binding (Figure 6B, lanes 5-6), 
whereas further deletion abrogates binding almost completely (Figure 6B, lanes 7-10). 




Effect of Salt Concentrations on SMN Binding to RNA 
Previous reports indicate that the RNA binding activity of SMN is largely resistant to 
salt, with strong binding at up to 250 mM and some residual binding at concentrations as 
high as 1 M (Lorson and Androphy 1998, Betrandy et al 1999). In order to test the 
binding of SMN to our selected RNA in various conditions of ionic strength, we 
performed our comparative binding assay in a range of salt concentrations (Figure 7).  
Notably, binding of P9-10 was almost completely lost at 200 mM NaCl (Figure 8A, lanes 
1-7). These results are not totally unexpected, since we performed selection experiment at 
150 nM. At 250 mM NaCl, binding is indistinguishable from reactions with SMN protein 
completely omitted (Figure 8A, lanes 6-7). We tested binding of two negative controls, 
P9-10 RV and P0-44 (Figure 7A, lanes 8-21). Both have weaker binding than the 
reference RNA at all concentrations of NaCl tested.  Our results also supported that a 
lower salt concentrations promoted non-specific RNA-SMN interaction (Figure 7B). 
However, as expected, the specificity was highest a 150 nM, the concentration used for 




In this study, we employed SELEX to identify sequence motifs required for a strong 
interaction between RNA and the SMN protein. We performed 9 rounds of selection, 
obtaining a ~35-fold enrichment in relative binding (Table 2). The selected sequences 
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with the highest binding affinity have apparent dissociation constants ranging from 20 to 
46 nM (Figure 3H). This is similar to the binding affinity of Gemin5 for snRNA, which 
binds U4 with a Kd of 30.5 nM (Lau et al 2009), and is typical for a specific interaction of 
an RBP with RNA, which can range from below 8 nM up to 200 nM or more (Ma et al 
2002, Cammas et al 2007, Bhardwaj et al 2013, Schwartz et al 2013, Workman et al 
2014).  
 Analysis of the sequences selected for interaction with SMN yielded a high 
enrichment for a GUGCG motif in several but not all clones. Interestingly, GUGCG is 
also present in the minor spliceosomal U11 snRNA and the 7SL RNA, which forms the 
RNA component of the SRP (Keenan et al 2001), both of which are known targets of the 
SMN complex (Lotti et al 2012, Piazzon et al 2013). However, several lines of evidence 
support that GUGCG motif was not sole criterion for RNA-SMN interaction. 
Consistently, several mutations outside the GUGCG motif reduced affinity for SMN 
interaction (Figure 5, Figure 6). Our results suggest that SMN contacts the RNA substrate 
at two or more sites. It is likely that one of the sites serves as the primary sites whereas 
the other sites serve as the secondary sites.  Such a mode of binding has been observed 
for the bacterial protein CsrA (Dubey et al 2005) and for the mammalian testes-specific 
protein RBMY (Skrisovska et al 2007). 
 Because the motif occurred at a conserved location relative to the flanking regions 
and because 3 of the top 5 binders formed strikingly similar structures, we hypothesized 
that selection favored particular structures formed in the context of the 5ʹ′ and 3ʹ′ constant 
sequences. In fact, it is common for SELEX-derived sequences to recruit portions of the 
constant flanking sequences to form structures required for binding (Dubey et al 2005). 
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Supporting this conclusion, both mutation and truncation of the 3ʹ′-most portion of the 
flanking sequence of clone P9-10 had a significant effect on binding to SMN (Figure 5, 
Figure 6A). In fact, all of the mutations in the flanking sequences that we tested had some 
impact on binding, indicating the strong pressure that context exerted on the type of 
sequences that were selected. 
 Of all the mutants that we tested in this study, only one had a positive impact on 
SMN binding. This mutant, P9-10 B+1D1, reinforced the 3ʹ′ stem within P9-10 by 
providing a base-pairing partner to the U residue at position 28, which is normally 
unpaired and forms a bulge within the predicted stem. This indicates two things. First, it 
reinforces the critical role that RNA secondary structure plays in the binding of SMN, 
especially the role of the 3ʹ′ stem. Second, it suggests that SELEX was not able to identify 
fully idealized binding sites for SMN, possibly due to limited complexity of the initial 
RNA pool used for selection, or due to other constraints introduced during selection 
itself. These results support the possibility of even better RNA ligands for RNA-SMN 
interaction that we have generated in this study.   
 Binding of SMN to RNA was strongly impacted by the amount of salt in the 
binding buffer, with binding almost completely lost at concentrations greater than 200 
mM NaCl. This is in direct contrast with previous studies, which found reduced but still 
measurable binding at concentrations as high as 500 mM-1 M (Lorson and Androphy 
1998, Bertrandy et al 1999). Interestingly, the protein-protein interactions which drive the 
formation of the SMN complex appear to be much more stable in high-salt conditions, as 
indicated by the ability to isolate core SMN complexes in concentrations as high as 500 
mM NaCl (Pellizzoni et al 2002). Our results support the likelihood of direct RNA-SMN 
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interactions at physiological conditions particularly in those cell types where SMN is 
excessively expressed compared to its interacting partners. Testis is one such tissue in 
which SMN is disproportionately expressed at high levels and role of SMN has been 
recently implicated in the development of testis (Ottesen et al 2016).  
 In this study, we establish that SMN preferentially interacts with sequence and 
structural RNA motifs with high specificity. The diversity of high affinity ligands 
isolated by SELEX support a broad spectrum of RNA-SMN interactions with 
implications to novel SMN functions in RNA metabolism. The extreme sensitivity of 
RNA-SMN interactions to salt concentrations suggests that the interface of RNA-SMN 
interaction is dynamic and may be amenable to manipulations by interacting proteins. 
Given the fact that multiple contacts within RNA is required for a tight RNA-SMN 
interaction, it is likely that the folding of the entire SMN determines the interface of 
RNA-SMN interaction. The nucleic acid-binding domain of SMN is located towards the 
N-terminus. Several SMN variants including a-SMN, SMNΔ7 and SMN6B retain the 
nucleic acid-binding domain of SMN. The overall folding of all other SMN variants are 
likely to be different due to the absence/difference of C-terminal residues. It will be 
interesting to see if the high affinity RNA ligands of SMN also interact with other SMN 
isoforms with similar affinity and specificity. Future studies will determine if the loss of 






Materials and Methods 
 
Chemicals, reagents, and enzymes 
The manufacturer and product catalog numbers of all chemicals, reagents, and enzymes 
used in this study are provided in Supplementary Table 1. All oligonucleotides were 
obtained from IDT and are listed in Supplementary Table 2. 
 
SMN Protein Purification 
SMN protein was expressed and purified using the IMACT protein purification kit 
(NEB). Briefly, the coding region of SMN was cloned into pTXB3 and transformed into 
ER2566 cells. A small-scale culture was inoculated overnight from a single colony and 
grown overnight at 37˚C, then diluted 1:100 into 1 L of LB media. After 2.5-3 hours after 
OD600 reached 0.6-0.8, expression of SMN-Intein was induced by addition of IPTG 
(Sigma) to a final concentration of  0.4 mM. Induction was carried out for 5 hours at 30 
˚C.  After induction, cells were placed on ice to cool and all steps from this point to the 
end of purification were carried out at 4 ˚C or on ice. Cells were collected by 
centrifugation at 6,000xg for 10 minutes, then resuspended in 20 mL of Column Buffer 
(20 mM Na-HEPES pH 8.5, 500 mM NaCl, 1 mM EDTA) supplemented with 0.1% 
Igepal CA-630 (Sigma) and 1X HALT protease inhibitor (Thermo Scientific). Cells were 
lysed by sonication on ice using a Microson XL ultrasonic cell disruptor (Misonix); 5-10 
pulses of 20-25 seconds each. After sonication, lysates were subjected to centrifugation at 
12,000xg for 15 minutes at 4 ˚C to remove debris, and the supernatant collected. Chitin 
columns were prepared by packing 10 mL of slurry (NEB) into a Poly-Prep 
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chromatography column (Biorad) and allowing the storage buffer to drain by gravity 
flow. Columns were then washed with 50 mL of Column Buffer. Clarified lysate was 
then applied to the washed column and washed with 100 mL of Column Buffer, followed 
by another 50 mL of Column Buffer with the NaCl concentration increased to 700 mM. 
Cleavage of the Intein tag was then induced by washing the column with 15 mL of 
Column Buffer supplemented with 50 mM DTT (Sigma) and 0.1% Igepal CA-630. The 
column was then capped to stop buffer flow and cleavage was allowed to proceed for ~32 
hours. After cleavage, protein was eluted in 14 mL of Column Buffer supplemented with 
0.1% Igepal CA-630 and concentrated using two Pierce Concentrators (20,000 KDa 
cutoff) (Thermo Scientific) to a final volume of ~1 mL. An equal volume of glycerol was 
added and protein stored in 80 µl aliquots at -80 ˚C. 
 
SELEX initial pool generation and in vitro transcription 
The double-stranded DNA template for the initial pool (P0) was generated by PCR using 
Taq polymerase (NEB) in a total volume of 1 mL containing 0.5 nMol of Temp-0 
oligonucleotide as template and 5ʹ′Pool and 3ʹ′Pool primers to amplify. Template 
oligonucleotide and primer sequences are given in Supplementary Table 4. Limited 
amplification (4 cycles) was carried out to reduce bias. After amplification, the PCR 
product was concentrated by ethanol precipitation, separated on an 8% acrylamide gel, 
and purified by the crush and soak method (see below) and resuspended in 40 µl 
nuclease-free water. A 1 µl aliquot of DNA was then run on an acrylamide gel and 
quantified by visual comparison to a DNA ladder of known concentration. For 
transcription, 10.5 µg of PCR product was used as a template in a 100 µl reaction using 
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Megashortscript T7 (Ambion) in the presence of 7.5 mM each of ATP, CTP, GTP, and 
UTP and 1X T7 reaction buffer. Transcription was carried out overnight at room 
temperature. The reaction was then run on a denaturing 8% Urea-PAGE gel, visualized 
by UV shadowing, and purified using the crush and soak method (see below). After gel 
purification, RNA was resuspended in a final volume of 50 µl and further purified using 
an RNase-free Micro Bio-spin column (Biorad). 
 
Gel extraction (crush and soak) 
Bands corresponding to DNA templates or RNA transcripts were excised, transferred to a 
1.5 ml microfuge tube, and crushed using a pipet tip. To elute nucleic acids from the gel, 
700 µl of elution buffer (500 mM ammonium acetate, 1 mM EDTA pH 8.0, 0.1% SDS) 
was added and tubes were placed on a rotating mixer at 55 ˚C for 1 hour. Samples were 
then centrifuged at maximum speed on a tabletop microcentrifuge for 5 minutes and 
supernatant transferred to a new tube. An equal volume of phenol:chloroform was added, 
then samples were vortexed and centrifuged at maximum speed on a tabletop 
microcentrifuge for 5 minutes and supernatants were transferred to a new tube. Nucleic 
acids were precipitated by addition of 2.5 volumes of 100% ethanol, followed by 
incubation on dry ice for 5 minutes or at -20 ˚C overnight. Samples were then centrifuged 
at 14,000 rpm at 4 ˚C for 20 minutes and supernatant discarded. Pellets were washed with 





In Vitro Selection 
Variable amounts of RNA and protein (See Table 1) were combined together in Binding 
Buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5 mM DTT). Selection 
was carried out in a total of 1 mL except for the first round, which was carried out in 4 
reactions of 1 mL each. Prior to addition of protein and DTT, RNA was refolded by 
briefly heating to 95 ˚C, followed by incubation at 37 ˚C for 1 hour. Binding was carried 
out for 20 minutes at room temperature. Protein-RNA complexes were then captured by 
passing through a Protran BA-85 nitrocellulose filter (Whatman) pre-soaked in Wash 
Buffer 1 (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2) and washed once with 
800 µl of Wash Buffer 1, followed by two washes with 800 µl of Wash Buffer 2 (20 mM 
Tris-HCl pH 7.5, 450 mM NaCl, 5 mM MgCl2). Filters were then collected and placed in 
a 1.5 mL microfuge tube for RNA. 
 To extract selected RNA from nitrocellulose filters, 400 µl of Tris-EDTA buffer 
(pH 7.5) and 600 µl of phenol:chloroform (OmniPur) was added to the filters and the 
samples were vortexed for 3 pulses of 30 seconds each. Tubes were then centrifuged at 
maximum speed for 5 minutes in a tabletop microcentrifuge. The aqueous phase 
containing RNA was transferred to a new tube and the organic phase and filter were 
discarded. RNA was then precipitated by addition of 1 µl of 20 mg/mL glycogen 
(Roche), 1/10 volume of 3 M potassium acetate (pH 5.2), and 2.5 volumes of 100% 
ethanol, followed by incubation on dry ice for 5 minutes or at -20 ˚C overnight. Samples 
were then centrifuged at 14,000 rpm at 4 ˚C for 20 minutes and supernatant discarded. 
Pellets were washed with 1 mL of 70% ethanol and dried. RNA was then resuspended in 
10 µl of RNase-free water. Half of the RNA was stored at -80 ˚C and the other half used 
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as a template for reverse transcription in a 20 µl reaction as follows: 5 µl of RNA was 
combined with 6 µl of nuclease-free water and 1 µl each of 10 mM dNTP mix and 50 µM 
3ʹ′Pool primer, then heated at 65˚C for 5 minutes and cooled on ice. Then 4 µl 5X FS 
buffer and 1 µl each of 100 mM DTT, RNaseOUT (Invitrogen), and SuperScript III 
(Invitrogen) were added and the reaction was incubated at 50˚C for 50 minutes followed 
by heat inactivation at 70˚C for 15 minutes. Following reverse transcription, half of the 
cDNA was stored at -20 ˚C and half used as template for PCR. The subsequent double-
stranded DNA pool was generated by PCR in a final volume of 1 mL. For each round, the 
number of PCR cycles ranged from 8-10 and was optimized by small-scale amplification 
before amplifying the entire pool. The pool was then purified and used for transcription 
as above. For cloning and sequencing, pools were amplified using the 5ʹ′Pool primer and 
3ʹ′Hind primer, digested with EcoRI and HindIII restriction enzymes (NEB), and cloned 
into the pUC19 vector. 
 
In vitro transcription for binding assays 
For standard binding assays containing a single RNA, radiolabeled RNA was generated 
as follows: Either 1 µg of HindIII-digested plasmid or 1 µl of PCR-amplified DNA was 
transcribed in a 20 µl reaction containing 7.5 mM each of ATP, CTP, and GTP, 0.75 mM 
of cold UTP, 50 µCi of [α-32P]UTP (Perkin-Elmer), 2 µl 10X T7 reaction buffer, and 2 µl 
MegaShortScript T7 enzyme mix (Ambion). Reactions were incubated overnight at room 
temperature. The reaction was then run on a denaturing 8% Urea-PAGE gel, visualized 
by UV shadowing, and gel purified using the crush-and-soak method. After gel 
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purification, RNA was resuspended in a final volume of 50 µl and further purified using 
an RNase-free Micro Bio-spin column (Biorad). 
 For transcription of high specific activity RNA for comparative binding assays or 
assays for determining Kdapp, 1 µg of HindIII-digested plasmid or 1 µl of PCR-amplified 
DNA was transcribed in a 20 µl reaction containing 0.5 mM each of ATP, CTP, and 
GTP, 14 µM of cold UTP, 60 µCi (1 µM) of [α-32P]UTP (Perkin-Elmer), 2 µl 10X RNA 
polymerase reaction buffer (NEB), and 1 µl each of 100 mM DTT (Sigma), RNaseOUT 
(Invitrogen), and T7 RNA polymerase (NEB). Reactions were incubated overnight at 37 
˚C. The reaction was then run on a denaturing 8% Urea-PAGE gel and bands were 
visualized by exposing the gel to a phosphor imager screen for 2 minutes and screens 
were scanned using a Fujifilm FLA-5100 phosphorimager. Gel printouts were aligned to 
the gel by lining up the wells, and bands corresponding to full-length RNA were excised 
using a razor blade and transferred to a 1.5 mL microfuge tube. RNA was extracted using 
the crush and soak method similar to previous extractions, except that 0.5 µl of glycogen 
was added to each tube of eluted RNA immediately before addition of ethanol for 
precipitation. 
 
Nitrocellulose filter paper binding assays 
For direct measurement of SMN-RNA binding, 10 pmol each of Megashortscript-
transcribed RNA and protein were combined together in 100 µl Binding Buffer (20 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2, 5 mM DTT) for a final concentration of 
100 nM of each. Prior to addition of protein and DTT, RNA was refolded by briefly 
heating to 95 ˚C, followed by incubation at 37 ˚C for 1 hour. Binding was carried out for 
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20 minutes at room temperature. Protein-RNA complexes were then captured by passing 
through a Protran BA-85 nitrocellulose filter (Whatman) pre-soaked in Wash Buffer 1 
(20 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM MgCl2) and washed once with 800 µl of 
Wash Buffer 1, followed by two washes with 800 µl of Wash Buffer 2 (20 mM Tris-HCl 
pH 7.5, 450 mM NaCl, 5 mM MgCl2). Filters were then collected and placed in a 7 mL 
liquid scintillation vial and Cerenkov emissions were measured in a Packard Tri-Carb 
3170TR/SL liquid scintillation counter alongside a portion of input and a negative control 
reaction where protein was omitted. 
 For determination of the dissociation constant, the same procedure was carried out 
as above, except that RNA was transcribed using the high specific activity procedure and 
30,000 cpm of RNA (an estimated 0.1 nM final concentration) as determined by 
Cerenkov counting was used as input for each assay. Protein input started at 100 pmol (1 
µM final concentration) and followed a 2-fold dilution series until a minimum final 
concentration of 0.244 nM was reached. Final relative binding values were determined by 
subtracting the negative control value from each bound sample, dividing by input, then 
dividing again by the maximum value obtained for each set of assays. 
 For the comparative binding assay, RNA input was 30,000 cpm of high specific 
activity transcript for both the experimental RNA and the P9-10E control. Protein input 
was 5 pmol (50 nM final concentration). After binding and washing, filters were then 
collected and placed in a 1.5 mL microfuge tube. RNA extraction was carried out 
following the same procedure used during selection. After precipitation, RNA pellets 
were resuspended in 20 µl of Gel Loading Buffer II (Ambion). Input samples were 
prepared by setting aside 1 µl of reaction mixture prior to addition of protein and diluting 
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1:20 into loading buffer. 4 µl each of input and bound RNA was loaded in each well of an 
8% Urea-PAGE denaturing gel. After running, gels were dried and exposed to phosphor 
image screens for 1 hour to overnight, depending on the strength of signal. Images were 
scanned using a Fujifilm FLA-5100 phosphorimager. Bands were quantified using 
Fujifilm MultiGauge software. Relative binding was determined by dividing the 
experimental band in each lane by the P9-10E control, then dividing the value of each 
‘bound’ lane by the value of input. Final corrections were made by dividing by the value 
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Figure 1. Overview of SELEX. (A) Oligonucleotide used for selection. Numbering is 
relative to the first transcribed base. T7 promoter is highlighted in red, variable region is 
highlighted in blue. Constant regions for primer binding are indicated. (B) Overview of 
the selection process. Briefly, RNA is transcribed from double-stranded PCR fragments, 
then mixed with SMN protein and passed through a nitrocellulose filter. Unbound RNA 
is washed away and bound RNA is then extracted, converted to cDNA, and amplified to 
provide a template for the next round of selection.  
 
Figure 2. Binding of SMN to individual clones from unselected and intermediate 
pools. (A) Top panel: Sequences of 10 transcripts randomly selected from unselected 
pool are given in the top panel. Boxed region indicates randomized region. Base positions 
are given above. Bottom panel: Quantification of binding of SMN to transcripts shown in 
the top panel. Y axis indicates percentage of RNA bound by SMN as measured by the 
nitrocellulose filter paper binding assay. (B) Top panel: Sequences of 9 transcripts 
randomly selected from pool 6. Bottom panel: Quantification of binding of SMN to 
transcripts from 10 randomly selected clones generated from pool 6. Labeling is the same 
as in (A). 
 
Figure 3. Properties of 5 selected clones with high binding affinities. (A) Sequences 
of the 5 highest-affinity molecules. Clone number is given on the left, base position is 
indicated on top. The selected region is indicated with a green box. Yellow highlighted 
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bases are exact matches for the GUGCG motif identified by MEME. (B-G) Binding 
curves to determine Kd of the top 5 binders as well as an unselected control. Clone 
designation is indicated at the top left of each graph. Y axis indicates relative binding, 
corrected for the highest value observed during each set of experiments. X axis indicates 
the SMN concentration for each reaction, on a log10 scale. Each point represents one 
binding reaction, lines are drawn by Kaleidagraph software by fitting the individual 
points to the Michaelis-Menten equation. Apparent Kd and r2 values are given (H) 
Predicted structures of top 5 selected sequences. Structures were predicted by Mfold. 
Clone numbers are indicated at the top left of each box. 5ʹ′ and 3ʹ′ ends are indicated, as 
are base positions. The selected region is indicated by blue bases, constant region is in 
black. Bases in bold indicate GUGCG motif. Base pairs are indicated by lines drawn 
between bases. 
 
Figure 4. Comparative binding of sequence mutants of clone P9-10. (A) Effect of 
extensive sequence mutations within the selected region of P9-10. Top panel gives names 
and sequence for each clone tested. Base position is indicated at the top. Black sequences 
indicate constant regions, blue sequences indicate bases that match the WT selected 
sequence, and red sequences indicate bases that differ from WT. Dashes indicate deleted 
bases. Lower panel shows autoradiogram of bound RNA. Sequence number is given at 
the top. Upper band is an extended version of the WT sequence used as a control. Lower 
band is the WT, unselected, or mutated sequence. Each lane is loaded to obtain equal 
band intensity of the upper band. I: RNA Input. B: Extracted and purified RNA after 
binding reaction. Lane numbers and percent activity relative to WT are given below each 
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autoradiogram. (B) Effect of smaller sequence mutations within the selected region of 
P9-10. Labeling is the same as in (A). 
 
Figure 5. Effect of mutations within constant regions of P9-10. Top panel gives names 
and sequence for each clone tested. Base position is indicated at the top. Black sequences 
indicate constant regions, blue sequences indicate bases that match the WT selected 
sequence, and red sequences indicate bases that differ from WT. Dashes indicate deleted 
bases. Predicted structures of P9-10 and all constant region mutants are shown. Each 
structure indicates the location within the P9-10 predicted structure of individual 
mutations made in the flanking regions of P9-10. The selected region is indicated by blue 
bases, constant region is in black. Mutated bases are shown in red. WT base pairs are 
shown as black lines black and novel base pairs formed by mutated bases as red lines. 
Lower panel shows autoradiogram of bound RNA. Sequence number is given at the top. 
Upper band is an extended version of the WT sequence used as a control. Lower band is 
the WT, unselected, or mutated sequence. Each lane is loaded to obtain equal band 
intensity of the upper band. I: RNA Input. B: Extracted and purified RNA after binding 
reaction. Lane numbers and percent activity relative to WT are given below each 
autoradiogram. 
 
Figure 6. Comparative binding of 5ʹ′  and 3ʹ′  truncations of clone P9-10. (A) 3ʹ′ 
truncations of P9-10. Top panel gives names and sequence for each clone tested. Base 
position is indicated at the top. Black sequences indicate constant regions, blue sequences 
indicate bases that match the WT selected sequence, and red sequences indicate bases 
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that differ from WT. Dashes indicate deleted bases. Lower panel shows autoradiogram of 
bound RNA. Sequence number is given at the top. Upper band is an extended version of 
the WT sequence used as a control. Lower band is the WT, unselected, or mutated 
sequence. Each lane is loaded to obtain equal band intensity of the upper band. I: RNA 
Input. B: Extracted and purified RNA after binding reaction. Lane numbers and percent 
activity relative to WT are given below each autoradiogram. (B) 5ʹ′ truncations of P9-10. 
Labeling and abbreviations are the same as in (A). 
 
Figure 7. Effect of salt conditions on binding of SMN to RNA. (A) Comparative 
binding of WT and mutated P9-10 RNA, as well as an unselected clone. Top panel gives 
names and sequence for each clone tested. Base position is indicated at the top. Black 
sequences indicate constant regions, blue sequences indicate bases that match the WT 
selected sequence, and red sequences indicate bases that differ from WT. Dashes indicate 
deleted bases. Middle panel and lower panel are autoradiograms of bound sequences. 
Sequence number is given at the top. The presence (+) or absence (-) of SMN protein in 
the reaction is indicated. The NaCl concentration of each reaction, in millimoles per liter, 
is indicated. Upper band is an extended version of the WT sequence used as a control. 
Lower band is the WT, unselected, or mutated sequence. Each lane is loaded to obtain 
equal band intensity of the upper band. I: RNA Input. B: Extracted and purified RNA 
after binding reaction. Lane numbers are given below each autoradiogram. (B) 
Quantification of bands from (A) Top row of graphs represents the total proportion bound 
relative to input. The X axis indicates the binding condition. The bottom row of graphs 
represents the relative binding of the lower band from (A) compared to the binding of the 
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constant control sequence. X axis indicates the NaCl concentration in the binding 
reactions. Since binding at 200 mM of NaCl and above is near background levels for all 
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A U C G
P0<1 A C G G G A G U G U U A G G A G G C A G C C A C G 6 3 5 11
P0<2 U G G C G G A G G C G G C G A U A C U C C G U A U 4 5 6 10
P0<3 G U G U A G A U G C C G A U U C G U C A U C G U A 5 8 5 7
P0<4 A U U G G A G G G U C C A G A G G A G G U C A U C 6 5 4 10
P0<5 U G C G C U G U A G U C C U A U U G U C G U G C U 2 10 6 7
P0<6 A U G C C C U U G U C C U A A G G G U U G G C C U 3 8 7 7
P0<7 G G C C C G U A A C U G A A U C C U A G G G G C U 5 5 7 8
P0<8 G G U U A C G A A C U A U U G U G U G A C A U G C 6 8 4 7
P0<9 A G C C U U U U G C U U G U G A A U A U A U A G C 6 10 4 5
P0<10 U A C A G C U C U A U C C C U G U C C A A A U G G 6 7 8 4
P0<11 U U G U U C U A G C C C U A U C U C U A G G C U G 3 10 7 5
P0<12 A G G A C G A A C C A G G A U C U G C U A G G G U 7 4 5 9
P0<13 G C G A C G C A A C A U G A G A G G C G G C G U A 7 2 6 9
P0<14 A G C C U G U A A A C U G A U G G C C U G G G C G 5 5 6 9
P0<15 C U A C G G G U C U G C G A G U U G C G C G U C A 3 6 7 9
P0<16 G C G U C C A A C G C C C A U A G U G G G C C G U 4 4 9 8
P0<17 C G U C A G G C C G U U A U A G G G G G C U A U C 4 6 6 9
P0<18 C A A U U G U A A U A A G U C G U U A G U C A C U 8 9 4 4
P0<19 U A C G A G C G G U U G G C U G G A U G U G G G U 3 7 3 12
P0<20 A G A U U C U A A A G A U G U U A C U C C U C C U 7 9 6 3
P0<21 U C A C A G C A G A A G A C G A A U G C C U G A A 10 3 6 6
P0<22 G U A C U C C G G A G U A C U G U C G U U G G A G 4 7 5 9
P0<23 A G C C U C C U A C U A A C U G G U C U U C U U G 4 9 8 4
P0<24 G U A A U G G G G A C A U G G G U C C U G U C A G 5 6 4 10
P0<25 U U U G A C U A C U A G U C U C G G C G C U U G A 4 9 6 6
P0<26 A A A U G G A C C U A C C G A A U C A C G U C C A 9 4 8 4
P0<27 G G G A C G C C U C G C G G A G C C A U G U G U C 3 4 8 10
P0<28 G G A G G A C G U U G C U C A G A C G C G A U A U 6 5 5 9
P0<29 G G A G U G G G A C C A U U G A C A U U C C C U U 5 7 6 7
P0<30 G A A A G C C G G G U C G U C G G U U U C C C U G 3 6 7 9
P0<31 C U A G A A C U A G G C U G U U U G A U C G G G C 5 7 5 8
P0<32 U C C A C U A U A G G A A U C G U U G C U U G U G 5 9 5 6
P0<33 A U G A A G A U C A G U U G U C C U G G G C C G U 5 7 5 8
P0<34 U A A G C C G G U C A G A A U G G A G G U U G G G 6 5 3 11
P0<35 G G G A G C G U A C U G U C C G C G C A A C U C G 4 4 8 9
P0<36 G A G C G G C G G A A G U A C U C A A A U C A G C 8 3 6 8
P0<37 C U U C U G U G U U G G A U G A C C C U A C C C C 3 8 9 5
P0<38 C G U C U C U U G G G A U C G U U G U U C C G C G 1 9 7 8
P0<39 G G G C A A G U C C C A U G A G A U C A A C A G U 8 4 6 7
P0<40 A U C G G G C U G A C U G U U C A G G U A A C A G 6 6 5 8
P0<41 A U C C U U C A U A G G C A A G C C U G U C U A A 7 7 7 4
P0<42 A G U C U U U A G A A U G A C U A C G A A C U G U 8 8 4 5
P0<43 A G C U G C G C A G U G U A U G C C A G G G C C U 4 5 7 9
P0<44 A C G U U U A C U U U G A C A G U C C G A U G U C 5 9 6 5
P0<45 A G U U G A U G G A A G G U G A A C G C U A G G U 7 6 2 10
P0<46 U G U C G A A G A G A C A A U C A G U C U C G A G 8 5 5 7
P0<47 A U G A C G A A U U A U G U U C U G A G G C U G A 7 8 3 7
P0<48 A C A A G C U C U U U C G A U U C U C G C G C U G 4 8 8 5
P0<49 C C A U G U U G C U G U C A C G C C C G G U A C C 3 6 10 5
P0<50 A U U U C U U G C G C G G U A G U C A C U A G C G 4 8 6 6
Base
A 19 7 14 10 9 7 9 13 13 13 11 10 12 15 12 8 10 5 11 8 8 6 8 8 8
U 10 15 10 12 14 8 16 14 9 14 13 11 15 13 20 10 13 13 10 13 13 12 11 12 14
C 7 8 10 17 10 15 12 7 9 13 11 13 7 11 7 8 11 19 14 10 13 19 13 14 10







Table 2. Conditions used for selection of high-affinity RNA targets of SMN 
Pool [RNA] (nM) [SMN] (nM) [NaCl] (mM) % Binding Enrichment 
P0 100 400 150 0.53% 1.00 
P1 100 200 150 1.35%  2.53 
P2 100 100 150 2.86% 5.36 
P3 100 85 150 5.09% 9.52 
P4 100 85 150 8.58% 16.1 
P5 100 85 150 14.9% 27.9 
P6  100 8.5 150 16.0% 30.0 
P7 100 85 150   
P8 100 85 150   





A U C G
P9<55* G U G C G C G G U A U A G U G G A U U U G G G G G - - - - - 3 7 2 13 117%
P9<10 G U G C G G G C U U G C U C G U G G A A C C G G C - - - - - 2 5 7 11 105%
P9<74 G U G C G C U G G A C U A U U A C G C G U G A G G - - - - - 4 6 5 9 104%
P9<71* G U G C G C G G A C U U G C A U U G G A C C U G G - - - - - 3 6 6 10 101%
P9<5 G G U G C G U G C U U U C C G U U G U G U U U G G - - - - - 0 11 4 10 87%
P9<81* C G U G C C G G C U U G U C C G U G U U U G G G G - - - - - 0 8 6 11 86%
P9<29 C G C C G G G U G C U U U C C G U U G G U C U G G - - - - - 0 8 7 10 85%
P9<67* G U G C G A A G U G G U A U U G C U G C G G U C G - - - - - 3 7 4 11 81%
P9<78 G U G C G U U U G A U U G C U G U A G G U C U G G - - - - - 2 10 3 10 76%
P9<75 U G U G C G C C U U C C C G U G U A G U A C U G G - - - - - 2 8 7 8 74%
P9<27* U G U G C G A U G C C A U G A G G U U G G G C G G - - - - - 3 6 4 12 73%
P9<63 G U G C U U U G C U U G A C C G G G A A U C G G G - - - - - 3 7 5 10 73%
P9<48 G G U G G U G G U U U G A C C G U U G G G U U U U U G U G G 1 13 2 14 73%
P9<60 G U G C G U U C A U C U U G U C U C G U A C U G G - - - - - 2 10 6 7 71%
P9<73 G U G C G C U G G U U U U A A U U U U U G C G C G - - - - - 2 11 4 8 69%
P9<38* G U G C G A U A A C G G G G U U A A G A C G G U G - - - - - 6 5 3 11 68%
P9<79 A U G G G U G G G G G G A A A G U G U G G U U C U - - - - - 4 7 1 13 60%
P9<52 G C G C A A C G G G G A A A A A A U G U G A G G G - - - - - 9 2 3 11 59%
P9<49 C G U G C G U U U U U U U G U C G U G C U G C U G G - - - - 0 12 5 9 59%
P9<59 G U G G C C U G G G G U A A U A G C G U G U A C A - - - - - 5 6 4 10 58%
P9<32 G U G U G U G A U U U U U A G C G U U A G G G G G - - - - - 3 10 1 11 57%
P9<28 C G U G G U C G A U U U U U G C G U U C G U G U G - - - - - 1 11 4 9 53%
P9<35* G U U U A G G U U G A G G U A U U G C G U G U U A - - - - - 4 11 1 9 49%
P9<69 G G G U U U G C G G C U U G C A C G G U A G G G G - - - - - 2 6 4 13 47%
P9<26 C U G G U G G G G C A A A U U G A G U G G C C C G - - - - - 4 5 5 11 47%
P9<41 G U G C G U U G C U G G G U U A U G G U G C G U G - - - - - 1 9 3 12 46%
P9<14 U U G G C G C G G G C U U G U U A U G G A A U G G - - - - - 3 8 3 11 45%
P9<31 C G U G G U U A A A U U U U A A G C G U U G U G G - - - - - 5 10 2 8 44%
P9<30 A G G U G G G G A U U C G U G G C G U G A C G A U - - - - - 4 6 3 12 44%
P9<22 G U G C G G C C U A G U G A G G A A G U G C G G A - - - - - 5 4 4 12 42%
P9<1 G U G C G G A G U U U U U G A G G U U G U G C G G - - - - - 2 9 2 12 41%
P9<58 G U G C G C U U G C U G A U G A A U U U C G U A C - - - - - 4 9 5 7 40%
P9<2 G U G C G C G U U U U U A G G U G G G G G A U G G - - - - - 2 8 2 13 40%
P9<36 A G U G C G U G G A G G U A U G C G U G G G U C C - - - - - 3 6 4 12 36%
P9<80 C G U G C U G G A A A U U U G U U G U G G C C G - - - - - - 3 8 4 9 35%
P9<47* G U G C G C G C U A A G U G A G G A U C G G U G C - - - - - 4 5 5 11 34%
P9<17 U U G C C A G U U U C A U U G C C A U G U A U G G G G - - - 4 10 5 8 34%
P9<53 G U G C G A C C U G U C C G U U U G G U G C G G G - - - - - 1 7 6 11 32%
P9<3 A G U G C G C G U G U U U G U U C G U A G G U C G - - - - - 2 9 4 10 31%
P9<19 A G U A C A A G G A C G A G G A U A U G U G U G G - - - - - 8 5 2 10 27%
P9<37 G U G C G G C C A A A G A G G G U U G C G U U C C - - - - - 4 5 6 10 27%
P9<23 G U G G C A U G U U A C U U U U U A U G G U G G G - - - - - 3 6 6 10 25%
P9<61* G U G C G U U G U G U U U A U U G G G A U U A C G - - - - - 3 11 2 9 25%
P9<42 G U G C A A C U U G C A U C U C U C C U U C C U A - - - - - 4 9 9 3 23%
P9<13 C G U G C G U A G G U U U U G U G C U G G U C G G - - - - - 1 9 4 11 21%
*&<&Sequences&which&were&observed&twice&in&selected&clones
Base
A 5 0 0 1 3 8 4 4 8 10 6 6 12 8 9 8 7 8 2 7 5 4 3 2 4 0 0 0 0 0
U 4 28 14 4 3 12 16 9 18 17 21 22 22 14 17 14 18 14 20 14 14 9 20 7 3 1 0 1 0 0
C 8 1 1 23 14 9 9 8 4 6 9 5 3 9 5 6 7 5 3 5 4 15 7 9 5 0 0 0 0 0









   
Table&3B:&Low&affinity&binders&from&Pool&9
A U C G
P9<57 G A C A C A U U G C C C U G G G G A A U U G G U G - - - - - 5 6 5 9 20%
P9<24 G G G G G C G A U U U G U G A G G U U U G C G U G - - - - - 2 8 2 13 19%
P9<21 G U G U G U G G U C U G U G G G A G G A U G G U G - - - - - 2 8 1 14 17%
P9<18 G U G C A U U G C C G U U U U U C U C A U G C C A - - - - - 2 10 7 5 16%
P9<72 G U G G U A A U U G U C U A U G G U G A U U G G G - - - - - 4 10 1 10 15%
P9<46 G U G U G U C G G A G G G U U U G G C U U G C G C - - - - - 1 8 4 12 15%
P9<43 U G U U G C G U A G A A A U U C G U U G G C U U G A - - - - 5 10 3 8 14%
P9<33 U G G G G G C G G U U U G C C G U U U U A U C G C - - - - - 1 9 5 10 13%
P9<50 G U G A A A U G G G G U U G A G G C A C C G C C U - - - - - 5 5 5 10 12%
P9<65 G G G G U G C G U U U U G U C A U G G U U C G G C - - - - - 1 9 4 11 11%
P9<62 C G A U U U U C G C A A A A C A U U U U C C C C A - - - - - 6 8 8 2 10%
P9<56 G G U G G G G A C G A U U G U G C C G G A U U G U - - - - - 3 7 3 12 10%
P9<34* U U G C C C U U C A U G C C U G G U A C G G G G G - - - - - 2 7 7 9 9.0%
P9<11 U U G G G A U G G G G A U A C U U A G G A G G C G G U A - - 6 7 2 13 8.9%
P9<25 G U G G G C C A A G G U G G G G U A U G C G U G U - - - - - 3 6 3 13 8.8%
P9<51 G U G G G C G U G G U U U U G G U G G G G G C G G - - - - - 0 7 2 16 7.8%
P9<16 G G U G G G G G G G G G U U G G C G U G A U U C C U - - - - 1 7 3 15 7.7%
P9<4 G U G G G C G U G G C U U U U A U U U C G G U G A - - - - - 2 10 3 10 7.5%
P9<66 U A U U G G G G G A U G A A U U U G U G G U U G G - - - - - 4 10 0 11 6.4%
P9<64 U U G C U U U U U G G U C C U U G C U U C G C U C C C - - - 0 13 9 5 6.2%
P9<44 G U G C A G U G G U U U A U U U U G C G U U U U G - - - - - 2 13 2 8 4.9%
P9<12 U U G C C A A G A A C U U G C C U U G G C C C G C - - - - - 4 6 9 6 4.8%
P9<68 U U G C C U U G C U U G C C A A A C U U G G G G G - - - - - 3 8 6 8 3.9%
P9<9 A U G G C G G A A A U G C G U C U U U A U A C U C G - - - - 6 8 5 7 3.4%
P9<15 G U G G G A G C G G A U G G U U G U G C G A C G U - - - - - 3 6 3 13 3.4%
P9<77 G C G G U G A U C G G A G G A U A G U G C G U C U - - - - - 4 6 4 11 2.8%
P9<76 U G U G C G U U G C G U G G U U U U U U G C U G U - - - - - 0 13 3 9 2.6%
P9<20 G G G G G G C A G G U G G G G U U U U G C G U G A - - - - - 2 6 2 15 2.5%
P9<39 G A C U U C U C U C U U C C C A C U C C C U C C C - - - - - 2 8 14 1 2.2%
P9<54 G U G G G C C A A G G U G G G G U U U G G U G U G - - - - - 2 7 2 14 1.6%
P9<6 G U G A G G A C G G U G A G G C A A U G U G G U A - - - - - 6 5 2 12 1.1%
P9<8 C U C C C C U C C C G C U C C C A C A U C C C U C - - - - - 2 5 17 1 <0.4%
P9<7 A C G G A G U A G G C G C A A A G A G G G G U C G - - - - - 7 2 4 12 <3.3%
Base
A 2 3 1 3 4 6 4 7 5 5 4 4 5 5 5 6 5 5 4 4 4 2 0 0 5 1 0 0 0 0
U 9 19 5 6 6 6 13 9 6 5 14 15 13 8 13 10 14 15 16 10 9 8 11 10 6 1 0 0 0 0
C 2 2 3 7 7 9 6 5 6 7 4 3 6 6 7 5 4 5 4 5 9 7 12 8 9 1 0 0 0 0
G 20 9 24 17 16 12 10 12 16 16 11 11 9 14 8 12 10 8 9 14 11 16 10 15 13 2 0 0 0 0
Table&3C:&Sequences&from&Pool&0&for&which&binding&was&not&tested
A U C G
P9<40 G U G U U U G G U U U C U U A U U G C G U U G U - - - - - - 1 14 3 7
P9<82 U U G C C A A G U U U U U U G C C A U G G U C C G G - - - - 3 10 6 7
P9<83 A G U G C G U C G U G G U U U U U G G A G G U C G - - - - - 2 9 3 11
P9<84 U U G C C G C U G C C G U A U G A C U U G A G G A - - - - - 4 7 6 8
P9<85 G U G C G U U G C G U G G A A G A C G G U G C G G - - - - - 3 5 5 12
P9<86 G U G G G C G U G U U A A U U U U G G U G A U G G - - - - - 3 10 1 11
P9<87 A G U G C G U G G A U C U A U G U G C G U U U G G - - - - - 3 9 3 10
P9<88 G U G C U U A A G C U G U G G U C U G U U G C G U - - - - - 2 10 4 9
P9<89 G U G C G U U U A U U U U C C A C U U U A C A U G - - - - - 4 12 5 4
P9<90 A G G G U G G G G A U G U A G A G U G U G G C A U - - - - - 5 6 1 13
Base
A 10 3 1 4 7 15 10 12 14 17 10 11 18 17 16 16 14 14 6 12 10 8 4 3 10 1 0 0 0 0
U 15 54 21 11 12 22 33 21 26 27 43 39 43 26 34 28 36 32 39 29 27 20 34 19 11 2 0 1 0 0
C 10 3 4 35 25 19 16 14 11 15 14 10 9 16 13 12 14 12 9 10 13 23 23 19 14 1 0 0 0 0













Clone Randomized/Selected&Region Base&Occurrence Binding
 135 
Table	  4A:	  Trinucleotide	  occurrence	  in	  selected	  sequences	  
	   	  
First	  nucleotide	  
	   	  
	   	  
A	   C	   G	   U	  











14	   13	   16	   11	   A	  
Third	  N
ucleotide	  
8	   7	   16	   12	   C	  
15	   3	   26	   17	   G	  
17	   17	   30	   22	   U	  
C	  
7	   15	   15	   5	   A	  
7	   15	   31	   22	   C	  
14	   22	   77	   25	   G	  
14	   19	   34	   16	   U	  
G	  
7	   11	   43	   30	   A	  
5	   23	   36	   102	   C	  
36	   41	   63	   111	   G	  
20	   68	   83	   52	   U	  
U	  
8	   6	   25	   26	   A	  
8	   13	   23	   25	   C	  
34	   26	   139	   98	   G	  
36	   36	   69	   60	   U	  
	   	   	   	   	   	   	   	  Table	  4B:	  Trinucleotide	  occurrence	  in	  unselected	  
sequences	  
	   	  
First	  nucleotide	  
	   	  
	   	  
A	   C	   G	   U	  











6	   11	   20	   6	   A	  
Third	  N
ucleotide	  
13	   7	   18	   12	   C	  
13	   19	   21	   17	   G	  
15	   12	   17	   10	   U	  
C	  
11	   13	   7	   10	   A	  
7	   11	   23	   12	   C	  
18	   14	   24	   12	   G	  
22	   25	   20	   12	   U	  
G	  
14	   16	   25	   19	   A	  
19	   15	   26	   15	   C	  
25	   18	   23	   46	   G	  
19	   22	   19	   1	   U	  
U	  
9	   25	   17	   3	   A	  
17	   16	   35	   10	   C	  
24	   28	   13	   17	   G	  





CHAPTER III SUPPLEMENTARY FIGURES AND TABLES 
 
Supplementary Figure Legends 
 
Supplementary Figure 1. Purification of recombinant SMN protein. (A) Purification 
scheme for IMPACT purification of recombinant SMN. Diagram of expression plasmid 
is shown. Expression construct contains entire SMN coding sequence followed by a 
fusion consisting of self-cleaving intein domain and the chitin binding domain. Primary 
steps of purification are indicated below. (B) Diagnostic coomassie-stained SDS-PAGE 
gel showing aliquots taken at several key steps of the isolation procedure. Final lane 
shows final, eluted SMN protein. 
 
Supplementary Figure 2. Initial screening of final selected pool. 78 clones from pool 
9 were screened by the nitrocellulose filter paper binding assay. Clones were screened 8-
10 at a time and individual values were normalized by binding value of pooled P9 RNA 
that was measured in parallel. Y axis gives relative binding to the pooled RNA, X axis 
indicates the clone number. Error bars represent the standard error of 3 separate binding 
experiments. 
 
Supplementary Figure 3. Characterization of the top 10 binders from pool 9. (A) 
Sequences of the 10 highest-performing molecules from a screen of 78 clones. Clone 
 137 
number is given on the left, base position is indicated on top. The selected region is 
indicated with a green box. Yellow highlighted bases are exact matches for the GUGCG 
motif identified by MEME, while pink highlighted bases are near-matches, where 4/5 
bases of the motif are present. (B) Relative binding affinities of each of the top 10 
binders, compared to P0 (unselected) and P9 (selected for 9 rounds) pooled RNA. 
Binding strength (y axis) is expressed as percentage bound corrected to P9 binding. Error 
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Supplementary Figure 2. Initial screening of final selected poo
 
 


































































HIGH AFFINITY RNA TARGETS OF THE SURVIVAL MOTOR NEURON 
PROTEIN DEFINED BY UV-CROSSLINKING AND IMMUNOPRECIPITATION 
 A	  manuscript	  under	  preparation 
Eric W Ottesen1, Ravindra N Singh1* 
 




Spinal muscular atrophy (SMA) is a genetic disease caused by low levels of the Survival 
Motor Neuron (SMN) protein. SMN is found in complexes with a number of RNA 
species within cells and has been shown to interact with RNA in vitro; however, a direct 
interaction with RNA in cells has not been explored. Here, we performed in vivo 
crosslinking and immunoprecipitation coupled with high-throughput sequencing (HITS-
CLIP) as well as knockdown of SMN levels followed by RNA-Seq to identify RNA 
targets of SMN within living cells. HITS-CLIP identified a variety of RNA targets of 
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SMN with an enrichment of mRNAs participating in a number of pathways, including 
ribosome function and actin cytoskeleton regulation. SPON2, LAMB2, and EEF1A2 in 
particular were all predicted by HITS-CLIP to be bound by SMN and were 
downregulated upon SMN knockdown, indicating a direct regulatory role for SMN on 




Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality (Wirth et 
al 2006). SMA is caused by low levels of the Survival Motor Neuron (SMN) protein due 
to homozygous mutation or deletion of the SMN1 gene (Lefebvre et al 1995). Humans 
have an additional copy of the SMN gene, SMN2 (Lorson et al 1999). SMN2 
predominantly produces an exon 7-skipped form of transcript due to a translationally 
silent point mutation in exon 7 (Lorson et al 1999). In SMA, SMN2 fails to fully 
compensate for lack of SMN1 due to a greatly reduced stability of the exon 7-skipped 
form of the protein, SMNΔ7 (Cho and Dreyfuss 2010).   
 RNP crosslinking and immunoprecipitation (CLIP) is a powerful approach to 
identifying RNA-protein interaction sites that has allowed researchers to identify in vivo 
interaction sites through irreversible crosslinking a protein to its interacting RNA (Ule et 
al 2003). CLIP identifies sites of actual contact that may be defined by additional 
interactions or extended RNA structure. With the advent of next-generation sequencing 
techniques, the method was modified to include high-throughput sequencing (HITS-
CLIP) (Licatalosi et al 2008, Darnell 2010).  
 144 
SMN is a multifunctional protein which has been implicated in numerous 
functions such as snRNP assembly (Meister et al 2001, Zhang et al 2008), signal 
recognition particle (SRP) biogenesis (Piazzon et al 2013) transcription (Zhao et al 2016), 
translation (Sanchez et al 2013), stress granule formation (Hua et al 2004, Zou et al 
2011), endocytosis and synaptic transmission (Dimitriadi et al 2016), and mRNP 
transport (Rossoll et al 2003, Akten et al 2011, Fallini et al 2011, Fallini et al 2014). Of 
note, a large number of these functions involve interactions with RNA, either directly or 
indirectly. In many cases, SMN carries out these functions through its interactions with 
numerous RNA-binding proteins (RBPs) (Mourelatos et al 2001, Pellizzoni et al 2001, 
Rossoll et al 2002, Tadesse et al 2008, Glinka et al 2010, Yong et al 2010, Fallini et al 
2011, Piazzon et al 2013, Fallini et al 2014, So et al 2016). SMN itself is capable of 
binding RNA in vitro (Lorson and Androphy 1998, Bertrandy et al 1999), indicating that 
it may be able to play a more direct role in RNA metabolism.  
In vivo RNA targets of SMN have been previously identified by UV crosslinking 
and pulldown followed by microarray analysis (RIP-Chip) (Rage et al 2013). These 
experiments were carried out in mouse motor neuron-like NSC-34 cells carrying an 
inducible FLAG-tagged form of SMN. RIP-Chip of FLAG-tagged SMN revealed a 
number of transcripts targeted by SMN, and the interaction highly correlated with altered 
mRNA distribution in cultured neurons upon knockdown of SMN (Rage et al 2013). Of 
note, due to technical limitations of the microarray platform, sequence information of 
RNA-SMN interaction sites is not available. In addition, a direct interaction between 
SMN and RNA was not investigated. 
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Here we employ HITS-CLIP to uncover in vivo RNA targets of SMN. We chose 
human neuroblastoma SH-SY5Y cells for this study due to SMA being a 
neurodegenerative disease and the types of transcripts generated in neuronal cells is 
distinct from those generated in non-neuronal cells. Our results of HITS-CLIP revealed a 
wide range of RNA targets including messenger RNAs (mRNAs), small nucleolar RNAs 
(snoRNAs), long noncoding RNAs (lncRNAs), and snRNAs. We observed a complex 
sequence preference of RNA-SMN interaction, with enrichment of G- and A-rich 
sequence motifs near crosslinking sites. In order to determine whether SMN interaction is 
playing a role in RNA expression or stability, we performed transcriptome profiling of 
SMN-depleted SH-SY5Y cells. Expressions of several transcripts including SPON2, 
LAMB2, and EEF1A2 that were identified as SMN targets by HITS-CLIP, were impacted 
by low levels of SMN. Our results support novel functions of SMN through direct 




Identifying in vivo interactions through HITS-CLIP 
In order to identify RNA sequences in direct contact with the SMN protein in vivo, we 
performed HITS-CLIP (Figure 1). This method utilizes UV light to form irreversible 
covalent bonds between nucleic acids and proteins, allowing for highly stringent 
purification (Ule et al 2003). Of note, it takes into account all interactions, including 
those that are not possible to recreate in vitro. Since SMA is a neurodegenerative disease 
(Burghes and Beattie 2009), and we wished to uncover interactions within neurons that 
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may have an impact on SMA disease progression, we performed these experiments in 
neuronal SH-SY5Y cells. Briefly, large numbers (>107) of neuronal SH-SY5Y cells were 
grown in culture, then exposed to UV light at 254 nm in order to induce crosslinking 
between cellular RNAs and proteins. Of note, these crosslinks form only in between 
molecules that are in close contact (<10 Å), so crosslinking indicates a direct interaction. 
SMN-containing complexes were purified by immunoprecipitation using anti-SMN 
antibody. After immunoprecipitation, transcripts were radiolabeled with 32P and the 
crosslinked complexes were separated on denaturing gels and transferred to nitrocellulose 
membranes.  
The SMN protein runs at a size of 42 kilodaltons (kDa) as shown by Western 
blotting (Figure 2A, left panel). Due to the low efficiency of the crosslinking reaction, 
only a very small fraction of total SMN is likely to crosslinked by this method. Imaging 
by autoradiography reveals a primary band at approximately 48 kilodaltons (kDa), which 
is consistent with the predicted size of SMN crosslinked to RNA with a modal size of 18-
20 nucleotides (Figure 6A, right panel). After excision of the crosslinked band from the 
nitrocellulose membrane, RNAs were eluted and libraries for Illumina sequencing were 
prepared, then sequenced at high depth in order to identify all of the cellular interaction 
partners of SMN. The details of sequencing libraries are outlined in Supplementary Table 
2. 
After removing duplicate reads to eliminate PCR bias, we mapped CLIP sequence 
tags to the human genome. As a control for total RNA abundance, we also sequenced and 
mapped total ribosome-depleted RNA derived from SH-SY5Y cells. The majority of 
unique mapped reads, which shows enrichment compared to total SH-SY5Y RNA, 
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overlapped known protein-coding genes (Fig. 2B). The next most abundant type of reads 
mapped to ribosomal RNA (Fig. 2B). We assume that these reads represent nonspecific 
pulldown of ribosomes. A non-negligible proportion of reads (11.2%) mapped to known 
long noncoding RNAs (lncRNAs), although they represented a smaller proportion of total 
HITS-CLIP reads (Fig. 2B). 
 
Identifying Individual Sites of Interaction 
 In order to identify individual candidate binding regions, we analyzed the mapped 
reads to identify peaks with significantly increased read density compared to a random 
distribution. Prior to peak calling and all future analyses, we removed all reads 
overlapping the Repeatmasker annotation track. Similar to the reads derived from CLIP, 
the majority of enriched peaks mapped to protein-coding genes (Figure 2B). A smaller 
proportion of peaks overlapped snoRNAs and lncRNAs, although both were enriched 
compared to the proportion of raw reads mapping to these RNA types  (Figure 2B). 
Within protein-coding genes, the majority of reads mapped to introns (Figure 2C). 
However, a reduced proportion was concentrated into significantly enriched peaks, 
indicating that few of the intron-derived reads represented high-confidence binding sites 
(Figure 2C). Within exons, CLIP reads and peaks followed a similar distribution to the 
SH-SY5Y transcriptome, with a slight enrichment of reads corresponding to the 5ʹ′ UTR 
and coding region (Figure 2C). 
 In order to determine whether specific families of genes or pathways are 
disproportionately bound by SMN, we examined the genes overlapping significant CLIP 
peaks for enriched gene ontology (GO) terms and Kyoto Encyclopedia of Genes and 
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Genomes (KEGG) pathways. The most enriched KEGG pathway is for ribosomal 
proteins, followed by a number of pathways related to the cytoskeleton (Fig. 2D). Many 
of the other pathways involve RNA metabolism and interaction with the extracellular 
environment (Figure 2D). 
 Next, we wished to compare our results of HITS-CLIP with previously identified 
RNA targets of SMN. We compiled a list of human orthologs to the significantly 
enriched RNAs identified in a previous study by RIP-Chip (Rage et al 2013) and found 
236 comparable human genes. We then matched those 236 genes to our list of 488 genes 
overlapping CLIP peaks and found an overlap of 33 genes (Supplementary Table 2). Of 
note, this overlap contains ANXA2, one of the highest-confidence targets identified in 
RIP-Chip, as well as U12 minor spliceosomal snRNA, genes encoding 5 separate 
ribosomal proteins and 7 snoRNAs. In addition, although not found to be significantly 
enriched by microarray, Rage et al also identified Vim as a target by RT-PCR and 
colocalization assays, which was also identified in our study. 
 In order to identify significantly enriched sequence motifs within regions 
potentially bound by SMN, we identified each peak that overlapped in 2 or more of the 
three replicates of CLIP and extracted the genomic sequence of the surrounding region. 
We then searched for significantly enriched motifs using MEME (Bailey et al 2009). In 
each condition that we tested, the highest enriched motif was purine-rich, generally with 





SMN binding to specific RNA targets 
We closely examined the pattern of mapped CLIP reads to several candidate RNAs 
(Figure 3). Eukaryotic elongation factor 1A2 (EEF1A2) and Laminin β2 (LAMB2) are 
novel high-confidence targets identified in our CLIP assay. The majority of CLIP tags 
mapping to EEF1A2 were concentrated in a single peak in the fifth exon (Figure 3A, top 
panel). In contrast, reads derived from RNA-Seq of SH-SY5Y cells were mapped 
throughout the length of the gene (Figure 3A, bottom panel). Similarly, CLIP tags 
mapping to LAMB2 primarily mapped to the 16th exon (Figure 3B, top panel), compared 
with an even distribution of RNA-Seq reads (Figure 3B, bottom panel). Vimentin (VIM), 
β-actin (ACTB), 7S RNA and U11/U12 RNAs have been previously identified as targets 
of SMN in previous studies (Lotti et al 2012, Piazzon et al 2013, Rage et al 2013, Rossoll 
et al 2003).  VIM CLIP tags primarily mapped to the 7th exon; however, there were also 
smaller peaks throughout the length of the gene (Figure 3C). ACTB, in contrast with the 
other genes, which had clearly defined peaks, had CLIP tags mapped throughout the 
length of the mRNA, although there are some regions of increased read density in exons 
2, 3, 4, and 6 (Figure 3D). All 3 of the small RNAs examined here had a single primary 
peak, but reads mapped throughout the length of the RNA (Figure 3E-3G). Interestingly, 
both U11 and U12 had reads derived from RNA-Seq that mapped beyond the annotated 
end of the snRNA (Figure 3F-3G, lower panels). This is consistent with a previous report 
that snRNAs initially exist as precursors that are cleaved during biogenesis (Yong et al 
2010). In contrast with RNA-Seq, CLIP tags only mapped to the annotated region of the 
snRNA genes, suggesting that SMN interacts only with the mature snRNA (Figure 3F-
3G, top panels). 
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Effect of SMN Depletion on SH-SY5Y Transcriptome 
Aside from its known roles in snRNP assembly and mRNP transport (Meister et al 2001, 
Zhang et al 2008, Rossoll et al 2003, Akten et al 2011, Fallini et al 2011), very little is 
known about the potential biological significance of RNA-SMN interactions. In order to 
determine whether SMN interactions may be linked to altered RNA expression, we 
performed depletion experiments using siRNA targeted against the SMN mRNA 
followed by RNA-Seq. We isolated RNA and protein from SMN-depleted SH-SY5Y 
cells at 24 and 48 hours after a single transfection with SMN-targeting siRNAs, as well as 
from cells transfected twice at 48-hour intervals for a total of 96 hours of treatment. As 
controls, we used a non-targeting pool of siRNAs as well as siRNA against TIA1, an 
RNA-binding protein known to regulate SMN exon 7 splicing (Singh et al 2011). To 
confirm efficient knockdown of SMN levels, we performed Western blotting using 
antibody against SMN. SMN levels were strongly reduced at all time points, with almost 
no visible expression at 96 hours. (Fig. 4A) Interestingly, there is an interaction between 
SMN and TIA1 protein levels, as SMN expression is strongly reduced in TIA1 
knockdown. Although TIA1 is predicted to increase SMN levels by stimulating inclusion 
of SMN2 exon 7 (Singh et al 2011), the effect on the protein levels of SMN appears to be 
even greater than expected from altered splicing alone. There is also an apparent effect of 
SMN depletion on TIA1 protein levels, as TIA1 expression levels are noticeably reduced 
upon SMN depletion. (Figure 4A) 
 In order to test whether SMN interaction with a given RNA is linked to altered 
expression or stability, we performed deep sequencing on RNA isolated from the SMN-
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depleted SH-SY5Y cells. Because SMN has been implicated in the biogenesis of multiple 
species of noncoding RNA (ncRNA), and the results of CLIP support an interaction with 
several ncRNAs, we performed ribosomal RNA depletion before sequencing rather than 
the standard poly(A) selection generally used for mRNA-Seq. Three replicates of each 
treatment were sequenced on an Illumina HiSeq 2500, resulting in 22.9-33.4 million 
reads per sample (Supplementary Table 3).  
 After mapping the RNA-Seq reads to the human genome (UCSC version hg38), 
we performed differential expression (DE) analysis. At 24, 48, and 96 hours post 
transfection, we identified 382, 297, and 3537 genes, respectively, with altered RNA 
levels (adjusted P value < 0.05) upon SMN depletion (Fig. 7B-D). TIA1 depletion 
resulted in a much smaller number of altered genes, likely due to the presence of a 
functionally similar homolog, TIAR (Wang et al 2010). A small number of genes (7, 2, 
and 12 for 24, 48, and 96 hours) were significantly altered in both SMN and TIA1 
knockdown. These genes may represent nonspecific responses to siRNA-mediated 
knockdown, or may represent genuine overlap between SMN and TIA1 function. Since 
they represent such a small minority of genes affected by SMN knockdown, they were 
not eliminated from further analyses. We compared the list of genes altered upon 
knockdown of SMN with those containing CLIP tags. Of 488 genes with CLIP tags, 113 
had altered expression levels upon knockdown of SMN in at least one of the time points 
tested, which is a highly significant level of overlap (p = 5.42 x 10-29). This indicates that 
SMN may be involved in regulating RNA expression. The strongest enrichment that we 
observed was in genes which are upregulated at 96 hours post-transfection (p = 7.50 x 10-
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28), although it is not known whether this is due to a stabilization of RNA in the absence 
of SMN or compensatory expression due to loss of SMN interaction. 
 We performed a KEGG pathway analysis with genes with altered expression 
levels upon SMN knockdown. The most strongly affected pathway at 24 hours is the 
MAP kinase (MAPK) signaling pathway (Fig. 7E). At 48 hours post transfection, the 
enriched pathways bear a strong resemblance to the pathways enriched in the identified 
binding partners of SMN (Figs. 6D, 7F). In particular, focal adhesion, RNA transport, 
and ECM-intracellular interaction pathways are all significantly enriched. At 96 hours 
post-transfection, the enriched KEGG pathways are dominated by protein translation and 
energy metabolism genes (Fig.7G). 
 Next, we identified a limited number of strong candidate genes to use for 
validation. It has previously been reported that CLIP experiments are prone to 
nonspecific pulldown of highly abundant RNA species (Friedersdorf et al 2014), so we 
chose to eliminate the top 10% of highest-expressing genes from our RNA-Seq 
experiment from further analysis. Likewise, genes that were expressed at very low levels 
in RNA-Seq may represent artifacts or non-specific mapping, so we eliminated the 
lowest-expressing genes as well. After visual inspection of mapped reads, we chose 15 
high-confidence targets (Table 3). Confirming that these have a high probability of being 
genuine targets of SMN, 6 of the 15 (SNX12, CDC42EP1, TXNIP, LAMB2, SPON2, and 
EEF1A2) high-confidence targets were predicted by RNA-Seq to be either upregulated or 
downregulated at one or more time points. We next tested the altered expression of these 
genes by QPCR. All three of the genes predicted to be downregulated after knockdown of 
SMN (LAMB2, SPON2, and EEF1A2) were genuinely reduced (Figure 8A). EEF1A2 
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showed the strongest response, with greater than 5 fold reduction at 96 hours post-
knockdown of SMN. The genomic organization of EEF1A2 and the location of CLIP 
reads is shown in Figure 8B. We obtained the greatest density of reads mapping to the 
first half of exon 5. We observed two single-base deletions among the reads mapping to 
this region, which is indicative of error-prone readthrough of reverse transcriptase at the 




We performed HITS-CLIP to identify in vivo RNA targets of the SMN protein in human 
neuronal SH-SY5Y cells. Similar to a previous study utilizing RIP-Chip performed in the 
mouse motor neuron-like NSC34 cells (Rage et al 2013), we observed a preponderance of 
reads mapping to mRNAs (Figure 6B). Surprisingly, despite the critical role for SMN in 
snRNP biogenesis, reads mapping to snRNAs were underrepresented compared to RNA-
Seq of total RNA from SH-SY5Y cells (Figure 6B). This could indicate that interactions 
with snRNAs are transient and only occur during snRNP assembly, while interactions 
with other types of RNAs such as mRNAs and lncRNAs could occur throughout the life 
of the RNA. Although slightly under-represented compared to total RNA-Seq, we also 
observed a significant portion of predicted binding sites mapped to lncRNAs, which we 
have recently shown to be affected by low levels of SMN in a mouse model of SMA 
(Ottesen et al 2016). snoRNAs made up the bulk of the remainder of predicted binding 
sites. Given that SMN interacts with snoRNP proteins Fibrillarin and GAR1 (Pellizzoni 
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et al 2001), an interaction with snoRNAs is not surprising. However, a direct role in 
snoRNP biogenesis has never been conclusively proven.  
 We observed an enrichment of purine-rich motifs within SMN target regions 
identified by CLIP, with the most enriched motifs following the repetitive pattern [WGA] 
x n (Fig. 6E). However, this motif was not universally conserved within predicted 
binding sites, indicating a binding mode that is more complex than binding to a single 
motif based on RNA sequence. In addition, many high-confidence target RNAs, 
including ACTB, have reads mapped throughout the length of the mRNA rather than one 
or two strong peaks, indicating that SMN may be binding multiple locations. Of note, 
SMN self-assembles to form oligomers, which could potentially bind cooperatively 
(Martin et al 2012, Gupta et al 2015). In addition, SMN can interact with a number of 
other RBPs (Rossoll et al 2002, Tadesse et al 2008, Yamazaki et al 2012, Fallini et al 
2011, Fallini et al 2014). The lack of a single strong, distinct binding motif may be due to 
recruitment by a variety of these RBPs. 
Many of the RNAs identified by CLIP are also functionally related (Figure 6D). 
The most enriched group of RNAs code for ribosomal proteins, consistent with the results 
of a previous study (Rage et al 2013). Many of the other pathways indicated by CLIP 
function in regulation and maintenance of the actin cytoskeleton (Figure 6D).  
Consistently, β-actin was one of the first mRNAs identified as an in vivo target of SMN 
(Rossoll et al 2003). Local translation of actin in the growth cone is critical for neurite 
outgrowth and steering (Willis et al 2005, Leung et al 2006). A role for SMN in the 
transport and localized translation of actin and other cytoskeletal components is therefore 
compatible with the increased sensitivity of motor neurons to low levels of SMN. 
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Several transcriptome-wide expression studies have been carried out in conditions 
of low SMN expression (Zhang et al 2013, Maeda et al 2014, Ng et al 2015, Ottesen et al 
2016), which allows us to look for similar trends between studies and high-confidence 
candidates for direct targets of SMN. Surprisingly, there is little overlap between genes 
identified by multiple studies, or even in different tissues isolated in parallel within the 
same study (Zhang et al 2013) (Table 1). Of note, the most divergent samples were 
obtained from laser capture microdissection of tissues, which are likely to undergo more 
complex regulation. There was a stronger overlap between RNA-Seq experiments 
performed in cultured cells; for example, we observed 32 up-regulated and 291 
downregulated genes which were similarly affected in our study and in another which 
examined motor neurons derived from induced pluripotent stem cells (iPSCs) derived 
from SMA mice (Maeda et al 2014) (Table 1). Of note, these include EEF1A2, SPON2, 
and LAMB2, which we identified as the highest-confidence targets of SMN by CLIP. 
EEF1A2 is of particular interest as a potential target of SMN, as this gene is specifically 
expressed in muscles and motor neurons (Abbott et al 2009) and is mutated in the wasted 
(wst) mouse model (Chambers et al 1998), which is one of the first mouse models of 
motor neuron degeneration, with a very similar progression to SMA (Newbery et al 
2005).  
In addition to identifying in vivo RNA targets of SMN, we also performed 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX) to identify in vitro 
RNA targets of the SMN protein (see Chapter 3 of this dissertation). Notably, the 
sequence preference that we identified by CLIP is distinct from the GUG, UGC, UGG, 
and GCG trimers observed in SELEX-identified sequences. However, many of the 
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trinucleotide motifs identified by SELEX were present in CLIP tags, suggesting that 
specificity of RNA-SMN interactions were driven by additional motifs and/or structural 
contexts that were not fully captured in CLIP experiment.  While SELEX and CLIP 
performed on the same RNA-binding proteins tend to identify similar motifs (Wang et al 
2010, Hafner et al 2010), there have been cases where differences arose even between 
SELEX experiments performed under differing conditions. For instance, results of two 
SELEX experiments on ASF/SF2 produced different motifs (Tacke and Manley 1995, 
Smith et al 2006).  A CLIP experiment on ASF/SF2 produced yet another consensus 
motif (Sanford et al 2008). Further, in vivo RNA-protein interactions are expected to be 
much more diverse due to the fact that several types of protein-protein complexes could 
interact with RNA, while in case of in vitro selection  only high affinity interactions 
against a single protein are captured (Jankowsky and Harris 2015). In vivo interactions 
are also subject to regulation by post-translational modification, of which SMN is a target 
(Grimmler et al 2005, Husedzinovic et al 2014) or recruitment by one of the many RBP 
binding partners of SMN (Rossoll et al 2002, Tadesse et al 2008, Yamazaki et al 2012, 
Fallini et al 2011, Fallini et al 2014). 
In summary, we have shown that SMN has a direct role in RNA regulation 
through physical interactions with specific RNAs in cells. CLIP tags had an enrichment 
of purine-rich sequences, generally consisting of repeated WGA trinucleotides. By 
combining HITS-CLIP with RNA-Seq after knockdown of SMN, we show that several 
candidate target genes have altered expression upon loss of SMN expression. This 
indicates a possible role for SMN in RNA expression or stability of those genes. Several 
targets of SMN, such as ACTB, VIM, and EEF1A2 have known roles in axon outgrowth 
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and motor neuron survival, establishing a possible direct link between SMN’s RNA 
binding ability and motor neuron health. 
 
Materials and Methods 
 
Reagents 
All reagents and chemicals used in this study and their catalog numbers are listed in 
Supplementary Table 4 
 
Cell culture and transfection 
Unless otherwise stated, all tissue culture media and reagents were purchased from Life 
Technologies. SH-SY5Y cells were obtained from the American Type Culture Collection 
(ATCC) and cultured in a 50:50 mix of minimal essential media (MEM) and F12 nutrient 
mixture supplemented with 10% fetal bovine serum (FBS). To transfect cells with 
siRNA, cells were trypsinized and 1.2-1.5 x 106 cells were reverse transfected with 20 
nM smartPOOL siRNA (Dharmacon) using Lipofectamine 2000 (Life Technologies) 
following the manufacturer’s instructions and plated on 100 mm dishes. For the 96-hour 
time point, cells were trypsinized 48 hours after the initial transfection and 1.5-2 x 106 
cells were re-transfected in a similar manner to the initial transfection. Trypsinized cells 
not used for the second transfection were collected and saved as the 48-hour time point. 
Cells were collected by scraping (24 and 96 hours) or trypsinization (48 hours). Cell 
suspensions were divided into two portions, one for future RNA isolation and one for 
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preparation of protein lysates, then centrifuged at 1000 x g for 4 minutes to collect cells; 
supernatant was removed and pellets flash frozen on dry ice and stored at -80 ˚C.   
 
Crosslinking and immunoprecipitation 
SH-SY5Y cells were grown (~1.2-2 x 107) in 12-20 150 mm dishes per replicate to 
approximately 70-80% confluency. Media was removed and plates were washed 2X with 
ice-cold phosphate-buffered saline (PBS). After removing the second PBS wash, plates 
were placed on ice and exposed to 150 mJ/cm2 of 254 nm UV light in a UV Stratalinker 
(Stratagene). Cells were collected by scraping in 4 mL of PBS per plate and centrifuged 
at 1000xg for 4 minutes. After removal of supernatant, pellets were flash frozen in liquid 
nitrogen and stored at -80˚C. For negative (uncrosslinked) control samples, all steps were 
identical except the UV crosslinking step was omitted. To lyse cells, pellets were 
resuspended in 250 µl of radioimmunoprecipitation assay (RIPA) buffer supplemented 
with 1X HALT protease inhibitor (Thermo) per original plate of cells and incubated on 
ice for 10 minutes. All further treatments and steps are described per 1 mL of lysate.  To 
remove genomic DNA and partially fragment RNPs, lysates were treated with 50 µl of 
RQ1 RNase-free DNase (Promega) and 10 µl of a 1:50 dilution of RNase A/T1 mix 
(Ambion) in a 37˚ C water bath for 10 minutes, then placed on ice for 5 minutes. Lysates 
were then centrifuged at 12,000xg for 15 minutes and supernatant was transferred to a 
new tube. SMN-containing complexes were immunoprecipitated using 100 µl of protein 
G Dynabeads (Invitrogen) coupled with 5 µg monoclonal anti-SMN (BD Biosciences) 
using the method described by Hafner et al (2010). After incubating with lysate for 30 
minutes at 4˚C, beads were washed 3 times in 1 ml RIPA buffer. RNA dephosphorylation 
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and labeling was carried out following the procedure outlined in Ule et al (2005). After 
labeling and washing, RNP complexes were eluted by boiling in 40 µl SDS-PAGE buffer 
for 5 minutes, then loaded onto 10% NuPAGE gels (Invitrogen). After SDS-PAGE 
separation, complexes were transferred onto Protran BA-85 nitrocellulose membranes 
(Whatman) and exposed to phosphorimager screens, which were scanned using a Fujifilm 
FPL-5000 imager. Printouts were lined up with reference points on the original 
membrane and bands corresponding to crosslinked RNP complexes were excised with a 
razor blade. RNA was eluted by incubating membrane slices in 200 µl of 4 µg/µl 
proteinase K in 1X PK buffer (100 mM Tris–Cl, pH 7.5, 50 mM NaCl, 10 mM EDTA) 
for 20 minutes at 37˚C, then adding an equal volume of 1X PK buffer supplemented with 
7M Urea and incubating for another 20 minutes. RNA was then purified by 
phenol:chloroform extraction followed by ethanol precipitation in the presence of 0.5 µl 
glycogen (Roche). Samples were resuspended in 8 µl RNase-free water, then Illumina 
sequencing libraries were then prepared using the TruSeq small RNA library preparation 
kit according to the manufacturer’s instructions, with the exception that an additional gel 
purification step was performed between 3ʹ′ and 5ʹ′ adapter ligation to prevent adapter 
dimers. For each replicate, PCR amplification was optimized separately using an aliquot 
of cDNA. For final library preparation, 20-24 cycles of PCR amplification was carried 
out, depending on the replicate. 
 
RNA isolation and RNA-seq library preparation 
RNA was isolated from pelleted cells using the miRVana miRNA isolation kit (Ambion) 
following the total RNA procedure. RNA concentration was measured using a UV 
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spectrophotometer and 6 µg was treated with RQ1 RNase-free DNase following the 
manufacturer’s instructions. After DNase treatment, RNA was repurified on Qiagen 
RNeasy columns according to the manufacturer’s instructions, except that prior to 
binding to the columns, 700 µl of ethanol was added to the samples instead of 250 µl in 
order to preserve binding of small RNAs. RNA quantity and quality was then assessed 
with an Agilent Bioanalyzer using the RNA Nano chip. Ribosome depletion was carried 
out on 1.5 µg total RNA using a RiboZero gold kit (Epicentre), and the entire rRNA-
depleted sample was then used as input for library generation using the TruSeq mRNA-
seq library preparation kit (Illumina). 
 
Illumina sequencing, mapping, and peak calling 
For sequencing of CLIP libraries, the samples for all three replicates were pooled and 
sequenced using an Illumina MiSeq following a 50-base single-end sequencing protocol. 
For sequencing of total SH-SY5Y RNA, 6-7 samples were pooled per lane of an Illumina 
HiSeq 2000 following a 100-base single-end sequencing protocol. Following sequencing, 
adapter and quality trimming was carried out using Cutadapt (Martin 2011). Identical 
reads which may indicate PCR duplication were removed from CLIP libraries using the 
Fastx toolkit. Mapping to the human genome (version hg38) was carried out using Tophat 
(Trapnell et al 2009) using the Gencode v20 transcriptome annotation (Harrow et al 
2012). Differential gene expression analysis was carried out using DESeq (Anders and 
Huber 2010). Regions of interest were determined from the CLIP sequencing data by 
Piranha (Uren et al 2012). Significantly enriched GO terms and KEGG pathways were 
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2.5 µg of total RNA was converted to cDNA using SuperScript III reverse 
transcriptase (Life Technologies) using random primers (Promega). For quantitative 
PCR, 1.5 µl of a 1:20 dilution of cDNA (equivalent to cDNA produced from 9.375 ng of 
RNA) was used as template in a 20 µl reaction containing 300 nM forward and reverse 
primers and 1X FastStart Universal SYBR Green Master containing ROX reference dye 
(Roche). QPCR was performed using a Stratagene MX3005P thermocycler (Agilent) and 
relative expression levels were determined using the ΔΔCt method using β-Actin as a 
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Figure 1. Overview of CLIP procedure.  Flowchart of experimental procedure is given. 
Briefly, SH-SY5Y cells were exposed to UV light at 254 nm to induce crosslinking. 
Afterwards, cells were lysed and subjected to RNase treatment. RNA-SMN complexes 
were isolated by immunoprecipitation and RNA was labeled with γ-32P ATP. Complexes 
were separated by SDS-PAGE and transferred to nitrocellulose membranes. After 
autoradiography, region of the membrane corresponding to RNA-SMN complexes were 
removed and subjected to Proteinase K digestion to elute RNA. Finally, RNA was 
prepared for Illumina sequencing by ligation of adapter sequences and RT-PCR 
amplification. 
 
Figure 2. RNA-SMN Crosslinking and Immunoprecipitation. (A) Verifying pulldown 
of SMN protein and RNA-SMN complexes. Protein size in kilodaltons (kDa) is given. 
Left panel: Western blot of input (I, 1% relative to eluted protein loaded) and eluted 
protein (E). Right panel: Autoradiogram of eluted protein without (-) and with (+) 
crosslinking of SH-SY5Y cells prior to immunoprecipitation. *: reactivity to anti-SMN 
antibody (B) Read mapping distribution across the transcriptome for RNA-Seq of SH-
SY5Y cells (RNA-Seq) and reads obtained from CLIP libraries (CLIP), and distribution 
of statistically significant enriched regions (CLIP peaks). Color code for RNA types is 
given on the right of the graph. (C) Mapping distribution of reads and peaks across 
different regions of protein-coding mRNAs. Color code for mRNA regions is given 
below the graph. (D) Top 20 enriched KEGG pathways with genes overlapping CLIP 
peaks. Y axis represents the Benjamini and Hochberg (B+H) corrected P value of 
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enrichment, X axis indicates the KEGG pathway name. (E) Top enriched motifs among 
CLIP peaks; from left to right, most enriched 6-mer, 7-mer, 8-mer, and 9-mer. 
 
Figure 3. Mapping of CLIP reads to candidate genes. Genomic view of several 
candidate genes are shown. (A-D) Genomic view of EEF1A2 (A), LAMB2 (B), VIM (C), 
and ACTB (D). Top panels represent mapping of CLIP tags, bottom panels represent 
RNA-Seq of SH-SY5Y cells. Height of blue indicate mapping depth of at each position. 
Blue lines below represent introns, thick boxes indicate coding region, and thin boxes 
represent untranslated regions. Exon numbers are given below gene diagrams. Direction 
of transcription is indicated with an arrow. (E-G) Overview of 3 small RNAs: 7S RNA 
(E), U11 (F), and U12 (G) snRNAs.  
 
Figure 4. RNA-Seq after siRNA-mediated knockdown of SMN. (A) Western blot 
verifying SMN and TIA protein knockdowns. A representative sample from 3 replicate 
experiments is shown. (B-D) MA plot depicting average expression level (X axis) against 
log2 fold change (Y axis) between WT and SMN knockdown samples at 24 hours (B), 28 
hours (C), and 96 hours (D) post transfection. Each dot represents one gene; red dots 
represent genes with significantly altered expression (B+H adjusted P val < 0.05). (E-G) 
MA plot depicting average expression level (X axis) against log2 fold change (Y axis) 
between WT and TIA1 knockdown samples at 24 hours (B), 28 hours (C), and 96 hours 
(D) post transfection. Labeling and coloring are the same as in (B-D) 
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Figure 5. Pathways enriched in genes affected by SMN knockdown (A-C) Top 20 
enriched KEGG pathways among significantly altered genes at 24 hours (A), 28 hours 
(B), and 96 hours (C) post transfection. Y axis represents the Benjamini and Hochberg 
(B+H) corrected P value of enrichment, X axis indicates the KEGG pathway name. 
 
Figure 6. Candidate genes regulated by SMN. Relative expression of 6 candidate CLIP 
targets. Gene expression was measured by QPCR 96 hours after transfection with siRNA. 
Y axis indicates relative expression as compared to samples transfected with a 
nontargeting pool of siRNA. X axis indicates genes tested. Error bars represent standard 
error of 3 replicates.  
 
Figure 1. Overview of CLIP procedure 
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Figure 2. RNA-SMN Crosslinking and Immunoprecipitation 
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Figure 3. Mapping of CLIP reads to individual genes 
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Figure 4. RNA-Seq after siRNA-mediated knockdown of SMN 
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Figure 5. Pathways enriched in genes affected by SMN knockdown 
 174 
 
Figure 6. Candidate genes regulated by SMN 
Table	  1A:	  Upregulated	  genes	  in	  multiple	  datasets	  
	   	  









SHSY	  RNAi	   1837	   3	   11	   13	   32	  
TIA1	  RNAi	   	  	   15	   0	   1	   0	  
Zhang	  et	  al,	  
motor	  neurons	   	  	   	  	   118	   6	   2	  
Zhang	  et	  al,	  
white	  matter	   	  	   	  	   	  	   103	   5	  
Maeda	  et	  al	   	  	   	  	   	  	   	  	   473	  
	   	   	   	   	   	  No	  overlaps	  of	  3	  or	  more	  groups	  were	  observed	  
	   	  
	   	   	   	   	   	  
	   	   	   	   	   	  Table	  1B:	  Downregulated	  genes	  in	  multiple	  datasets	  
	   	  









SHSY	  RNAi	   1880	   14	   12	   9	   291	  
TIA1	  RNAi	   	  	   81	   0	   0	   8	  
Zhang	  et	  al,	  
motor	  neurons	   	  	   	  	   99	   2	   10	  
Zhang	  et	  al,	  
white	  matter	   	  	   	  	   	  	   61	   7	  
Maeda	  et	  al	   	  	   	  	   	  	   	  	   2235	  
	   	   	   	   	   	  SMN1	  was	  observed	  in	  SMN	  RNAi	  and	  both	  Zhang	  et	  al	  datasets	  




Table 2. 15 candidate RNAs identified by CLIP and the impact of SMN knockdown 
on their expression 
 









ENSG00000147164 SNX12 152.82 0.52 0.42 0.61 
ENSG00000128283 CDC42EP1 259.36 0.12 0.08 0.55 
ENSG00000265972 TXNIP 443.74 0.08 0.36 0.40 
ENSG00000101335 MYL9 69.98 0.11 0.00 0.40 
ENSG00000099624 ATP5D 115.59 0.22 0.03 0.33 
ENSG00000142552 RCN3 103.09 0.06 0.17 0.30 
ENSG00000253626 EIF5AL1 15925.16 0.20 0.08 0.22 
ENSG00000198003 CCDC151 82168.48 0.05 -0.45 0.12 
ENSG00000206503 HLA-A 40.99 -0.02 0.23 0.11 
ENSG00000244486 SCARF2 2849.59 -0.17 -0.34 0.10 
ENSG00000120029 C10orf76 624.27 0.06 0.04 -0.16 
ENSG00000159335 PTMS 129.96 -0.13 0.01 -0.16 
ENSG00000172037 LAMB2 211.43 0.06 -0.05 -0.40 
ENSG00000159674 SPON2 10473.52 0.14 -0.39 -0.72 
ENSG00000101210 EEF1A2 49.74 -0.38 -0.99 -1.82 




CHAPTER IV SUPPLEMENTARY TABLES 
 
Supplementary	  Table	  1:	  CLIP	  sequencing	  libraries	  
Library	   Total	  reads	   Reads	  >	  12bp	   Unique	  reads	   Mapped	  reads	  
CLIP	  1	   2914929	   2760342	   183538	   72562	  
CLIP	  2	   3146154	   3141746	   349262	   189913	  
CLIP	  3	   2810360	   2772958	   408371	   272892	  	  







































Supplementary	  Table	  3:	  Summary	  of	  RNA-­‐Seq	  libraries	  
siRNA	   Time	   Replicate	   Total	  reads	   Mapped	  reads	  
siControl	  
24h	  
1	   27523152	   25581717	  
2	   27011860	   25734476	  
3	   26648822	   25097965	  
48h	  
1	   24740995	   23936976	  
2	   25413631	   24575908	  
3	   29493699	   28455013	  
96h	  
1	   22790618	   21843487	  
2	   25354493	   24123169	  
3	   31885211	   30392446	  
siTIA1	  
24h	  
1	   33339926	   30987619	  
2	   27664336	   26210554	  
3	   22935960	   21470938	  
48h	  
1	   24984828	   24194767	  
2	   25217183	   24415289	  
3	   30772576	   29785296	  
96h	  
1	   22920758	   21937515	  
2	   26158856	   24889520	  
3	   29034564	   27732772	  
siSMN	  
24h	  
1	   24983284	   23236101	  
2	   24975108	   23753407	  
3	   26924239	   25092504	  
48h	  
1	   23379766	   22590497	  
2	   24879232	   24029327	  
3	   31080328	   30027407	  
96h	  
1	   23144840	   22070042	  
2	   26679555	   25253512	  
3	   27198256	   25790180	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Supplementary	  Table	  4:	  Chemicals,	  reagents,	  and	  enzymes	  used	  in	  this	  study	  
Reagent	  name	   Manufacturer	  
Product	  Catalog	  
#	  
Minimum	  Essential	  Medium	   Life	  Technologies	   11095-­‐080	  
F12	  nutrient	  mixture	   Life	  Technologies	   11765-­‐054	  
Fetal	  Bovine	  Serum	   Life	  Technologies	   26140-­‐079	  
Trypsin	  0.25%	   Life	  Technologies	   25200-­‐056	  
PBS	   Life	  Technologies	   14190-­‐094	  
Lipofectamine	  2000	   Life	  Technologies	   11668-­‐019	  
TriZOL	  reagent	   Life	  Technologies	   15596-­‐026	  
UV	  Stratalinker	   Agilent/Stratagene	   2400	  
RIPA	  buffer	   Boston	  Bioproducts	   BP-­‐115	  
HALT	  Protease	  Inhibitor,	  100X	   Thermo	  Scientific	   78425	  
RQ1	  RNase-­‐free	  DNase	   Promega	   M6101	  
RNase	  A/T1	  mix	   Ambion	   AM2286	  
Protein	  G	  Dynabeads	   Life	  Technologies	   10004D	  
anti-­‐SMN	  antibody	   BD	  Biosciences	   610646	  
anti-­‐Gemin2	  antibody	   Sigma	   G6669	  
anti-­‐Actin	  antibody	   Sigma	   A2066	  
[γ-­‐32P]UTP	   Perkin-­‐Elmer	   BLU502Z001MC	  
2X	  Laemmli	  buffer	   Biorad	   161-­‐0737	  
10%	  NuPAGE	  precast	  gels	   Invitrogen	   NP0301BOX	  
Protran	  BA-­‐85	  nitrocellulose	   Whatman	   10401197	  
Proteinase	  K	   Sigma	   P6556	  
Tris	  base	  (Trizma)	   Sigma	   T1503-­‐5KG	  
Sodium	  Chloride	  (NaCl)	   Sigma	   S3014-­‐10KG	  
Ethylenediaminetetraacetic	  acid	  (EDTA)	   Sigma	   EDS-­‐1KG	  
Urea	   Sigma	   S1456-­‐25KG	  
Phenol:chloroform	  1:1	   Calbiochem	   6810	  
Glycogen	   Roche	   10901393001	  
TruSeq	  small	  RNA	  library	  preparation	  kit	   Illumina	   RS-­‐200-­‐0012	  
miRVana	  miRNA	  isolation	  kit	   Ambion	   AM1560	  
Qiagen	  RNeasy	  columns	   Qiagen	   74104	  
RNA	  Nano	  chip	   Agilent	   5067-­‐1529	  
RiboZero	  Gold	  rRNA	  removal	  kit	   Epicentre	   MRZG12324	  
TruSeq	  mRNA-­‐Seq	  library	  preparation	  kit	   Illumina	   RS-­‐122-­‐2001	  
Superscript	  III	  reverse	  transcriptase	   Invitrogen	   18080-­‐044	  
FastStart	  SYBR	  Green	  master	  mix	  with	  
ROX	   Roche	   4913914001	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Supplementary	  Table	  5:	  Primers	  used	  in	  this	  study	  
Primer	  
name	   Sequence	  
SNX12-­‐F	   CCGCCAAGTAACTTCCTGGAGA	  
SNX12-­‐R	   CACTCAAAGTCACTGTAGCGCC	  
CDC42EP1-­‐
F	   GTTGGCAAGCTCAGCTTCGAC	  
CDC42EP1	  
R	   CTCAGAGGGGAAGGAACCATCC	  
TXNIP-­‐F	   ACTCGTGTCAAAGCCGTTAGGA	  
TXNIP-­‐R	   CAACAGGTGAGAATGAGATGGTGATC	  
LAMB2-­‐F	   TGTCTGCCTTGAGCCTGGTATC	  
LAMB2-­‐R	   ACATCTCTAGCACCAGGACACG	  
SPON2-­‐F	   GACGTAGCGAGTCCTGCTCTTG	  
SPON2-­‐R	   AGATTGTAGACAGCGCCTCAGT	  
EEF1A2-­‐F	   GCGCCTACATCAAGAAGATCGG	  






 The Survival Motor Neuron (SMN) protein is a multifunctional protein that is 
required in all cells. Low levels of SMN result in spinal muscular atrophy (SMA). The 
most well-characterized function of SMN is in the biogenesis of the spliceosomal small 
nuclear ribonucleoproteins (snRNPs); however, a number of roles have also been 
proposed for SMN in diverse processes such as transcription, translation, stress granule 
formation, mRNA transport, and actin cytoskeleton regulation. Likewise, although SMA 
is broadly considered to be a disease of motor neurons, secondary symptoms have also 
been identified in muscle, heart, lungs, and intestine. In this study, we aim to expand the 
scope of SMN functions, both system-wide and at the molecular level. 
 In Chapter 2, we identified a previously uncharacterized phenotype of a mild 
mouse model of SMA (C/C model) which presented as greatly reduced testis size and 
severe defects in spermatogenesis. As a result, male C/C mice were almost completely 
infertile and had a ~10-fold reduction in sperm count. We determined that SMN protein 
expression was extremely high compared to all other tissues tested, indicating an 
increased requirement for SMN in testes. We characterized the testis transcriptome of 
C/C mice by RNA-Seq, which revealed drastic alteration of gene expression across a 
number of critical pathways. We found that SMN levels in C/C testes were 
developmentally regulated, due to a splicing switch that coincided with the onset of 
spermatogenesis. Strangely enough, although SMN levels were lowest at early stages of 
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testis development, we only observed altered gene expression and splicing in sexually 
mature mice, indicating that either there is a delay between low SMN expression and 
presentation of the phenotype, or adult testes are affected by loss of SMN expression in 
other tissues or a small subset of cells within the testis. Our findings underscore the status 
of SMA as a multi-system disease rather than a strictly neuromuscular disorder and 
provide new targets for observation in any potential treatment for SMA. 
 In Chapter 3, we characterized the RNA binding properties of the SMN protein. 
Although it has long been known that SMN has an RNA binding domain, only a limited 
amount of research has been done characterizing the specificity of RNA- SMN 
interactions. We performed iterative in vitro selection (Systematic Evolution of Ligands 
through Exponential Enrichment or SELEX) to identify high-affinity RNA targets of the 
SMN protein. Analysis of selected sequences revealed high incidence of GUG, UGC, 
UGG, and UUG trinucleotides, as well as a GUGCG motif that was strongly enriched. 
However, mutation of sequences outside of the GUGCG also had a strong effect on 
binding affinity, indicating that multiple factors, including RNA structure, influenced 
binding. We demonstrate that both affinity and specificity of RNA-SMN interaction are 
influenced by salt concentrations. Our results bring new perspective to the mode of action 
of SMN and may suggest new functions of SMN in RNA metabolism. 
In Chapter 4, We used in vivo crosslinking and immunoprecipitation (CLIP) to 
identify direct interactions between SMN and RNA in living cells. We observed an 
enrichment of mRNAs in the CLIP-purified RNAs and identify several candidate genes. 
Although CLIP did not identify the same target motif as SELEX, such a result is not 
surprising given the increased complexity of in vivo interactions. We identified a variety 
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of RNA targets of SMN with an enrichment of mRNAs participating in a number of 
pathways, including ribosome function and actin cytoskeleton regulation.  Overall, we 
confirm that SMN is a bona fide RNA binding protein that exhibits sequence specificity, 
shedding new light on a number of critical functions of this essential protein.  
 	  
